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1 1    The invention of new sequencing technologies 
 
1.1  From first  to second generation sequencing 
 
1.1.1  Historical background 
 
The DNA structure was discovered in the early 1950’s by Watson and Crick
[1a] 
who described it as follows: The deoxyribonucleic acid is a double stranded 
polymeric molecule with a phosphate deoxyribose backbone consisting of the 
four  nucleobases  2′ deoxyadenosine,  2′ deoxycytidine,  2′ deoxyguanosine  and 
2′ deoxythymidine. Today it is known that DNA stores the genetic information 
of every living organism and is therefore the blueprint of the phenotype of any 
individual.  Only  certain  sequence  regions  of  the  DNA  are  transcribed  by 
enzymes into messenger ribonucleic acid (mRNA), which is a very similar, often 
single stranded polymeric ribonucleotide (see figure 1). The mRNA serves as 
matrix  for  the  translation  into  the  corresponding  amino  acid  sequence  that 
forms a particular protein depending on the sequence of the mRNA. Not every 
sequence of the entire genetic code is transcribed and translated, which means 
that the expression of the genetic heritage is regulated by epigenetic processes 
like e.g. methylation of DNA, paramutations
[1b] and gene silencing
[1c].  
 
 
Figure 1: Function of DNA and regulation of gene expression by epigenetics 
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In  order  to  understand  the  complex  coherence  between  a  gene  and  the 
phenotype of an individual (i. e. expression of proteins), the sequence of the 
DNA is of high interest. Hence several motivated research groups investigated 
in sequencing of biological relevant genes: The first innovative breakthrough 
was  achieved  by  Maxam  and  Gilbert  as  well  as  by  the  Sanger  group  in  the 
1970’s. Both research groups published the first two effective and competitive 
techniques for the determination of a DNA sequence
[2,3].  
The  Maxam Gilbert  method
[2]  is  based  on  chemical  degradation  of  the  DNA 
template, which means that the four nucleobases are cleaved in nucleobase 
specific reactions, giving DNA fragments of different sizes. The lengths of these 
32P radiolabeled  fragments  identify  the  positions  of  the  nucleobases  in  the 
sequence. These fragments from four base specific reactions are resolved by 
their size by polyacrylamide gel electrophoresis (PAGE) and the sequence can 
be directly read out from the band pattern provided by autoradiography.  The 
accuracy  of  this  sequencing  method  is  limited  by  the  length  of  the  DNA 
template:  The  method  is  applicable  for  sequences  not  longer  than  ca.  750 
nucleobases (duration of sequencing roughly one day). One big success in the 
application  of  the  Maxam Gilbert  method  was  the  decoding  of  the  DNA 
sequence of bacteriophage T7 in 1983
[4]. 
The  competitive  technique  developed  by  Sanger  et  al.  is  an  enzymatic 
sequencing method which was published in the same year as the Maxam Gilbert 
sequencing  (1977).  Similar  to  the  “plus  and  minus”  method
[5],  the  single 
stranded DNA template is extended by the addition of 2′,3′ dideoxynucleotides 
which act as specific chain terminators for the DNA polymerase. The resulting 
radiolabeled fragments from the PCR products are separated and detected as 
described  for  the  Maxam Gilbert  method  (PAGE).  But  in  contrast  to  the 
chemical sequencing technique, the Sanger method delivers the sequence of 
the complementary strand of the DNA template. Translation of the determined 
sequence into its opposite gives the requested one. With the Sanger technique 
in hand the decoding of the bacteriophage φX174 sequence in less than one 
year  consisting  of  roughly  5000  nucleobases  was  achieved
[6]  (Nobel  Prize  in 
1980). Unlike the Maxam Gilbert method, the Sanger technique was refined and 
commercialized which led to its broad dissemination throughout science and 
clinical diagnostics. The Sanger method has a few advantages over the Maxam The invention of new sequencing technologies                          
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Gilbert technique. The reason for this is that it is a faster and more accurate 
technique,  enabling  the  decoding  of  longer  DNA  templates  in  shorter  time 
(standard template of 1000 nucleobases sequenced in 1 2 hours). Second, the 
Sanger  method  enables  alternative  labeling  techniques  like  fluorescence 
labeling that avoids the use of toxic radioactive 
32P labeled material. Third, the 
Sanger  method  can  be  automated  by  use  of  fluorescence  detectors  and  is 
therefore  applicable  to  the  routine  laboratory  (i.  e.  dye primer
[7]  or  dye 
terminator
[8]  sequencing  using  capillary  electrophoresis).  The  biggest 
milestones in the application of Sanger sequencing were the determination of 
the whole genome of E.coli bacteria
[9] (4,639,221 bp) and finally the decoding 
of the whole human genome (3,069,431,456 bp), published by Craig Venter in 
Science 2001
[10]. In 2003, this goal was accomplished by the Human Genome 
Project (HUGO) in a 13 year effort with an estimated cost of $2.7 billion. As a 
comparison to this, it was possible in 2008 to sequence the human genome over 
a 5 month period for ca. $1.5 million
[11].  
These overwhelming results encouraged the development of new and improved 
sequencing strategies, since the DNA sequence information from humans and 
microorganisms has the potential to improve many facets of human life and 
society, including the understanding, diagnosis, treatment and prevention of 
diseases. During the past 5 years, “next generation” sequencing technologies 
have rapidly evolved opening new perspectives in diagnostics. 
 
1.1.2  The need for second generation sequencing 
    
Although the whole human genome has already been deciphered and also more 
than 150 different genomes are sequenced and partially analyzed, there is still 
a strong need for detailed sequence information in order to understand the 
functions of many genes. Such information would benefit the development of 
personalized medicine and significantly improve human health and the quality 
of life. The two already described sequencing methods, the enzymatical
[3] and 
the  chemical one
[2]  have in  common  that they use  the  time demanding and 
expensive  gel  electrophoresis.  Although  the  Sanger  method  used  to  be  the 
method of choice within the last 30 years of sequencing, it is too laborious and The invention of new sequencing technologies                          
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expensive  to  meet  future  demands.  This  method  is  mainly  based  on 
fluorescence  detection  of  dideoxynucleotide terminated  DNA  extension 
products that are resolved by PAGE or capillary electrophoresis systems
[12,13], 
where  the  sequence  “read  length”  is  no  longer  than  approximately  1000 
nucleotides.  To  decipher  3  billion bases  more  than  3  million runs  would  be 
needed, so that   together with overlaps and resequencing   the number of 
sequencing runs would be several millions.  
For an improved insight into the structure and function of the human genome 
as well as for full realization of individual health care a need for much faster, 
simpler and cheaper sequencing technologies than the PAGE based ones exists. 
Therefore several techniques were developed within the last two decades, such 
as  pyrosequencing
[14a e],  mass  spectrometry assisted  sequencing
[15a c], 
sequencing  by  hybridization
[16a c],  sequencing  by  ligation
[17a,b],  sequencing  of 
single DNA molecules
[18a,b] and sequencing by synthesis
[19a d], with some of them 
already having led to commercialized sequencers.    
 
1.2  Sequencing by hybridization 
 
The technique of Sequencing by hybridization (SBH) was first brought up in the 
late 1980’s by Drmanac et al. introducing the read out of a 100 bp sequence by 
a gelelectrophoresis free method
[16a,20]. This method enables the determination 
of  a  immobilized  sequence  by  the  maximal  overlap  and  hybridization  of  its 
constituent  octamers  (or  nonamers)
[16a].  The  100 bp  segment  from  922 bp 
EcoRI Bgl II human genomic fragment containing the β interferon gene, which 
had already been sequenced
[21], served as template for resequencing and for 
the proof of principle. Based on the evaluation of this method, Drmanac et al. 
successfully applied this technique on sequencing of larger templates such as 
the determination of a few sequence regions in the p53 gene
[16c]. Also other 
research  groups  designed  SBH approaches  for  the  determination  of  genomic 
sequences: Broude et al. developed the so called termed position SBH (PSBH) 
published  in  1993
[16b]  which  is  very  similar  to  the  method  developed  by 
Drmanac et al.  
The  PSBH  method  is  based  on  the  use  of  immobilized  duplex  probes  that 
contain  single stranded  3′-overhangs  instead  of  single stranded  probes  (see The invention of new sequencing technologies                          
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Drmanac
[16a]). The PSBH principle is shown in figure 2a in detail: The duplex 
probe  possesses  a  double stranded  constant  region  and  a  variable  single 
stranded  3′ overhang.  The  probe  is  5′ biotinylated  and  immobilized  on 
Streptavidin coated  magnetic  beads,  then  treated  with  the  single stranded 
target DNA (
32P labeled on 5′ terminus) annealing selectively to the 3′ terminal 
sequence of the duplex probe. The double stranded probe provides sequence 
stringency in detection of the 3′ terminal sequence of the target DNA caused by 
base stacking  between  the  preformed  DNA  duplex  and  the  newly  formed 
duplex
[22]. The DNA ligases’ adjacency to the duplex probe target complex is 
directed by the probe target configuration, also the enzyme is susceptible to 
single base mismatches near the ligation site
[23].  As a consequence of this, the 
ligation step allows discrimination between perfectly matched and mismatched 
target DNAs.  
 
 
Figure 2a: The PSBH method: Outline of experiments to test ligation discrimination for  
matched and mismatched targets bound to duplex probes
[16b]  
 
Both unligated and ligated targets are removed by washing the beads at 4 °C The invention of new sequencing technologies                          
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(cold wash) first, then at 90 °C (hot wash): At 90 °C the nonbiotinylated strand 
is melted from the immobilized biotinylated strand. The ligation efficiency is 
taken as the ratio of 
32P released at 90 °C to the total amount of 
32P used and 
defined  as  the  ratio  of  ligated  target  to  the  total  target  used.  The 
discrimination factor therefore is defined as the relative ligation efficiency of 
perfectly  matched  and  mismatched  targets.  One  attempt  to  enhance  the 
discrimination  between  matched  and  mismatched  target  sequences  was  the 
polymerase extension reaction of the free 3′ terminus of the duplex probe (see 
figure 2b). 
Extension  of  the  duplex  probe's  free  3′ terminus  with  a 
32P labeled  dNTP  is 
performed using a DNA polymerase with lack of 3′ >5′ exonuclease and terminal 
transferase activity. This process requires a correct duplex formation between 
the free 3′ terminus and the ligated target to be able to distinguish between 
matched and mismatched probes. 
 
 
Figure 2b: PSBH enhancement by the use of polymerase extension reaction
[16b] 
 
Based  on  the  disadvantage  that  the  PSBH method  only  detects  3′ terminal 
sequences, Broude et al. improved this technique by designing a set of nested 
3′ deletions  possessing  a  common  5′ terminus  derived  from  the  target 
sequence.  The  positional  information  about  the  distance  between  the  3′ 
sequence and a known reference point in the sequence was achieved by using 
such a kind of nested targets (i. e. overlapped fragments). One decade later, 
the  nested  target  SBH  method  was  defined  by  Shamir  et  al.  as  the 
reconstruction of a DNA sequence that is based on its k mer content with k as 
length of the target fragments
[24].  
According to Drmanac
[25] the SBH method has the advantage of reading whole The invention of new sequencing technologies                          
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“words”  and  not  only  single bases  within  a  sequence,  but  this  technique  is 
hampered in broad application by its disadvantages like biochemical difficulties 
and a high error rate during the hybridization process for longer sequences (> 
400  bp)
[24].  Thus  the  need  for  improvement  of  the  read out  of  longer  and 
unknown sequences by complex algorithms
[24,26] still remains challenging. The 
SBH technique is also hardly applicable to de novo sequencing, although it is a 
reliable method for resequencing. 
 
1.3  Pyrosequencing 
 
Pyrosequencing  is  a  nonelectrophoretic,  real time  DNA  sequencing  method 
which was first reported by Hyman et al. in 1988
[27]. The sequencing technique 
is  based  on  the  detection  of  released  pyrophosphate  (PPi)  during  the  DNA 
polymerization  reaction.  Similar  to  the  Sanger  method,  the  complementary 
strand  is  synthesized  via  PCR  and  can  be  translated  afterwards  into  its 
opposite. Ronaghi et al. significantly improved the pyrosequencing technique 
and  thus  published  two  pyrosequencing  methods  in  the  1990’s,  the  solid 
phase
[14b] (see figure 3a) and the liquid phase method
[14c] (see figure 3b).  
 
 
Figure 3a: Scheme of solid phase pyrosequencing according to Ronaghi et al.
[14d] 
 
Solid phase  pyrosequencing  is  enabled  by  the  immobilization  of  the  DNA 
template on an array (e. g. Streptavidin coated magnetic beads) and treatment The invention of new sequencing technologies                          
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with  the  dNTPs  and  a  three enzyme  system:  The  visible  light  which  is 
generated  during  a  cascade  of  enzymatic  reactions  is  proportional  to  the 
number of incorporated nucleotides. These coupled enzymatic reactions were 
already successfully applied by Nyren et al.
[28] for certain polymerase activity 
assays.  
As depicted in scheme in figure 3a, the nucleotide incorporation done by the 
polymerase (often the Klenow fragment of Escherichia coli DNA Pol I) leads to 
the release of inorganic PPi, which is then converted by ATP sulfurylase
[14d] into 
ATP. The released ATP is an energy source for the enzyme luciferase (from the 
American firefly  Photinus pyralis), which subsequently oxidizes luciferin and 
consequently generates light with the wavelength of 560 nm. The amount of 
emitted  light  is  detected  by  a  charge coupled  device  (CCD)  camera  or  a 
photodiode.  The  whole  process,  from  DNA  polymerization  to  light  emission, 
happens within 3 4 seconds. The concentration of DNA polymerase is selected 
to be much higher than the template concentration enabling the immediate 
start of polymerization reaction. For each incorporation step, one particular 
known nucleobase (dATP, dCTP, dGTP or dTTP) is added and the light signal 
can  only  be  detected  if  the  appropriate  nucleotide  is  incorporated 
complementary to the template strand. 
 
 
Figure 3b: Scheme of liquid phase pyrosequencing according to Ronaghi et al.
[14d] 
 
After light signal detection, the array is washed for removal of excess substrate The invention of new sequencing technologies                          
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and the next incorporation cycle can take place. Ronaghi et al. often observed 
false signals when dATP was added to the solid phase sequencing system. The 
reason for this is that dATP is not only a substrate for the incorporation by the 
polymerase, but also for the luciferase. The problem of competitive reactions 
resulting  in  false  signals  could  be  solved  by  substitution  of  dATP  with 
dATPαS
[14b].  The  sulfur containing  nucleotide  was  found  to  be  efficiently 
incorporated  into  the  template  while  being  inert  towards  the  luciferase.  A 
solid support  free  method  of  pyrosequencing,  named  liquid phase 
pyrosequencing, is enabled by the extension of the three enzyme system to a 
four enzyme system introducing the nucleotide degrading enzyme apyrase (see 
figure 3b). With the use of apyrase no intermediate washing step is required so 
that  pyrosequencing  can  take  place  in  solution.  Apyrase  possesses  a  high 
catalytic activity and therefore degrades the unincorporated dNTPs (products 
marked as (d)XMP in figure 3b) by hydrolyzing the triphosphates first to form 
diphosphates and finally monophosphates. 
This four enzyme system combined with the removal of inhibitory substances 
and with minimization of the dilution effect enables accurate sequencing of 
200 nucleobases. The signal to noise ratio of pyrosequencing is relatively high, 
but longer reads are limited by misincorporation. Misincorporation of a dNTP 
terminates  the  primer  strand  causing  reduction  of  the  signal  intensity.  This 
problem is even more inherent to de novo sequencing of polymorphic regions in 
heterozygous DNA templates.  
However, pyrosequencing allows high throughput sequencing and is a powerful 
technique  for  genotyping  (i.  e.  detection  of  SNPs),  microbial  typing, 
resequencing, tag sequencing and for analysis of difficult secondary structures 
such as hairpins.   
The pyrosequencing technique is also applicable to different instrumentation 
methods like solid phase pyrosequencing in microfluidics
[14e] or pyrosequencing 
in an automated microtiter plate format
[29]. 
The  first  next generation  DNA  sequencer  based  on  the  pyrosequencing 
technique was released to the market in 2005 which was developed by the 454 
Life Sciences Roche company. With this instrument (named Genome Sequencer 
FLX  with  GS  FLX  Titanium  series  reagents
TM)  it  is  possible  to  sequence 
approximately 400 600 megabases of DNA per 10 hour run
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known for its straight sample preparation and long sequence reads (400 500 
base pairs in length) with high accuracy at the same time (including paired 
reads).  
Here, the already described solid phase pyrosequencing method is embedded 
into a cyclic array sequencing method
[30] as shown in figure 3c: The adapter 
ligated DNA fragments are immobilized on small DNA capture 28µm beads in an 
emulsion and clonally amplified by PCR. These DNA bound beads are randomly 
placed into a ~29  m well (~29  m is the dimension where only one single bead 
fits  per  well)  on  a  PicoTiterPlate  then  and  treated  with  a  mix  of  DNA 
polymerase, ATP sulfurylase, and luciferase. The whole loaded PicoTiterPlate is 
placed into the sequencer, where one surface of this semi ordered array has 
the function of a flow cell allowing reagent addition and removal, whereas the 
other surface enables CCD based signal detection while it is bound to a fiber 
optic  bundle
[30].  The  PicoTiterPlate  is  treated  with  the  sequencing  reagents 
(containing buffers, one particular nucleotide per cycle (daTPαS, dCTP, dGTP, 
dTTP) and luciferin) across the wells. During a sequencing run the four dNTPs 
are  added  sequentially  in  a  fixed  order  across  the  PicoTiterPlate  device 
enabling  massive  parallel  sequencing.  Pyrosequencing  and  therefore  light 
emission only takes place in wells were the particularly added nucleotide is 
incorporated into the bead supported template and the released light signals 
are then recorded by the CCD camera in the instrument. The signal strength is 
proportional  to  the  number  of  nucleotides  incorporated:  homopolymeric 
sequences generate a stronger light signal than single nucleotides during one 
nucleotide flow. 
 
 
 Figure 3c: Cyclic array pyrosequencing method applied to Roche’s 454 sequencing system
[29,30] 
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general is the appearance of false signals during sequencing of homopolymeric 
regions  (such  as  AAA  or  GGG).  Multiple  incorporation  of  one  particular 
nucleobase  per  one  nucleotide  flow  cycle  cannot  be  prevented  by  any 
terminating  function  which  makes  the  interpretation  of  the  detected  light 
signal intensity inaccurate. Nevertheless, one big advantage of the 454 system 
with optimized pyrosequencing technique is its high read length: With the use 
of the 454 sequencer deciphering of the complete Neanderthal mitochondrial 
genome was achieved thus leading to a big publication
[31] in Nature in 2006. 
 
1.4   Sequencing by synthesis 
 
1.4.1  The invention of reversible terminators for SBS 
 
One  of  the  first  prototypes  of  the  PAGE free  method  called  Sequencing by 
Synthesis was published by Metzker et al. named “Base Addition Sequencing 
Scheme” (BASS)
[32]. 
  
 
Figure 4a: Principle of the Base Addition Sequencing Scheme (BASS)
[32] 
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Like Sanger sequencing, this method is an enzymatical technique but uses 3′ 
O modified dNTPs instead of ddNTPs as chain terminators. These nucleotides 
have the ability to stop the polymerase reversibly after the incorporation of 
one modified nucleotide. The scheme of the BASS method is shown in figure 
4a.  The  DNA  template  is  biotinylated  and  bound  to  a  solid  support.  After 
primer  annealing,  the  four  3′ blocked  dNTPs  are  added,  each  of  them 
possessing  a  spectroscopically  unique  blocking  group.  Several  polymerases 
were found to accept and incorporate these 3′ modified nucleotides, such as 
the  Klenow  fragment  of  DNA  polymerase  I,  AmpliTaq®  DNA  polymerase, 
VentR® (exo
 ) DNA polymerase and others
[32]. The polymerase is immediately 
stopped after the incorporation of one single 3′ modified dNTP and the base 
specific 3′ blocking tag is detected and photolytically cleaved. With the 3′ 
group  removal,  the  3′ end  of  the  primer  is  regenerated  and  the  next 
incorporation detection cycle is enabled. Because of their 3′ blocking group 
stability during polymerase incorporation, but photolytical cleavability of this 
3′ tag, these 3′ modified nucleotides were named “reversible terminators”. 
The  publication  of  Metzker  introducing  the  BASS  method  presents  only  one 
successful  cycle  of  incorporation,  detection  and  3′ tag  cleavage.  Seven 
different fluorescent aromatic labels were used as 3′ modifications, which were 
tolerated  by  the  polymerase  differently  among  each  other:  It  could  be 
determined that 3′ O (2 nitrobenzyl) 2′ deoxyadenosine was incorporated best 
compared to the other 3′ blocked nucleotides which weren’t employed for a 
whole BASS cycle.  
Over a decade later, Metzker et al. surprisingly found out that the claimed 
structure of the reversible terminator, 3′ O (2 nitrobenzyl) 2′ deoxyadenosine, 
was incorrect and that the correct structure of this terminator was assigned as 
N
6,N
6 bis (2 nitrobenzyl) 2′ deoxyadenosine
[33]  by  NMR  spectroscopy.  The 
confusion  about  the  structure  of  2′ nitrobenzyl labeled  dATP  motivated  the 
Metzker group to synthesize both compounds as well as the monobenzylated 
nucleotide N
6 2 nitrobenzyl) 2′ deoxyadenosine and compare their acceptance 
and termination properties in polymerase assays. As a result of these tests, the 
researchers established that the 3′ blocked dATP acted as a poor substrate for 
the polymerase compared to the other both N
6 mono  and dialkylated dATPs
[33]. 
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promising candidates for further SBS applications.  
Until  now,  the  BASS  method     later  named  as  cyclic  reversible  termination 
(CRT)   was not developed further, but due to the presentation of these labeled 
dNTPs the concept of a “reversible” terminator was born.  
Nearly  at the  same  time  a  3′ O dye labeled  terminator  was  synthesized and 
published by Hovinen et al.
[34a] in 1994, which can be regarded as one of the 
first  complete  terminators  (see  figure  4b).  Compared  to  Canard’s
[34b]  and 
Metzker’s
[33] terminators, this dTTP derivative possesses an aminoalkoxymethyl 
linker which is attached to the 3′ hydroxy function and labeled with fluores 
ceinisothiocyanate  (FITC).  This  labeled  nucleotide  shows  good  termination 
properties by using the thermostable Tet/z DNA Polymerase, an enzyme that 
accepts and incorporates this substrate in high fidelity. 
 
  
Figure 4b: Variety of reversible terminators for different SBS approaches 
 
One significant difference between Canard’s and Metzker’s terminator is the 
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supposed to carry a remarkably stable 3′ dye linker system that may not be 
cleavable under mild conditions. Therefore this nucleotide cannot be regarded 
as  reversible  terminator,  although  it  has  terminating  properties.  These  3′ 
modified reversible terminators developed in the 1990’s were used for the first 
attempts in developing the SBS method, but one decade later, another type of 
reversible terminators became popular: Seo et al. introduced in 2004 new 3′ 
unmodified nucleotides wearing a fluorescent label attached to the base motif 
as reversible terminators, enabling a couple of mass spectrometry assisted SBS 
cycles
[35a,b]. Companies such as Solexa (now Illumina) and Roche came up with 
publications
[19d,36]  and  patents
[37,38a,38b]  covering  the  design  and  synthesis  of 
reversible terminators, which dye linker system is annealed to the nucleobase 
moiety, accepted by the polymerase and quantitatively cleavable (see figure 
4). This clarifies that the 3′ blocking group is not absolutely necessary for any 
SBS technique which also depends on some other issues.    
In most of the cases, the reversible terminators presented have to possess the 
following properties for fulfillment of a PCR based SBS method: 
   The nucleotide is a 5′ triphosphate. 
   The nucleotide is labeled with a spectroscopically unique group like a  
fluorophore or dye, attached either to the base moiety or to the 3′ end. 
   The modified nucleotide is accepted and incorporated into the template by  
the polymerase. 
   The modification (3′ blocking group, fluorophore, linker etc.) is  
quantitatively  removable  after  incorporation  and  detection  of  the 
nucleotide. 
Nucleotides addressing all these points would have the potential to enable the 
development of a Sequencing by synthesis technique leading to high troughput 
DNA sequencing. 
 
1.4.2  The array based SBS technology 
 
The  array based  sequencing by synthesis(SBS) technology  is  a  promising 
diagnostic  tool  which  provides  fast  and  cost effective  sequence  information 
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short  gene  sequences,  no  time consuming  gel  electrophoresis  is  needed 
because the sequence can be directly read out by a four color code. 
Within  the  last  years,  several  researchers  from  the  industrial  and  academic 
field have focussed on the development of an accurate SBS technique using 3′ 
O modified reversible terminators, which are efficiently incorporated into the 
DNA template by a highly tolerable polymerase. 
 
 
Figure 5: Structures of the four reversible terminators for Ju’s SBS method
[19b] 
 
Especially the Columbia University research group developed a SBS technique 
based on reversible terminators possessing a 3′ O modification
[19b,39a d], e.g. an The invention of new sequencing technologies                          
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allyl group
[19b,39c d] and a dye labeled cleavable linker containing a particular 
fluorophore for each nucleobase (see figure 5): The four nucleobases carry four 
different dye labels attached to the base motif with a cleavable linker that 
contains an allyl moiety. An allyl function serves as 3′ blocking group which is 
elegantly cleavable under the same conditions like the dye linker system: In 
aqueous  buffered  solution,  the  nucleotide  is  deallylated  quantitatively  by 
incubation of the template for 5 min at 60 °C using a Pd catalyst. The four 
reversible terminators employed for the SBS approach are illustrated in figure 
5. The principle of the SBS method is shown in figure 6a part A: 
 
 
Figure 6a: Scheme of the array based SBS method according to Ju et al.
[19b] 
 
Step 1: A hairpin shaped self priming template immobilized on a chip is treated 
with all four reversible terminators (dNTPs with N = A, C, G, T and different 
dye  label  on  each  nucleobase)  and  a  highly  tolerable  polymerase,  which 
incorporates the correct nucleobase complementary to the template strand (at 
68 °C within 10 min incubation time). 
Step  2:  After  one  washing  step  and  the  capping  reaction  (i.  e.  blocking  of 
unreacted primers with unlabeled 3′ O allyl dNTPs), the fluorescence signal is 
detected and the dye linker system as well as the 3′ blocking group is cleaved 
off using Thermopol I reaction buffer/Na2PdCl4/P(PhSO3Na)3 and incubation for 
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Step  3:  The  terminal  3′ group  is  regenerated,  the  chip  immersed  in  a  3  M 
tris HCl  buffer  (pH  8.5)  and  incubated  again  for  5  min  at  60  °C  for  Pd cat 
removal.  The  surface  is  washed  again  and  scanned  for  confirmation  of 
complete fluorophore removal. The second elongation cycle is enabled and a 
new  mixture  of  polymerase  and  the  four  labeled  reversible  terminators  is 
added. 
The  four color  fluorescence  scanner  delivers  a  plot  of  the  raw  fluorescence 
emission  intensity  at  the  four  designated  emission  wavelength  of  the  four 
chemically cleavable reversible terminators (see figure 6b).  
 
 
Figure 6b: Four color sequencing data plot obtained from SBS
[19b] 
 
The  sequence  of  the  template  can  directly  be  read  out  by  its  color  code 
obtained from the raw data plot (see figure 6a part B) without any processing. 
Before  the  fluorescence  scanner  was  used  as  detector,  the  SBS  method  has 
been evaluated in solution and each incorporation and deallylation step was 
checked  by  MALDI TOF  analysis
[19b,39c d].  With  this  first  SBS  experiment  the 
efficiency  of  the  reversible  terminators  regarding  their  incorporation  and 
cleavage was confirmed. The SBS system was transferred to an array system 
then
[19b]:  As  the  DNA  chip  offers  a  large  surface,  many  templates  can  be 
sequenced in parallel leading to simultaneous sequencing of a large number of 
DNA templates.  
When Ju et al. launched their first de novo sequencing on the chip, they had 
chosen  a  self priming  DNA  template  which  was  treated  with  a  solution 
containing all four dye labeled reversible terminators and the 9°N mutant DNA 
polymerase.  One  important  thing  to  mention  here  is  that  a  so called 
synchronizing  step  (also  known  as  capping  step)  had  to  be  introduced  for The invention of new sequencing technologies                          
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avoiding  any  lagging  fluorescent  signal  caused  by  previously  unextended 
priming strands
[19b].   
One big advantage over pyrosequencing as claimed by Ju et al. is the accurate 
determination of homopolymeric sequences by using the SBS method, a demand 
that is only poorly fulfilled by pyrosequencing. In order to confirm this fact, Ju 
et  al.  made  a  sequencing  experiment
[19b]  with  a  self priming  DNA  template 
bearing  two  homopolymeric  regions  (10  T’s  and  5  T’s)  and  used  their  SBS 
approach  as  well  as  pyrosequencing  for  comparison.  As  a  result  of  this,  all 
bases  as  well  as  the  homopolymeric  sequences  of  the  template  were 
unambiguously  identified  by  the  SBS  method.  Pyrosequencing  of  the  same 
template  gave  an  unprecise  sequence  data:  The  first  four  individual 
nucleobases were identified, but the homopolymeric  regions caused two big 
broad  peaks  in  the  plot  not  exactly  quantifying  the  number  of  the 
homopolymer. With the SBS technique in hand Ju et al. could sequence up to 
20  nucleobases  with  high  accuracy,  making  this  technique  interesting  for 
automatized  application.  By  2006,  the  Illumina  (former  Solexa)  Genome 
Analyzer as a “short read“ sequencing platform based on the SBS technique was 
commercially launched. The illustration in  figure 6c displays the sequencing 
principle: 
In  a  flow  cell  consisting  of  an  optically  transparent  slide  where  oligo 
nucleotide  anchors  are  bound,  an  adapter modified,  single stranded  DNA 
template is added and hybridized to these anchors. The bound templates are 
amplified then by “bridged” PCR: The captured DNA strands bend over and 
hybridize to an adjacent anchor. These arched templates are then amplified 
with  PCR  converting  the  single molecule  DNA  template  into  a  clonally 
amplified arching “cluster”. The clusters are denaturated, chemically cleaved 
and washed in a manner that only the single stranded templates remain on 
the  surface.  The  primer  is  then  hydridized  complementary  to  the  adapter 
sequences  and  a  mixture  of  polymerase  and  four  differently  dye labeled 
reversible  terminators  are  added.  The  polymerase  incorporates  the  dye 
labeled  nucleotide  complementary  to  each  template  strand  in  a  clonal 
cluster, then the excess of reagents is removed by a washing step and the 
clusters  are  optically  scanned  by  recording  the  fluorescence  signals.  The 
reversible dye terminators are then chemically unblocked, the fluorescence The invention of new sequencing technologies                          
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labels are removed and washed away and the next sequencing cycle can take 
place.  With  read lenghts  of  36  bases  within  2.5  days  the  Illumina  Genome 
Analyzer sequences much slower than the 454 pyrosequencing system from 
Roche. 
 
  
  Figure 6c: Scheme of the Illumina Genome Analyzer sequencing
[11]  
 
One disadvantage of the Illumina sequencer is that the base call accuracy is 
lowered by sequencing longer read lengths
[11]. This may be caused by under  or 
overincorporation of the nucleotides, also the removal of the blocking group 
might sometimes fail. These signal aberrations accumulate during successive 
sequencing cycles and form a heterogeneous population within a cluster. As a 
result of this, the fluorescence signal purity decreases and the base calling is 
hampered. Investigations in improving the sequencing technique as well as the 
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progress. 
1.4.3  The EU project “ArraySBS” and its aim 
 
The SBS method offers a new technology for detecting point mutations (SNPs) 
or  homopolymeric  regions  very  fast  and  in  high  accuracy.  Within  the  last  5 
years,  the  invention  of  a  commercially  available  sequencer  using  the  SBS 
technique based on 3′ modified dye labelled dNTPs was a big leap forward for 
the development of new sequencing techniques. Although the SBS technique is 
currently only applicable to shorter DNA sequences, it has already been put 
into practice and can be improved. 
As a consequence of this, competitive projects in developing an applicable SBS 
technique  were  started  in  the  last  years,  such  as  the  EU  craft  project 
“ArraySBS”. It was funded by the EU and started in august 2005
 consisting of a 
scientific and industrial consortium. The aim of the ArraySBS project was to 
provide proof of principle for the SBS setting on an array of primer features, 
where the 3′ end of the primer is extended with a reversible terminator. The 
project and its participants were divided into five main objectives, each of 
them dealing with different particular operational objectives as follows: 
 
    The development and synthesis of four dNTPs (A, C, G, T) with blocked 3′ 
end and labeled with a fluorescent dye, i. e. the four complete reversible 
terminators. 
 
    The  identification,  isolation  and  development  of  a  DNA  polymerase  that 
accepts  these  four  dye labeled  reversible  terminators  including  the 
polymerases’ evolution and improvement. 
 
    The development of a microfluidic device prototype that allows array SBS 
reactions  by  integrating  incubation  steps  at  different  temperatures  with   
controlled  agitation  of  reaction  components  over  the  entire  area  of  a 
microarray, including washing and regeneration procedures. 
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of  sequencing by synthesis  generated  data.  Besides  this  objective,  the 
base caller  should  be  modified  and  suitable  primers  for  the  p53 
resequencing  should  be  identified.  As  an  outcome  of  this,  software  for 
primer prediction and sequence data handling should be delivered at the 
end of the project. 
 
    The validation of the SBS technology through the resequencing assay of a 
coding  sequence  of  a  gene.  At  the  end  of  the  project,  the  array  SBS 
procedure should have reached a proof of principle stage with up to 100 
primer features on a microarray, in the best case the p53 gene should be 
sequenced by using the array SBS procedure. 
 
Besides the design and the development of 3′ modified reversible terminators, 
the  identification  of  a  DNA  polymerase  that  is  capable  to  accept  these 
reversible terminators was considered as one of the central goals of the Array 
SBS project. Rather limited success of such experiments described in literature 
indicated it to be a highly challenging endeavor. Several aspects of the system 
designed  to  incorporate  reversible  terminators  appeared  to  be  critical.  A 
polymerase suitable for our SBS approach needs to possess proper affinity as 
well  as  selectivity  towards  modified  nucleotides  along  with  an  adequate 
turnover  rate  and  propensity  to  form  terminated  DNA  which  remains  stable 
until the removal of 3′ modification by chemical means. In turn, the reversible 
terminator  itself  must  display  an  appropriate  balance  between  its  chemical 
stability during enzymatic incorporation and the ability to be unblocked under 
conditions that are mild enough for the DNA structure to be maintained for 
further manipulations. The necessity for tight compatibility of both partners 
makes the challenge even more profound. 
A strong collaboration within three years between the consortium members of 
the ArraySBS project should lead to the SBS proof of principle, putting great 
emphasis on the chemical and biochemical part of the project. 
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2 2    Development of an array based SBS method 
 
2.1  Selection of an appropriate polymerase for SBS 
 
2.1.1  Function and properties of a polymerase 
 
In any organism the replication of DNA happens based on a complex biological 
process that is supported by auxiliary enzymes such as ligases and helicases, 
but in principle catalyzed by polymerases. The first polymerase isolated was E. 
coli DNA Polymerase I obtained from cell extraction and purification of E. coli 
bacteria. This enzyme is one of the few well explored polymerases due to the 
fact that its crystal structure is known
[40]. The E. coli DNA Polymerase I has 
multifunctional properties within one polypeptide chain that contains various 
enzymatic activities which can be separated into different domains
[41] forming 
active  sites.  Consequently,  E.  coli  DNA  Polymerase  I  does  not  only  act  as 
replicant agent for DNA, it has also the ability of repairing DNA.  
For  efficient  PCR  as  well  as  for  other  applications  such  as  DNA  labeling, 
sequencing and amplification, a polymerase has to be reliable, accurate and 
fast. The property of incorporating the correct nucleobase into the template 
strand  is  called  “accuracy”  or  “fidelity”  of  a  polymerase.  The  fidelity  of 
polymerases is still of high interest and until now not fully understood: How 
does the enzyme know which nucleotide is to be incorporated in one particular 
position complementary to the template strand? 
First of all, recognition of the correct nucleotide by the polymerase is hardly 
ever  caused  by  suitable  hydrogen  bonding  between  the  complementary 
substrate nucleobase and the template nucleobase. Thus hydrogen bonding has 
a very low effect on the selectivity of the polymerase as it was demonstrated in 
studies  by  Kool  et  al.
[42a,b]  on  base pairing  behavior  of  universal  bases  and 
natural bases. The geometric selection of a nucleobase given by its size and 
shape influences more strongly the incorporation accuracy.  
Due to the sterical and electrostatical effects the active site of the polymerase 
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nucleobase substrate
[42,43]. An example of such a ternary complex, consisting of 
a nucleotide (ddCTP) and the template primer system bound to the active site 
of rat DNA Polymerase β was published by Pelletier et al. in 1994
[43]. Detailed 
data of this complex provided us with a deeper insight into the active site of a 
polymerase.  The  idea  behind  these  studies  was  to  crystallize  polymerase  β 
under  nearly  physiological  conditions  with  and  without  complexing  the 
template primer ddCTP  system  for  spectroscopical  analysis.  From 
crystallization a sort of “freezed” complexes were obtained and resolved by X 
ray  diffraction  analysis.  Moreover  Pelletier  et  al.  utilized  the  advantage  of 
stopping the DNA extension directly after nucleotide incorporation by the use 
of ddCTP instead of the naturally occurring dNTPs as substrates. One of the 
observations derived from the structural analytics was that the interaction of 
the enzymes’ amino acid residues between the atoms of the nucleobases (from 
primer template complex) plays an important role in bringing the template into 
the active site and giving it a preferred conformation.  
Another conclusion obtained from the X ray structural analysis was that Mg
2+ 
ions  in  the  active  site  of  the  polymerase  directly  induce  the  nucleotidyl 
transfer  reaction
[43,44]  (shown  in  figure  7):  A  new  phosphordiester  linkage  is 
formed while the 3′ hydroxyl of the terminal dNMP on the primer strand attacks 
the 5′ α phosphate. 
 
    
Figure 7: The nucleotidyl transfer reaction occurring in the active site of the polymerase
[43]  
 
In this manner the primer strand with n dNMPs is elongated up to (n+1) dNTPs 
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hydroxy function, where the next incorporation step can take place.  
A scheme of the active site of the polymerase with its ddCTP binding pocket is 
shown in figure 8 illustrating the transition state with the pentacoordinated α 
phosphate of ddCTP
[43]. 
 
 
Figure 8: The transition state during ddCTP incorporation on the polymerase β active site
[43] 
 
In the binding pocket of the active site, two Mg
2+ ions are clustered around the 
amino  acids  Asp  190,  Asp  192  and  Asp  256  from  the  polymerases’  primary 
structure. One of these cations is bound specifically to the β and γ phosphates 
of ddCTP while the negative charge on the α phosphate is neutralized by the 
second cation and the attack of the 3′ hydroxy group can occur in an in line 
fashion with release of pyrophosphate
[43]. This means that during the transition 
state the attacking (3′ hydroxyl of primer strand) and the leaving group (PPi) 
have to be in linear position relatively to the α phosphate occupying the two 
apical positions of the pentacoordinated α phosphate. The polymerase β active 
site is  very  similar to  the  3′ >5′ exonuclease  domain  of  E.  coli polymerase I 
which also possesses a two metal center involved in exonucleic activity
[45]. It is 
nonetheless still not clear which catalytic role the particular amino acids of the 
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play, although the structures of these enzymes are already resolved. 
Polymerases  that  are  optimal  for  DNA  replication  often  possess  the  already 
mentioned  3′ >5′  exonuclease  activity,  which  means  in  praxis  that  these 
enzymes do “proofreading”
[43,45] during PCR reaction as depicted in figure 9.  
Such a “high fidelity” polymerase has the ability to recognize if mismatched 
pairing  occurred  during  strand  extension  and  moves  the  mismatch  from  the 
polymerization  domain  to  the  3′ >5′ exonuclease  domain.  At  this  site  of  the 
polymerase, the mismatched base is cut off and the DNA template strand is 
then  transferred  back  into  the  polymerization  domain.  The  proofreading 
effectiveness often depends on the sequence of the  template: It was found 
that pyrimidine rich sequences are more effectively proofread than purine rich 
ones  due  to  the  lower  stability  of  AT stretches,  a  fact  that  facilitates  the 
proofreading.     
 
 
Figure 9: Proofreading (3′ >5′ exonuclease activity) during PCR 
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DNA polymerization behavior with ddCTP, Canard et al. found out that some 
polymerases lacking 3′ >5′ exonuclease activity (such as Taq DNA Polymerase 
and Sequenase) are capable of incorporating 3′ esterified dNTPs into the DNA 
template
[46]. Several incorporation tests were done using Taq DNA polymerase 
and  high  concentrations  of  3′ modified  dNTPs  because  natural  nucleotides 
occurring as impurities were preferentially incorporated over the 3′ modified 
ones.  The  Taq  polymerase  showed  to  be  tolerant  against  2′ deoxy 3′ 
anthranyloyl  nucleoside  triphosphates  (3′ ant dNTPs)  and  incorporated  these 
nucleotides correctly paired to the template strand. Canard et al. also made a 
fascinating observation when using especially Sequenase for the DNA extension: 
An 3′ esterified primer strand was synthesized chemically and hybridized with 
its complementary strand possessing an (dG)5 overhang (see figure 10). This 
template (3′ ant 21 mer) was incubated with Sequenase and titrated with [α 
32P]dCTP, which means that this radioactively labeled substrate was added in 
various concentrations as indicated by lanes 1 9 of gel picture in figure 10 (e. 
g. lane 1: 2.5 nM, lane 4: 25 nM, lane 6: 50 nM and lane 9: 1000 nM).  
 
 
Figure 10: (a) Structure and deprotection reaction of 3′ ant 21 mer with Sequenase and 
32P  
labeled dCTP; (b) Gel of the extension reaction under various dCTP concentrations 
(lane C: kinase treated control)
[46] 
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polymerization and the primer strand was extended up to a 25 or even 26 mer. 
This implies that the Sequenase has the ability of hydrolyzing the 3′ blocking 
group  from  the  primer  strand  enabling  incorporation  and  primer  strand 
extension,  a  behavior  which  the  Taq  polymerase  did  not  show  during  the 
incorporation  tests.  This  unexpected  result  was  named  “catalytic  editing”, 
which means that Sequenase exhibits a strong 3′ esterase like activity on the 3′ 
end  of  the  DNA  template
[46].  In  further  incorporation  assays  done  with 
Sequenase and 3′ amido dTTP and 3′ thioureido dTTP analogues
[47] the enzyme 
showed  the  same  result:  It  incorporates  these  3′ blocked  nucleotides  and 
hydrolyzes  them  leaving  a  3′ amino terminated  DNA  chain.  With  these 
incorporation tests Canard et al. could demonstrate that nucleotides bearing a 
bulky blocking group on the 3′ position are accepted and incorporated into the 
template by several polymerases, some of them, e. g. Sequenase, even able to 
hydrolyze the 3′ blocking group. 
The  research  group  of  Marx  et  al.  investigated  further  in  determining  the 
criteria for both selectivity and fidelity of several polymerases like the Human 
DNA Polymerase and E.coli DNA Polymerase I
[48]. The polymerase incorporation 
assays carried out with 4′ alkyl
[49a] or 4′ acyl
[49b] modified 2′ deoxythymidine 5′ 
triphosphates stressed the strong dependence of the polymerases’ selectivity 
from sterical effects. The close fitting of the Watson Crick geometry to the 
active site of the polymerase is claimed as one very important factor for the 
selectivity  in  nucleotide  insertion
[48,49].  When  a  nucleotide  is  not  properly 
inserted,  polymerases  often  generate  errors  by  deletion  of  a  nucleotide  or 
insertion of an additional nucleotide resulting in frame shift mutations
[48c]. As a 
reason  for  these  errors  misalignment  of  the  primer  template  complex  is 
claimed
[48c]. This means that polymerases exhibiting high misalignment fidelity 
might  form  tighter  binding  pockets  for  the  primer  template  binding.  These 
enzymes would tolerate only little geometric deviation and therefore prevent 
frame shift  mutations  resulting  from  nucleotide  deletions  and  insertions.  In 
contrast  to  that,  low  misalignment  fidelity  enzymes  would  tolerate  more 
geometric deviations resulting in a decreased fidelity
[48c].  
In order to enhance fidelity and selectivity of DNA polymerases, combinatorial 
enzyme design
[50] is an appropriate method for tailoring optimized polymerases 
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polymerase mutants which can be used for screenings of particular reaction 
conditions or substrates, e. g. the SBS technique.        
       
2.1.2  Polymerase selection with unlabeled reversible terminators 
 
The  effectiveness  of  the  sequencing by synthesis  technique  in  principle 
depends  on  the  quality  of  two  features:  The  polymerases’  fidelity  and 
selectivity is crucial on the one hand, on the other hand there exists a strong 
need for suitable 3′ blocked nucleotides that are unambiguously accepted and 
incorporated  by  the  polymerase.  For  the  development  of  our  SBS approach, 
several principal sources of enzymes were considered for screening, including 
commercially available and Fermentas proprietary polymerases, representing 
all families of DNA polymerases. After an initial screening performed using a 
number of 3′ modified nucleotides, the list of polymerases was narrowed to 23 
representatives with lower or even with absence of exonucleolytic activity.  
 
 
Figure 11: Our first 3′ modified reversible terminators without dye labeling
 
 
Further  polymerase  acceptance  tests  were  carried  out  with  some  selected 
unlabeled 3′ modified triphosphates shown in figure 11. For the SBS purpose 
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also patent protected like e.g. the allyl function
[51] (see figure 5 in chapter 
1.4.2). There was a need for alternative 3′ modifications that are not protected 
by patent like the already known and published 3′ blocking groups. A full range 
screening  program  was  executed  focusing  on  the  four  unlabeled  potential 
reversible  terminators  shown  in  figure  11,  featuring  methyldithio tert butyl 
(DTM),  methylthiomethyl  (MTM),  (2 cyanoethoxy)methyl  (CEM)  and  2 
cyanoethyl  (CE)  as  3′ protection  groups  albeit  many  more  were  investigated 
using  the  most  promising  polymerases  for  final  evaluation,  too.  The  DTM 
protective  group  as  one  of  the  first  reversible  3′ blocking  groups  for  chain 
terminators published by Kwiatkowski et al.
[52] has been found to be unstable 
during the enzymatical incorporation into the DNA template. In contrast to that 
the screening performed using 3′ O MTM dTTP was highly successful. However, 
efforts in identifying an appropriate method for 3′ protecting group removal 
while keeping the DNA structure intact failed. As a consequence of this, we 
were looking for similar 3′ modifications such as the formacetal type CEM and 
the  ether type  CE  protecting  group.  The  2′ deoxythymidine 5′ triphosphates 
possessing these groups as 3′ modifications were found to be incorporated very 
well  into  DNA  by  several  polymerases  and  also  terminated  further  primer 
extension. The results from the incorporation tests with these unlabeled 3′ 
modified triphosphates served as starting point for the design of the complete 
dye labeled reversible terminators as well as for the polymerase evolution.  
 
2.2  Polymerase acceptance tests 
 
2.2.1  Materials and methods 
 
The  following  incorporation  assays  were  done  at  Fermentas’  labs  in  Vilnius, 
Lithuania.  An excessive amount of enzymes was used, at a range of ten times 
over the substrate DNA or more. In some cases the exonucleolytic activity of 
the  polymerases  was  attempted  to  be  inhibited  by  the  addition  of  dTMP 
following recommendations found in literature
[53]. The 3′ modified dTTPs were 
cleaned in a so called “mop up” reaction
[54] for removal of the natural dTTPs 
that  were  often  present  in  a  small  concentration.  After  the  mop up,  the   Development of an array-based SBS method                                                                    
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polymerase  screening  was  performed  at  37  °C.  The  following  DNA  duplex 
template  was  used  in  experiments  featuring 
33P 5′ labelled  primer  strand 
(denoted by an asterisk): 
 
5′    *TGCAGGCATGCAAGCTTGGCGTA   3′        23nt 
3′     ACGTCCGTACGTTCGAACCGCATAAAAAAAAAAAA – 5′   35nt 
 
Polymerization was performed in 20 µl of the reaction mixture at 37 °C. After 
certain time periods (5, 15 and 60 minutes), an aliquot of the reaction mixture 
was  supplemented  with  dTTP  (up  to  50  µM  final  concentration)  and  the 
reaction was allowed to proceed for additional 5 min at the same temperature. 
The  reactions  were  stopped  by  adding  an  equal  volume  of  a  STOP  solution 
(Fermentas  catalogue,  item  #K1711:  CycleReader
TM  DNA  sequencing  kit) 
containing EDTA, then the products were resolved on 15 % 29:1 denaturing (7 M 
urea) polyacrylamide (PAA) gel run at 50 °C, dried on a Whatman paper sheet 
and autoradiographed using the Fuji phosphorimager screen. 
 
2.2.2  Incorporation of 3′ O CEM dTTP 
 
Some  polymerases  representing  different  classes  were  found  to  possess 
markedly  different  efficiencies  regarding  the  incorporation  of  3′ modified 
nucleotides into the DNA template.  
 
 
Figure 12: Primer extension by nine polymerases (numbered from 1 to 9) using 3′ O CEM dTTP  
after 60 min incubation time   Development of an array-based SBS method                                                                    
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The  gel  picture  displayed  in  figure  12  was  obtained  from  the  incorporation 
experiment  employing  3′ O CEM dTTP  as  reversible  terminator.  After  60  min 
incubation  time,  the  incorporation  of  the  CEM blocked  nucleotide  by  nine 
different  polymerases  is  controlled.  The  addition  of  the  naturally  occurring 
nucleotide  dTTP  after  the  incorporation  of  3′ O CEM dTTP  results  either  in 
elimination of the modified nucleotides from the extended primer or in further 
primer  extension  by  incorporation  of  dTTP.  Here,  only  two  polymerases 
(numbered  4  and  5)  exhibit  the  capability  for  both  primer  extension  and 
termination  as  indicated  by  the  red  circles.  However,  polymerase  5  is 
recognized by rather intensive exonucleolytic activity (primer shortening) and 
thus  is  barely  suitable  for  our  SBS approach.  In  case  of  polymerase  4  the 
provided  3′ blocked  nucleotide  is  not  only  incorporated  into  DNA  but  also 
terminates further extension by addition of dTTP.  
Regarding polymerase 4, also a small amount of (n+2) product is observed (see 
weak band above (n+1) band). To explain this, several mechanisms enabling 
the polymerase to avoid 3′  blocking of the primer and succeed with the DNA 
extension are known. One of them is the polymerase guided direct deblocking 
of this group, known as “editing” activity
[46]. This would result in removal of 
the 3′ blocking group without affecting the whole nucleotide. Another way is 
the  removal  of  the  whole  3′ modified  terminating  nucleotide  through 
triphosphate mediated  pyrophosphorolysis
[55a].  Both  mechanisms  are 
compatible with further primer extension when dTTP is present after the 3′ 
CEM dTTP incorporation step. 
 
2.2.3  Incorporation of 3′ O CE dTTP 
 
Besides the 3′ modified nucleotide 3′ O CEM dTTP, the similar compound 3′ O 
CE dTTP was also found to be incorporated into DNA by several polymerases 
and terminating further primer extension. The gel picture shown in figure 13 
illustrates the incorporation of 3′ O CE dTTP by selected polymerases. Here, 
polymerases  2,  4  and  5  possess  the  ability  to  incorporate  3′ O CE dTTP 
(indicated  by  red  circles)  while  the  efficiencies  of  incorporation  and 
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the primer; however, the termination is barely detectable. Thus, polymerases 4 
and 5 should be considered as the most effective in this experiment. 
 
 
Figure 13: Primer extension by nine polymerases (numbered 1 to 9) using 3′ O CE dTTP
 after 60  
min incubation time 
 
The ability of the polymerases to incorporate 3′ O CEM dTTP and 3′ O CE dTTP 
appears to be dependent on the size of the 3′ blocking group: The first one 
bears a bigger 3′ tag and is incorporated by only two polymerases compared to 
six different mutants in case of the 3′ CE labeled nucleotide. In addition, 3′ O 
CE dTTP  is  incorporated  nearly  two  times  fasted  under  identical  reaction 
conditions than 3′ O CEM dTTP (see figure 14). Based on the results described 
above, the 2 cyanoethyl (CE) group was recognized as the most promising for 
further work on optimization of primer extension and addressing the specificity 
issue for the polymerization reaction. 
  
 
Figure 14: Primer extension efficiencies using 3′ O CEM dTTP or 3′ O CE dTTP 
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Fine tuning of the reaction mixture increased the reaction speed up to the ten 
fold, driving the reaction of the primer extension to near completion in 5 min 
(not  shown).  This  timescale  is  considered  to  be  compatible  with  our  SBS 
approach. 
 
2.2.4  Concluding remarks 
 
Several  principal  sources  of  enzymes  were  considered  for  the  screening, 
including  commercially  available  and  Fermentas  proprietary  polymerases, 
representing all families of DNA polymerases. After initial screening tests done 
at Fermentas’ labs using number of 3′ modified nucleotides, 23 polymerases 
showed acceptance towards 3′ modified dTTPs with lower or absent nucleolytic 
activity,  both  of  mesophylic  and  thermophylic  origin.  A  full range  screening 
program was executed focusing on four 3′ modified dTTP’s, featuring methyldi 
thioterbutyl (DTM), methylthiomethyl (MTM), (2 cyanoethoxy)methyl (CEM) and 
2 cyanoethyl (CE) as 3′ protective groups albeit many more were investigated 
using the most promising polymerases for final evaluation, too.  
As  a  result  of  these  first  screenings,  3′ O CEM dTTP  and  3′ O CE dTTP  were 
found to be incorporated into the DNA template by several polymerases and 
terminating further primer extension thus fulfilling the requirements raised. In 
summary,  two  polymerases  capable  to  incorporate  3′ O CEM dTTP  and  six 
polymerases  incorporating  3′ O CE dTTP  were  discovered  making  the  2 
cyanoethyl  blocking  group  more  attractive  for  further  enzymatic  tests 
regarding the complete reversible terminators.            Goal of PhD thesis                                                                                                             
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3 3    Goal of this PhD thesis 
 
Based on the encouraging results from the polymerase acceptance tests with 
unlabeled 3′ O modified dTTPs, the main objective of the ArraySBS project was 
the design and the synthesis of four complete reversible terminators. This PhD 
thesis covers the synthesis of the four 3′ modified key compounds needed as 
building  blocks  for  the  synthesis  of  the  complete  dye labeled  reversible 
terminators as shown in figure 15. Using these reversible terminators further 
enzymatic tests and the development of a polymerase affording the SBS proof 
of principle should be performed. The design and synthesis of the linker, the 
triphosphate synthesis and the dye linker attachment will be published soon in 
another PhD work
[55b]. 
 
 
Figure 15: The four key compounds of the complete reversible terminators 
 
For successful preparation of the four key compounds (highlighted by circles in 
figure 15), the following points had to be addressed within this work: For each             Goal of PhD thesis                                                                                                             
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key compound, a multi step procedure consisting of nucleoside preparation and 
nucleoside  modification  had  to  be  designed  and  put  into  practice.  Another 
important  issue  was  the  spectroscopic  characterization  of  each  synthetic 
intermediate, which often had no spectroscopical reference data. 
Another main objective of this PhD thesis was the evaluation of quantitative 
cleavage of the 3′ modifications like the (2 cyanoethoxy)methyl (CEM) and the 
2 cyanoethyl (CE) group. Therefore a suitable experimental procedure as well 
as  simple  model  compounds  and  appropriate  cleavage  reagents  had  to  be 
identified. The results from the cleavage tests on a simple model compound 
should be applicable to the complete SBS system then, consisting of a defined 
template like e. g. the p53 suppressor gene immobilized on a chip, the four 
complete dye labeled reversible terminators bearing the 3′ blocking group and 
a highly tolerable polymerase designed for these special nucleotides.Synthesis of reversible terminators for SBS                                                                          
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4 4    Synthesis of reversible terminators for SBS    
4.1  Retrosynthesis of the four 3′ O modified key compounds 
4.1.1  Retrosynthesis of the key compound for the A terminator 
 
The retrosynthesis of the key compound that is needed for the preparation of 
the A terminator is shown in scheme 1. 
 
 
Scheme 1: Retrosynthesis of the key compound for the A terminator 
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As it is depicted in scheme 1, the nucleobase 4 amino 5 iodo 7 (2 deoxy β D 
erythro pentofuranosyl) 7H pyrrolo[2,3 d]pyrimidine  had  to  be  synthesized 
first.  This  means  that  a  multi step  procedure  containing  the  heterocyclic 
chemistry and a glycosylation step had to be used for building this particular 
nucleoside  since  this  compound  is  hardly  commercially  available  and  very 
expensive. The heterocycle preparation, the glycosylation and the protecting 
group strategy form a laborious synthetic procedure, starting from gram scale 
and ending up in milligram scale leading to the desired key compound. The 
synthesis  here  looks  straight  forward  at  first  sight,  but  it  also  had  to  be 
elaborated initially because only parts of this synthetic pathway were known in 
literature: For example, the preparation of the heterocycle was already well 
established  by  Davoll
[56]  in  the  1960’s,  the  chlorination,  iodination  and 
glycosylation  were  optimized  by  others  decades  later.  The  challenging  part 
after  the  synthesis  of  the  5 iodo pyrrolo[2,3 d]pyrimidine  nucleoside  was  to 
find the shortest protecting group strategy enabling selective introduction of 
the cyanoethyl group to the 3′ end via Michael addition. After introduction of 
the propargylamine moiety  to  the  nucleobase, the  key  compound  should  be 
obtained. 
  
4.1.2  Retrosynthesis of the key compound for the G terminator 
 
The G terminator was prepared in a similar manner like the A terminator as 
displayed in scheme 2a. Here, all reactive functional groups on the heterocyclic 
moiety had to be protected as well as the 5′ hydroxyl function for selective 3′ 
introduction of the CE group. This multistep protection group strategy had to 
be evaluated first on 2′ deoxyguanosine to give the shortest synthetic pathway 
with optimized yields for each step. Another big difference in the synthesis of 
the  G terminator,  compared  to  the  synthesis  of  the  A terminator,  is  the 
modified  attachment  of  the  dye linker  system
[55b]  that  did  not  need  the 
introduction of the propargylamine moiety anymore, saving two extra synthetic 
steps.  In  general,  the  synthesis  of  2 amino 5 iodo 7 (2 deoxy β D erythro 
pentofuranosyl) 7H pyrrolo[2,3 d]pyrimidin 4 one  (see  scheme  2b)  employs  a 
few steps more but is based on the same strategy of heterocycle preparation Synthesis of reversible terminators for SBS                                                                          
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and  glycosylation  method  as  the  one  used  for  the  synthesis  of  the  key 
compound for the A terminator.  
 
 
Scheme 2a: Retrosynthesis of the key compound for the G terminator part 1 
 
 
Scheme 2b: Retrosynthesis of the key compound for the G terminator part 2 
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the 2 amino group is masked as methylthio function
 for simplification of the 
glycosylation. Besides this strategy, there are several publications about the 
glycosylation  step  employing  the  amino protected  heterocycle.  This  work 
covers and discusses both possibilities and which one of them proved to be 
more successful in our hands. Aside from the nucleoside preparation, the whole 
protecting  group  strategy  for  enabling  3′ O selective  introduction  of  the  CE 
function is elaborated within this work. In our case the preparation of the 5 
iodo pyrrolo[2,3 d]pyrimidine nucleoside itself was crucial due to huge loss of 
product during the multi step synthesis. For this reason we decided to purchase 
2 grams of this nucleoside at the final stage of the project.  
 
4.1.3  Retrosynthesis of the key compound for the C terminator 
 
The retrosynthesis of the C terminator key compound is shown in scheme 3.  
 
 
Scheme 3: Retrosynthesis of the key compound for the C terminator 
 
Only the iodine function has to be introduced into 5 carbon position, then a 
smart protection group strategy enables 3′ O selective introduction of the CE Synthesis of reversible terminators for SBS                                                                          
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function followed by the attachment of the propargylamine moiety. Compared 
to the syntheses of the A  and the G terminator few steps less are needed to 
obtain  the  3′ O CE blocked  key  compound  with  the  propargylamine  linker 
attached to the base moiety. The preparation of the C terminator is shorter 
and more economical than the syntheses of the pyrrrolo[2,3 d]pyrimidine base 
terminators delivering sufficient amount for further synthetic steps
[55b]. 
 
4.1.4  Retrosynthesis of the key compound for the T terminator 
 
The synthesis of the T terminator is the shortest and simplest one compared to 
the methods for the preparation of the other three terminators as shown in the 
retrosynthetic analysis (scheme 4).  
 
 
Scheme 4: Retrosynthesis of the T terminator 
 
One  big  advantage  is  the  commercial  availability  of  5 iodo 2′ deoxyuridine 
providing us with enough starting material for the preparation of the whole 
terminator in larger amounts. Here an elegant protecting group strategy was 
evaluated for enabling selective introduction of the 2 cyanoethyl function on 
the 3′ hydroxyl (see scheme 4). As described before, the CE function can only Synthesis of reversible terminators for SBS                                                                          
50 
be introduced selectively if any other acidic protons are protected during the 
Michael reaction. The Sonogashira reaction with subsequent liberation of the 
amino  function  enables  the  dye linker  attachment
[55b].  These  four  retro 
syntheses presented in this work are four possible synthetic solutions for the 
preparation the desired key compounds. We have chosen these four strategies 
because  they  meet  the  criteria  of  the  shortest  syntheses  with  yield 
optimization for many of the synthetic steps.  
 
4.2  Strategy for selective 3′ alkylation of 2′ deoxyguanosine  
4.2.1  Dialkylation of partially protected 2′ deoxyguanosine 
 
As already presented in the retrosynthetic analysis of the G terminator, a smart 
protecting  group  strategy  for  the  selective  introduction  of  the  2 cyanoethyl 
function on the 3′ position had to be developed. As test nucleoside for this 
evaluation,  we  used  2′ deoxyguanosine  instead  of  the  expensive  2 amino 5 
iodo 7 [2 deoxy β D erythro pentofuranosyl] 7H pyrrolo[2,3 d]pyrimidin 4 one. 
 
 
 Scheme 5: Dialkylation of partially protected 2′ deoxyguanosine 
 
One  obstacle  in  selective  alkylation  via  the  Michael  addition
[57a]  of  the  3′ Synthesis of reversible terminators for SBS                                                                          
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position is the high reactivity and therefore poor selectivity of acrylonitrile that 
is  added  to  any  nucleophilic  function  of  2′ deoxyguanosine.  We  could 
demonstrate the low selectivity by carrying out the following test alkylation, 
see scheme 5. The dialkylated nucleoside 4 was formed as single product as 
confirmed  by  mass  spectrometry  and 
1H NMR  analysis  (mass  spectrum  see 
Annex). The reason for this may be explained by having a closer look at the 
reaction on the nucleoside as shown in scheme 6.  
 
 
Scheme 6: Concurring sites during Michael addition 
 
Cesium carbonate acts as base and preferentially deprotonates the more acidic 
amide  proton.  The  resulting  anion  is  well  stabilized  and  is  alkylated  with 
acrylonitrile. The attempt to remove the CE group selectively from the  N3 
position of compound 4 was not successful: this moiety could not be cleaved 
without  affecting  the  3′ O (2 cyanoethyl)  group  by  treating  the  dialkylated 
nucleoside with TBAF/THF. As a conclusion from this experiment we decided to 
change our synthetic strategy for enabling selective 3′ alkylation. 
 
4.2.2  Selective 3′ alkylation of fully protected 2′ deoxyguanosine 
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guanosine was protected except the 3′ hydroxy group. The formamidino moiety 
on the exocyclic amino function showed to be stable enough during further 
synthetic steps, also the MMT function on the 5′ position could be introduced in 
good yield, but still the 3 amido function remained unprotected and could not 
be  selectively  protected  in  the  presence  of  the  free  3′ hydroxy  function. 
Transient  protection  of  the  3′ hydroxy  function  with  chlorotrimethylsilane 
(TMSCl) and subsequent benzoylation on 3 nitrogen position failed, so we had 
to use a different approach, as it is demonstrated in scheme 7a. 
 
 
Scheme 7a: Transient protection for selective benzoylation of the N3 position 
 
For quantitative protection of the hydroxyl functions, we discovered that the 
Markiewicz group
[58] was the appropriate choice: It is not as labile as the TMS 
groups, but on the other hand not too stable like e. g. tert butyltrimethylsilyl 
groups. Another big advantage of the Markiewicz protection is its quantitative 
and highly selective introduction, even though the isolation of the Markiewicz 
protected  2′ deoxyguanosine  is  difficult  due  to  the  fact  that  the  nucleoside 
tends to form emulsions during the aqueous workup. In order to achieve a high 
yield  of  protected  nucleoside  6  ready  for  selective  benzoylation,  the 
formamidino  function  was  introduced  in  situ:  After  quenching  the  first 
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was  not  isolated  but  immediately  treated  with  N,N dimethylformamide 
dimethyl  acetal  in  methanol  giving  the  desired  compound 6  in  an  excellent 
yield of 83 % over two steps. The benzoylation of the 3 nitrogen function gave 
in moderate yield the fully protected compound 7. We also suggested other 
protecting groups for the 3 nitrogen position, even though there were only few 
alternatives published
[59]. One example we tried before the benzoyl protection 
was the triisopropylbenzenesulfonyl group readily introduced to the 4 carbonyl 
position
[59c]. 
 
 
Scheme 7b: Preparation of fully protected 3′ O CE 2′ deoxyguanosine 
 
Nevertheless  this  group  was  too  labile  and  substituted  easily  with  good 
nucleophilic  bases  like  ammonia
[59c]  or  fluoride,  making  it  useless  for  our 
synthetic strategy. Also the benzyl
 protection
[60] of the 4 oxygen position is not 
the  best  choice  here:  it  is  only  Pd catalyzed  and  removable  under  harsh 
conditions
[60] and therefore too stable for our purposes. In contrast to that, the 
benzoyl  group  is  quantitatively  cleavable  in  aqueous  ammonia,  but  stable 
during the next synthetic steps (see  scheme 7b). The Markiewicz protecting 
group  was  removed  quantitatively  under  mild  conditions,  i.  e.  deprotection 
with  triethylamine  trihydrofluoride  in  THF
[57a]  instead  of  TBAF  in  THF.  The 
resulting nucleoside 8 had to be dried very well for the next step, the selective 
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depending on the type of protecting group: Contrary to our expectation, the 
MMT protection step
[57b,c] (see scheme 7b) was quite ineffective so that half of 
the starting material 9a was isolated even though DMAP was used as catalyst 
for  this  reaction.  In  contrast  to  that,  the  5′ benzoylation  at   20  °C  as  an 
alternative protection delivered compound 9b in a satisfying yield of 86 %. The 
Michael addition for introduction of the CE group gave the opposite results: 
Here,  the  reaction  with  MMT protected  nucleoside  9a  was  more  efficient 
yielding 81 % product 10a than the Michael addition performed with the 5′ 
benzoyl protected starting material 9b. Besides that, the obtained compound 
10b was hard to purify and therefore used without further purification for the 
deprotection step. The removal of both benzoyl  and MMT protection groups 
gave an unexpected outcome as it is illustrated in scheme 7c. 
 
 
Scheme 7c: Deprotection of benzoyl  and MMT protected nucleosides 
 
At  first,  the  attempt  to  remove  the  N3 benzoyl  and  the  formamidino  group 
from  the  MMT protected  nucleoside  10a  was  ineffective:  The  formamidino 
group was hardly removable and extremely stable while the benzoyl function 
was cleaved in high amount. The solvents and the ammonia were then removed 
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spectroscopy. In order to prevent loss of material, it was decided to skip the 
purification of the product and subject it directly to the next deprotection step 
for  MMT removal.  Employing  an  excess  of  pTSA  did  not  lead  to  the  desired 
deprotection  first,  but  the  addition  of  a  slight  excess  of  TFA  started  the 
reaction.  Unfortunately  the  reaction  did  not  proceed  as  expected:  The 
resulting products detected via TLC showed a high polarity complicating the 
isolation and purification of the crude product. The main fraction isolated after 
a short flash chromatography was analyzed with ESI mass spectrometry. The 
spectrum is shown below in figure 16 revealing the peak of the deprotected 
nucleoside 13, but also signals from lower masses. 
 
 
Figure 16: ESI(+) mass spectrum of the product from the MMT deprotection 
 
We  assume  that  nucleoside  12  hydrolyzed  under  these  strong  acidic 
conditions.  Unlike  nucleoside  10a, the  5′ benzoyl  protected compound  10b 
was deprotected with aqueous ammonia delivering the desired product 11 in 
moderate  yield.  The  design  of  the  described  test  synthesis  of  3′ O (2 
cyanoethyl) 2′ deoxyguanosine helped us at last to achieve the ultimate goal, 
the efficient preparation of 2 amino 7 [2 deoxy β D erythro pentofuranosyl] 
7H pyrrolo[2,3 d]pyrimidin 4 one.  
 
 
 
 Synthesis of reversible terminators for SBS                                                                          
56 
4.3  Synthesis of the 3′ modified key compounds 
4.3.1  Synthesis of the pyrrolo[2,3 d]pyrimidine moiety: Strategy 1  
 
For  the  preparation  of  both  the  A   and  the  G   terminator,  the  natural 
nucleosides 2′ deoxyadenosine and 2′ deoxyguanosine are not applicable due to 
the fact that it is impossible to attach a linker dye system at their 5 position. 
For  enabling  such  an  attachment,  both  nucleobases  have  to  be  iodinated 
pyrrolo[2,3 d]pyrimidine nucleosides. Herein and also in the following chapters 
we have chosen the systematic numbering for all compounds formed during the 
syntheses of the A  and the G terminator (see figure 17). 
  
 
Figure 17: Systematic numbering and purine numbering 
 
The most common synthetic strategy reported in literature is to prepare the 5 
iodo pyrrolo[2,3 d]pyridine  derivative  following  Davoll’s  protocol
[56]  first  and 
glycosylate the heterocycle afterwards. One attempt for the synthesis of the 
nucleobase moiety we have chosen is shown in scheme 8. We selected 2 amino 
6 hydroxy 2 mercaptopyrimidine 14 as commercially available starting material 
here due to the fact that 2 amino 6 hydroxypyrimidine is hardly available and 
of high cost. 
Therefore we started the synthesis with the methylation
[61] of compound 14: 
Iodomethane acts as a very selective sulfur methylation agent under alkaline 
conditions in water. The thiol function is deprotonated with sodium hydroxide 
and undergoes a nucleophilic substitution to form the methylated heterocycle.  
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Scheme 8: Preparation of the pyrrolo[2,3 d]pyrimidine moiety, method A 
 
   
Scheme 9: Mechanism of the condensation reaction 
 
Converting  product  15  into  compound  16  was  achieved  by  using  Barnett’s 
method
[62],  but  the  resulting  yield  was  only  moderate  around  50  %  due  to 
workup  problems:  During  the  alkylation  of  the  pyridine  ring  with 
bromoacetaldehyde diethylacetal in water the product precipitated not only as 
crystals, but as well as a yellow sticky mass. This kind of polymerized product 
was often formed in large quantities if the suspension was too concentrated 
and not stirred vigorously. The reason may be that the open heterocycle, which Synthesis of reversible terminators for SBS                                                                          
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exists  during  the  alkylation  with  bromoacetaldehyde,  does  not  only  react 
intramolecular, but intermolecular as well. It was not possible to prevent this 
problem  completely  even  while  running  the  reaction  in  high  dilution.  The 
mechanism of the reaction is shown in scheme 9 illustrating the condensation 
between the pyrimidine ring and the bromoacetal: In an extra flask, the acetal 
protected  bromoaldehyde  was  activated  with  hydrochloric  acid.  The  acidic 
solution was then buffered with sodium acetate and added to the suspension of 
compound  15.  With  heating  and  strong  stirring,  the  condensation  reaction 
could  take  place  and  the  heterocycle  16  was  formed.  The  2 methylthio 
function of heterocycle 16 was selectively removed then by using Raney nickel 
under  conditions  as  described  in  literature
[66].  It  is  recommended  that  the 
reaction mixture should not reflux longer than 3 h, otherwise the heterocycle 
decomposes. The nickel aluminum alloy was removed via filtration over Celite 
while  the  solvent  was  still  hot.  This  technique  prevented  that  most  of  the 
product 17 got stuck in the filter cake and could be isolated in moderate yield 
after concentration of the filtrate.  
For  further  synthesis,  it  was  useful  to  mask  the  4 hydroxy  moiety  with  a 
chlorine function as reported in literature by Seela et al.
[63]. The chlorination 
with POCl3 had to be carried out carefully without overcoming the reaction 
time of roughly 4.5 h. This reaction often led to low yields: Using the very 
protic  and  reactive  phosphorus  oxychloride  as  reagent  and  solvent  made  it 
impossible to monitor the reaction via TLC. A reaction time of less than 45 min 
did not convert the starting material 17 into the desired product 18. We also 
used N,N dimethylaniline once for activating phosphorus oxychloride
[64] and ran 
the  reaction  longer  (between  2  and  4.5  h),  but  the  yield  of  the  desired 
compound  18  did  not  increase.  According  to  this  unhandy  chlorination,  the 
extraction of the product from the acidic aqueous layer was also not optimal. 
The product showed only low solubility in any organic solvent like methylene 
chloride, n hexane, chloroform, diethyl ether etc., complicating its isolation. 
The most efficient extraction solvent was ethyl acetate, but still big amounts 
of this solvent were needed for the extraction of product 18. In some cases the 
yield was only around 30 % of pure and crystalline product and although this 
reaction was repeated a few times the yield did never surpass roughly 50 %. In 
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well. In principle, both 5  and 6 carbon may abstract the electrophilic iodine, 
but if only 1.1 equiv. of N iodosuccinimide are added, the 5 carbon position is 
preferentially  iodinated.  The  reaction  was  carried  out  in  dry  methylene 
chloride or DMF and gave always compound 19 as single product with yields 
ranging from 80 to 90 %. Looking at synthetic strategy 1 for the preparation of 
heterocycle 19 an overall yield of roughly 7 % over 5 steps was achieved. This 
means the synthetic strategy was still not optimized and had to be started in 
large gram scale for isolation of sufficient amount of product.  
 
4.3.2  Synthesis of the pyrrolo[2,3 d]pyrimidine moiety: Strategy 2 
  
Besides the first strategy starting with the Barnett method, we tried another 
more conventional synthetic route shown in scheme 10. The second route has 
one  reaction  step  more  and  uses  the  first  steps  as  reported  in  Davoll’s 
protocol
[56].  
 
 
Scheme 10: Preparation of the pyrrolo[2,3 d]pyrimidine moiety, method B 
 
The synthesis started again with bromoacetaldehyde diethylacetal that forms 
the α cyanoester 21 with ethylcyano acetate under alkaline conditions and in 
moderate yields of about 60 %. This α cyanoester could then be condensated 
with  thiourea  to  give  compound  22  in  moderate  yield.  The  following  ring 
closure always worked quantitatively in acidic medium. The 2 thiol function Synthesis of reversible terminators for SBS                                                                          
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was also removable with Raney nickel, but this time we ran the reaction in 
aqueous ammonia
[56] for forming a clear solution of starting material 23. The 
chlorination  as  well  as  the  iodination  of  compound  17  was  carried  out  as 
already described for synthetic route 1. The overall yield of synthetic strategy 
2 was 19 % over 6 steps. Comparing synthetic strategy 1 (overall yield ca. 7 %, 
see chapter 4.3.1.) with synthetic strategy 2, the desired heterocycle 19 was 
delivered in more than double amount. Although synthetic strategy 2 employs 
one step more than strategy 1, it reveals a much higher efficiency during the 
desulphurization and therefore is the more efficient one. 
 
4.3.3  Synthesis of 4 amino 7 [2 deoxy β β β β D erythro pentofuranosyl] 5 iodo 
7H pyrrolo[2,3 d]pyrimidine 
 
With the halogenated pyrrolo[2,3 d]pyrimidine moieties 18 and 19 in hand, one 
part  of  the  nucleoside  was  already  successfully  prepared.  The  second  part 
needed for building the adenosine derivative was the sugar moiety.  
 
 
Scheme 11: Preparation of the sugar moiety according to Rollard et al.
[67] 
 
The  sugar  compound  2 deoxy 3,5 di O p toluoyl α D erythro pentofuranosyl 
chloride 27 (see scheme 11) was synthesized by using the conventional method 
of  Rolland  et  al.
[67]  This  three step  procedure  started  with  a  simple  acetal 
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at room temperature into compound 25. After quenching and aqueous workup, 
the  residual  oily  acetal  25  was  coevaporated  three  times  with  pyridine, 
dissolved in dry pyridine and cooled down to 0 °C. Roughly 2.1 equiv of p 
toluoyl chloride were added drop wise within 1 h and after stirring the mixture 
overnight at 4 °C the reaction was complete. After an aqueous workup and 
evaporation of the solvent, the resulting syrup containing fully protected sugar 
26 was diluted in 40 ml acetic acid. In an Erlenmeyer flask, the HCl generating 
mixture was prepared by addition of acetyl chloride to acetic acid on cooling. 
The optimal temperature range for this was around 5 – 15 °C, then a small 
amount of water was added to that mixture starting the generation of HCl. The 
diluted sugar was subsequently added to this mixture via pipette on cooling. 
The  colorless  crystals  consisting  mainly  of  the  α isomer  of  27  precipitated 
immediately  after  completion  of  sugar  addition.  They  were  subsequently 
filtered  off,  washed  with  dry  diethyl  ether  for  acid  removal  and  dried  in 
vacuum. This kind of fast handling made it possible to isolate the desired α 
isomer in high purity: Usually only less than 1 or 2 % consisted of the β isomer, 
although the overall yield of the desired compound 27 is often low. The high 
isomeric purity was necessary due to the difficult  purification of the chloro 
sugar. This compound is very sensitive to humidity so that only crystallization in 
tetrachlorocarbon or chloroform can be employed as purification step without 
separating both isomers.  
In  our  case,  the  chloro  sugar  was  used  without  further  purification  for  the 
glycosylation  reaction  with  the  base  moiety  like  compound  18  or  19.  In 
principle, one can chose different glycosylation methods: One possibility is the 
method employing sodium hydride
[64,68f] (60 % in mineral oil) as strong base in 
dry acetonitrile, like it is shown in scheme 12a (method C). An alternative to 
this is the phase transfer glycosylation which Seela et al. used several times for 
the preparation of different nucleobases
[63,65,68a e] (see scheme 12a methods A 
and B). The phase transfer catalyst Seela group often used was tris(3,6 dioxa 
heptyl)amine (TDA 1): TDA 1 complexes the potassium cation from potassium 
hydroxide and releases the free alkaline anion to deprotonate the heterocycle 
18 (or 19) in acetonitrile. Subsequently the chloro sugar 27 is added to the 
mixture, and the anionic heterocycle reacts immediately at its 7 nitrogen with 
it in a nucleophilic substitution type reaction. Synthesis of reversible terminators for SBS                                                                          
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Scheme 12a: The glycosylation method according to Seela
[68] 
 
The chloride function of the sugar can readily be replaced with inversion of the 
configuration.  That  means  pure  α isomer containing  chloro  sugar  27  is 
converted  into  pure  β isomer  of  nucleoside  29.  Characterization  of  these 
isomers was achieved by an ROESY NMR experiment. If the sugar consisted of 
both  isomers,  a  mixture  of  α   and  β nucleosides  was  obtained  after 
glycosylation.  This  issue  makes  it  so  important  that  nearly  α isomeric  pure 
sugar compound 27 is applied. We achieved the highest yields of nucleoside 29 
with glycosylation method C
[64,68f](see scheme 12a): In this case, yields between 
75  and  90  %  of  the desired  β isomer  were  obtained.  Compared  to this, the 
phase transfer  catalyzed  glycosylation  had  one  big  disadvantage  when  using 
potassium  hydroxide  as  base:  After  the  hydroxyl  anion  had  deprotected  the 
heterocycle, it turned  into  water  which  led  to  sugar hydrolysis.  In  order to 
prevent  this,  potassium  hydroxide  was  substituted  by  using  potassium 
hexamethyldisilylamide (KHDMSA). The yield of the desired α isomer increased 
from 30 % to 51 %, but still was not satisfying. One reason for this might be the 
lowered  reactivity  of  the  heterocycle  anions:  Regarding  the  nucleophilicity, 
heterocycle  19  is  even  less  nucleophilic than heterocycle  18  caused  by the 
electron withdrawing 5 iodine substituent. 
Contrary to our assumption, the introduction of iodine in 5 carbon position of 
nucleoside 28 after glycosylation was not possible in our hands. For prevention Synthesis of reversible terminators for SBS                                                                          
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of this problem, it was decided to introduce the iodine into the pyrrolo[2,3 
d]pyrimidine moiety first. At that stage, only two more steps in the synthesis of 
4 amino 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]pyri 
midine  31  were  needed.  One  of  them  was  the  cleavage  of  the  p toluoyl 
protecting groups (see scheme 13). This was achieved in nearly quantitative 
yield by simply stirring nucleoside 29 in aqueous methanolic ammonia at room 
temperature overnight. The chlorine in 4 carbon position is very sensitive to 
nucleophiles,  so  we  had  to  be  aware  of  the  reaction  temperature  not 
surpassing 30 °C. At elevated temperatures, the chlorine is partially replaced 
by a methoxy group resulting in formation of the undesired nucleoside 32. 
 
 
Scheme 13: Deprotection and conversion of the 4 chloro function 
 
For the aminolysis of the chlorine function, the conventional autoclave method 
was  used
[68a].  For  that  purpose  the  starting  material  30  was  dissolved  in 
methanol and aqueous ammonia, sealed in a Parr autoclave and heated several 
hours under the pressure being generated while heating. This reaction was also 
tried twice in microwave which led to shorter reaction times. Under conditions 
B depicted in scheme 13 it was possible to reduce the reaction time to 3 h. 
Although the aminolysis worked quite well employing both methods, no further 
microwave assisted  trials  were  done  due  to  handling  problems  by  using 
methanolic  ammonia.  This  aggressive  solvent  tends  to  spill  over  in  the Synthesis of reversible terminators for SBS                                                                          
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microwave  apparatus  so  that  parts  of  it  may  get  affected  and  broken.  For 
bigger  amounts  of  starting  material,  the  Parr  bomb  method  was  the  more 
applicable one. Using the most efficient steps of the routes shown in schemes 
12a  and  13,  we  achieved  an  optimal  overall  yield  of  67  %  of  4 amino 7 [2 
deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]pyrimidine 31 over 
three steps, starting from the glycosylation until deprotection and aminolysis.  
 
4.3.4  Synthesis of 4 amino 5 [3 amino prop 1 ynyl] 7 [3 O (2 
cyanoethyl) 2 deoxy β β β β D erythro pentofuranosyl] 7H pyrrolo[2,3 
d]pyrimidine  
 
In order to enable the attachment of a dye linker system on nucleoside 31, a 
propargylamine moiety had to be introduced to the 5 carbon position.  
 
 
Scheme 14a: The 3′ O selective introduction of the CE function on nucleoside 31 
 
In addition to that the 3′ end of the nucleoside had to be blocked with the 2 
cyanoethyl function (see scheme 14a). For the 3′ O selective insertion of the CE 
group it was essential that all acidic protons of the nucleoside 31 except the 3′ 
hydroxy function itself were protected. We employed the formamidino group 
for protecting the exocyclic 4 amino function
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was  highly  amino selective,  furnishing  compound  33  in  good  yield  without 
formation of any side products. Compared to this the 5′ O benzoylation of the 
deoxyribose  moiety  could  only  reach  high  5′ selectivity  if  the  reaction  was 
carried  out  at  low  temperatures
[70]:  Here,  the  best  yield  of  the  desired 
nucleoside  34  was  achieved  by  dropwise  addition  of  approximately  1  equiv 
benzoyl chloride, diluted with dry dichloromethane, at  20 °C in dry pyridine. 
The  resulting  nucleoside  34  showed  excellent  solubility  in  the  tert butanol 
/acrylonitrile  solvent  system  employed  for  the  Michael  reaction
[57a].  For 
complete conversion of the starting material it was necessary to apply a certain 
experimental setup: The suspension caused by the insoluble cesium carbonate 
was  vigorously  agitated  in  an  Erlenmeyer  flask  (instead  of  a  common  used 
round flask) with a triangle stirring bar. This geometry of the reaction vessel 
enabled sufficient mixing and activating of the inorganic base. Besides that, it 
avoided the polymerization of the excess acrylonitrile during the reaction. 
After  isolation  of  the  cyanoethylated  nucleoside  35  both  protecting  groups 
could  be  removed  with  a  mixture  of  saturated  methanolic  ammonia  and 
concentrated  aqueous  ammonia.  The  resulting  compound  36  underwent  a 
Sonogashira reaction
[72] for the introduction of the propargylamine function on 
5 carbon position
[73] (see scheme 14b).  
 
 
Scheme 14b: Final steps for preparation of key compound 38 
 
In  principle,  this  reaction  was  always  carried  out  in  the  same  manner:  The 
nucleoside 36 was dissolved in dry DMF and treated with 5 equiv TEA, degassed 
three times, then allowed to warm up to room temperature and treated with 
0.2 equiv copper iodide, 0.1 equiv tetrakis(triphenylphosphine)palladium and Synthesis of reversible terminators for SBS                                                                          
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with 2 equiv of trifluoroaceto 3 aminopropargyl. The mixture was stirred under 
argon with absence of light until all starting material was consumed, which was 
the case after 4 h reaction time. Once the mixture was stirred overnight, but 
prolongation of the reaction time did not increase the yield. 
The mechanism
[74] of the Sonogashira coupling is shown in scheme 15. 
 
 
Scheme 15: Mechanism of the Sonogashira coupling
[72,74] 
 
The  palladium  catalyst,  a  Pd(0)  or  Pd(II)  species,  inserts  into  the  carbon 
halogene bond of the aromatic system (step 1: oxidative addition). The alkyne 
is deprotonated with an excess base (here triethylamine, see scheme 15, step 
2b) and gets negatively charged resulting in binding to the copper cation from 
CuI (co catalyst). The activated alkyne is transferred via transmetalation to the 
Pd complex regenerating the copper salt at the same time (see step 2a). The 
Pd complex now carries both the alkyne and the aromatic system, forming a 
new carbon carbon bond after cis/trans isomerization (step 3) and reductive 
elimination (step 4). During the last step, the product is released and the Pd 
catalyst regenerated   another coupling cycle can start. As also described in 
literature
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37  in good yield (70 %) by employing the ratio of 2/1 copper iodide/palladium 
catalyst (Pd(0) species). The TFA function is easily cleaved off with aqueous 
ammonia in methanol to form the target key compound 38 in moderate yield.  
 
4.3.5  Synthesis of 2 amino 7 [2 deoxy β β β β D erythro pentofuranosyl] 5 
iodo 7H pyrrolo[2,3 d]pyrimidin 4 one: Strategy 1 
 
Several  attempts  for  the  synthesis  of  2 amino 7 [2 deoxy β D erythro pento 
furanosyl] 5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one are published
[68a,68c,75,76]. 
 
 
Scheme 16: First trial to synthesize the desired nucleoside 54 
 
The best evaluated methods are known from Seela et al. who used quite similar 
strategies like the ones for the preparation of 4 amino 7 [2 deoxy β D erythro 
pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]pyrimidine  31.  One  big  difference  of 
the guanosine compound is its solubility: It tends to crystallize much more than 
the  adenosine  analog  and  is  therefore  often  insoluble  in  various  organic 
solvents like e.g. methylene chloride. As a result of this, various approaches 
had  been  tested  until  a  suitable  synthetic  route  was  found.  Similar  to 
nucleoside  31,  the  guanosine  analog  cannot  be  prepared  directly  from  2′ 
deoxyguanosine. Here also the 5 iodo pyrrolo[2,3 d]pyrimidine moiety had to 
be  prepared  first,  followed  by  glycosylation  and  3′ modification  in  order  to 
obtain the key compound for the G terminator preparation. The first trial to Synthesis of reversible terminators for SBS                                                                          
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prepare the deazapurine heterocycle 42 with subsequent glycosylation is shown 
in  scheme  16.  Starting  from  commercially  available  2,4 diamino 6 hydroxy 
pyrimidine  39,  the  pyrrolo  ring  could  be  attached  in  moderate  yield  using 
Barnett′s method. As an amino protecting group for the subsequent iodination, 
the pivaloyl moiety was chosen
[76] and introduced by treating heterocycle 40 
with an excess of pivaloyl chloride at elevated temperature
[77]. The resulting 
product  41  precipitated  as  brown  crystals  when  the  pH  was  adjusted  to 
neutrality. Barnett et al. published a method for the selective introduction of 
iodine in the 5 carbon position
[62]: The in situ silylation of both 4 oxygen and 7 
nitrogen  (see  scheme  17)  using  bis (trimethylsilyl) acetamide  should  fix  the 
heterocycle 41 in a defined electron configuration.  
  
 
Scheme 17: Mechanism of selective iodination of 5 carbon position
[62,78] 
 
For pyrrolo[2,3 d]pyrimidines it is reported that the position of the electro 
philic substitution strongly depends on the particular base substituents as well 
as on the reaction conditions
[78]. If the 2 amino function were not protected by 
the pivaloyl group, it would direct the electrophilic attack of the iodine into 
the undesired 6 carbon position. The 6 iodinated product would be a result of 
the mesomeric stabilized σ complex 1 shown in scheme 17. On the other hand, 
protection of the 2 amino function forms σ complex 2, which would then favor 
the formation of the desired product. The silyl groups are labile enough for 
being removed quantitatively during the aqueous workup afterwards. Another 
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were carried out in the presence of light, a small amount of elemental iodine 
would be formed which could also lead to unselective iodination. Therefore we 
ran the iodination of heterocycle 41 in the absence of light, providing us with 
product 42 in moderate yield. 
Unlike the synthetic steps before, the glycosylation of compound 42 employing 
Seela′s  method  (see  scheme  16)  was  not  successful:  Monitoring  the 
glycosylation  reaction  via  TLC  showed  that  both  the  sugar  as  well  as  the 
heterocycle moiety did not react. The attempt to purify the crude reaction 
mixture  on  a  short  silica  gel  column  delivered  the  heterocycle  and  the 
hydrolyzed sugar moiety, but not the desired nucleoside 43. One reason for the 
inhibited glycosylation might be the competitive deprotonation of the three 
acidic  protons  of  compound  42  (see  protons  in  positions  H2,  H4  and  H7  of 
compound 42 in scheme 16). Another effect may be that the iodine substituent 
in 5 carbon position lowers the nucleophilicity of the heterocycle and therefore 
hinders the nucleophilic attack on the chloro carbon on the sugar. As a result of 
this, no nucleophilic substitution would occur and the chloro sugar 27 would 
hydrolyze after 20 to 30 minutes if traces of water were present. 
 In order to enhance the reactivity of the heterocycle and to avoid unselective 
deprotonation it was decided to mask the 4 oxygen as chlorine function
[65,76] 
(see scheme 18).  
 
 
Scheme 18: Alternative method with masking the 4 hydroxy function 
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The chlorination step readily converted compound 41 into the heterocycle 44: 
The pivaloyl protected heterocycle was refluxed for 2.5 h in a high excess of 
phosphorus oxychloride, then the excess was distilled off and the product 44 
precipitated from aqueous ammonia
[79]. The additional back extraction of the 
aqueous layer furnished a smaller fraction of the chlorinated compound, too.  
The selective 5 carbon iodination was accomplished again by using the Barnett 
method
[62]: the best amount of product 45 was obtained when the iodination 
step was carried out in the absence of light. The iodinated product could also 
be  isolated  via  precipitation  with  cold  water  and  back extraction.  Both 
halogenations  had  to  be  carried  out  in  the  order  chlorination  first,  then 
iodination.  Once  the  reverse  order  was  tried,  but  in  that  case  it  could  be 
observed that the iodine in the 5 carbon position was partially removed during 
the chlorination. This was obvious when violet wads of gaseous iodine were 
generated during the refluxing of the reaction mixture consisting of phosphorus 
oxychloride and heterocycle 42.  
Due to the low solubility of compound 45 in acetonitrile causing low reactivity, 
the  glycosylation  following  Seela′s  method  still  did  not  form  the  desired 
nucleoside 46. Hence we changed the glycosylation conditions as follows: First, 
the solvent acetonitrile was exchanged by a mixture of THF and acetonitrile. 
Second, the more reactive base sodium hydride was applied. Both changes led 
to complete solvation and activation of the deazapurine moiety which finally 
reacted with the sugar ring to give the desired product 46.  
 
 
 
Exp. 
No. 
 
Reagent 
 
n [mol] 
 
solvent 
     
T [°C] 
  
Reaction 
time [h] 
              
    Yield 
1   NaOMe
[80]    1.1  MeOH  25  4    0 
2   NaOMe
[63]  2  MeOH  70 (reflux)  4  0 
3  NaOH
[77]  1  H2O  25  72  0 
4  HCl
[81]  6  MeOH/H2O  69  2  0 
5  NH4OH
[76]  excess     100  3  0 
Chart 1: Results of the pivaloyl deprotection attempts 
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The  removal  of  the  pivaloyl  group  on  the  2 amino  function  using  the 
unglycosylated heterocycle 45 caused unexpected problems: It was extremely 
stable  under  the  conditions  tested  with  and  listed  in  chart  1.  Although 
conditions  1  to  4  (see  chart  1)  are  described  in  literature
[63,76,77,80,81],  the 
pivaloyl group could not be removed neither under alkaline nor under acidic 
conditions. Treatment with sodium methoxide in methanol did not convert the 
starting  material  into  the  deprotected  product  after  stirring  at  room 
temperature  for  several  hours
[80].  Besides  that,  the  4 chlorine  function  of 
heterocycle  45  could  be  replaced  by  nucleophiles  like  water  or  methoxide 
during  heating,  which  led  to  the  following  conclusion:  If  the  cleavage 
conditions induce pivaloyl removal, the chlorine group is also affected – a fact 
that made this synthetic strategy useless for our purpose.  
 
4.3.6  Synthesis of 2 amino 7 [2 deoxy β β β β D erythro pentofuranosyl] 5 
iodo 7H pyrrolo[2,3 d]pyrimidin 4 one: Strategy 2 
 
It was decided to drop the idea of using the pivaloyl protection for the 2 amino 
function and try a completely different synthetic approach, as shown in scheme 
19. Here, both the 2 amino and the 4 carbonyl functions are masked
[82]: The 4 
carbonyl is replaced by chlorine and the 2 amino by a thiomethyl group so that 
no reactive protons, except the proton on 7 nitrogen, would be left.  
 
 
Scheme 19: Preparation of the masked heterocycle 48 
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This  circumstance  should  enable  an  efficient  glycosylation  with  subsequent 
conversion of the masked groups into the original functionalities. The desired 
heterocycle 48 was accessible over four synthetic steps. The first three were 
described earlier for the synthesis of nucleoside 31, but in this case the 2 
methylthio group is not removed. 
 
 
Scheme 20: The glycosylation with heterocycle 47 and subsequent iodination trial 
 
Masking the 4 carbonyl function by refluxing heterocycle 16 in an excess of 
phosphorus  oxychloride  with  subsequent  quenching,  aqueous  workup  and 
recrystallization  gave  compound  47.  Like  it  was  already  mentioned,  the 
extraction  and  purification  of  the  product  worked  poorly  due  to  its  low 
solubility which caused moderate yields around roughly 40 %. Compared to the 
chlorination  step,  the  iodination  in  5 carbon  position  using  N iodo 
succinimide
[62c] worked better and with high regioselectivity: In principle, the 
2 methylthio  function  does  not  act  as  π electron  donor  for  the  aromatic 
system, therefore the addition of iodine is not guided to 6 carbon, but to 5 
carbon position. Performing the glycosylation
[64] with sodium hydride (60 % in 
mineral oil) and heterocycles 47 or 48 in acetonitrile at room temperature led 
to  the  desired  β isomer  49.  Once  it  was  also  tried  to  introduce  the  iodine 
function after the glycosylation like it is mentioned in literature
[82]: With the 
lack  of  the  iodine  function  the  heterocycle  seems  to  be  a  slightly  better 
nucleophile so that the glycosylation gave a higher yield (see scheme 21). The Synthesis of reversible terminators for SBS                                                                          
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treatment of the resulting nucleoside with an excess N iodosuccinimide in DMF 
at 96 °C led to an unexpected product. Instead of the formation of compound 
51, the corresponding oxidized nucleoside 50 was formed. This could be proven 
by 
1H NMR and ESI(+) mass spectroscopy as shown in figure 18. The mass of the 
expected product is 677.94, but in the ESI(+) spectra taken from the product 
two  different  main  peaks  occur.  Compared  to  the  mass  of  the  oxidized 
compound (calculated 693.94), one signal can be found at 694.1 which belongs 
to the molpeak, another signal at 716.0 which corresponds to the sodium salt of 
the oxidized nucleoside. 
 
 
Figure 18: ESI(+) MS spectrum of compound 50 
 
Finally the reconversion of the 2 amino and the 4 carbonyl function as shown in 
scheme  21  delivered the  desired  nucleoside  2 amino 7 [2 deoxy β D erythro 
pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one 54: The chlorine in 4 
carbon position of compound 51 could be replaced by using an excess of the 
oxygen donating reagent syn pyridine aldoxime in combination with the strong 
base  1,1,3,3 tetramethylguanidine:  The  aldoxime  substutitutes  the  chlorine 
function supported by the base 1,1,3,3 tetramethylguanidine. Quenching the 
reaction under acidic aqueous conditions always led to the desired product 52 
in  very  good  yield.  For  the  replacement  of  the  2 methylthio  function  of 
nucleoside  52,  it  had  to  be  converted  into  a  better  leaving  group  first: 
oxidation of the sulfur atom with mCPBA led to the activated intermediate 53 
which was purified on a short silica gel column. The activated species 53 was 
dissolved without further analysis in saturated ammonia/dioxane solution then, 
filled in a Parr bomb and heated at 110  °C for 15 h. Compared to what is Synthesis of reversible terminators for SBS                                                                          
74 
reported  in  literature  the  yield  of  the  fully  substituted  and  deprotected 
nucleoside 54 was low. 
 
 
Scheme 21: Final steps and reconversion of both the 4 chloro and the 2 methylthio group
[82]  
 
The reason for this is that the conversion of the starting material led to some 
partially  deprotected,  partially  substituted  by products  during  the  reaction. 
Besides the low efficiency of the reaction some of the starting material also 
decomposed  under  these  harsh  conditions.  Due  to  the  time demanding 
synthesis  with  poor  overall  yield  (9  %  over  4  steps)  regarding  the  target 
compound 54, we decided to acquire 2.0 grams of this compound which served 
as starting material for the preparation of the 3′ modified key compound. 
 
4.3.7  Synthesis of 2 amino 5 iodo 7 [3 O (2 cyanoethyl) 2 deoxy β β β β D 
erythro pentofuranosyl] 7H pyrrolo[2,3 d]pyrimidin 4 one 
 
With  2  grams  of  2 amino 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H 
pyrrolo[2,3 d]pyrimidin 4 one 54 in hands we started with half amount of this 
material first to repeat the efficient protecting group strategy that was already 
evaluated by using 2′ deoxyguanosine. For the purpose of selective 3′ alkylation 
five steps for introduction of protecting groups were needed.   Synthesis of reversible terminators for SBS                                                                          
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The first three steps are depicted in scheme 22a. The starting material 54 had 
to be well dried for the introduction of the Markiewicz protection, therefore 
the nucleoside was coevaporated three times with pyridine and dried over two 
days  in  vacuum before  use.  Treatment of the nucleoside  54  with  1.1  equiv 
1,1,3,3 tetraisopropyldichlordisiloxane  in  pyridine  and  stirring  overnight  at 
room temperature gave the protected nucleoside 55 in quantitative yield. 
 
 
Scheme 22a: Two reaction one pot synthesis of fully protected compound 57  
 
We  did  not  purify  compound  55,  but  quenched  the  reaction  by  addition  of 
methanol and the solvent removal under reduced pressure. We tried then to 
dissolve the oily residue in methanol, but unlike the Markiewicz protected 2′ 
deoxyguanosine the nucleoside 55 did not dissolve. Therefore methanol was 
removed  and  DMF  was  added:  Fortunately  nucleoside  55  formed  a  clear 
solution  then  and  was  treated  with  an  excess  of  N,N dimethylformamide 
dimethylacetal.  After  stirring  the  mixture  overnight  at  room  temperature, 
product 56 was isolated after purification in excellent yield. The 3 nitrogen 
position was protected afterwards by treatment with 2 equiv benzoyl chloride 
(added in two portions) in pyridine in satisfying amount delivering the fully 
protected  nucleoside  57.  The  1,1,3,3 tetraisopropyl disiloxane  moiety  was 
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in THF (see scheme 22b). After thoroughly drying of nucleoside 58, the MMT 
protection was carried out, catalyzed by the addition of 0.1 equiv of DMAP. The 
resulting compound 59 was now fully protected except its 3′ hydroxy group for 
enabling selective 3′ alkylation via the Michael addition
[57a]. This time 40 equiv 
of acrylonitrile were needed for enhancing the solubility and conversion of the 
starting material. As a result of this we isolated the desired nucleoside 60 in a 
moderate yield of 69 %. With an excess of para toluenesulfonic acid the MMT 
group  was  easily  cleaved  off  to  furnish  compound  61  in  76  %  yield.  Both 
formamidine and benzoyl protecting group are known to be removable under 
alkaline  conditions:  By  treatment  of  the  nucleoside  61  with  an  excess  of 
ammonia in water and methanol for 24 h, most of the starting material was 
converted into the deprotected nucleoside 62. 
 
 
Scheme 22b: The 3′ O selective introduction of the CE function on compound 59 
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aqueous  workup  and  purification,  was  3 O [(2 cyanoethyl) 2 deoxy β D 
erythro pentofuranosyl] 2 (N,N dimethylaminomethylidenyl) 5 iodo 7H pyrro 
lo[2,3 d]pyrimidin 4 one.  Based  on  this  result  we  could  conclude  that  the 
formamidino group on the 2 amino function is more stable than the benzoyl 
group  on  the  5′ end.  In  contrast  to  the  other  three  3′ O (2 cyanoethyl)  key 
compounds, nucleoside 62 was not modified further via Sonogashira reaction 
for the introduction of the dye linker system
 [55b]. 
 
4.3.8  Synthesis of 5 [3 amino prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ 
deoxycytidine 
 
In  contrast  to  the  syntheses  of  both  3′ modified  pyrrolo[2,3 d]pyrimidine 
nucleosides 38 and 62, the third key compound 72 was prepared in a different 
way.  
 
 
Scheme 23a: Synthetic route for the preparation of nucleoside 69 
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We started with commercially available 2′ deoxycytidine 63 and introduced the 
iodine  function  on  the  5 carbon  position.  The  desired  nucleoside  5 iodo 2′ 
deoxycytidine  66  could  be  obtained  in  moderate  yield  over  three  steps 
according to Bobek’s method
[83b] (see scheme 23a). The acetylation of both 3′ 
and 5′ hydroxyl functions worked in good yield
[83a], although in our case the 
reaction  often  proved  to  be  much  more  time consuming  due  to  the  low 
solubility  of  the  starting  material.  The  iodination  in  the  5 carbon  position 
proceeded highly selective: No diiodinated or 6 carbon iodinated product was 
ever observed and isolated. The selective iodination can be explained by its 
mechanism  as  already  claimed  by  Chang  et  al.
[84]  (see  scheme  23b):  They 
assume that two modes of iodination happen simultaneously, i. e. substitution 
and addition of iodine.  
 
 
Scheme 23b: Proposed mechanism of the selective 5 carbon iodination by Chang et al.
[84] 
 
Carrying out the iodination with iodic acid
[83b,84] as oxidizing agent favors the 
substitution and therefore the formation of the desired 5 carbon substituted 
product 65 without destroying the glycosidic bond. The substitution may be 
preferred because the 5,6 double bond of intermediate II (see scheme 23b) is Synthesis of reversible terminators for SBS                                                                          
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more  reactive  in  acidic  medium  favors  substitution  reaction.  The  addition 
reaction is less favored due to the fact that the imino group of intermediate III 
is  more  labile  than  before  the  addition  of  iodine.  Therefore  5,6 diiodo 2′ 
deoxycytidine IV is the minor product, which might lead to deamination with 
formation of 5,6 diiodo 2′ deoxyuridine and further synthetic steps
[84].  
After  cleavage  of  the  acetyl  protecting  groups  the  very  polar  and  nearly 
insoluble  product  5 iodo 2′ deoxycytidine  66  was  obtained.  Its  low  solubility 
caused only moderate yields in the next two steps, the formamidino protection 
of the 4 amino function
[69] and the 5′ O benzoylation
[70]. The CE moiety was 
attached  to  the  3′ end  by  using  the  already  described  Michael  reaction
[57a]. 
When this reaction was carried out first, we observed that starting material 68 
did only hardly dissolve in acrylonitrile and tert butanol. Although 20 equiv of 
acrylonitrile  and  a  few  milliliters  of  tert butanol  were  added  extra,  only 
roughly 50 % of the starting material was consumed after 3.5 h reaction time. 
After 4 h we stopped the reaction and isolated the product after purification on 
column causing cleavage of the protecting groups. 
 
 
Figure 19: ESI( ) mass spectrum of 2′ deoxy (3′,3N dicyanoethyl) 5 iodocytidine 
 
Thus we decided to completely cleave off both the formamidino
[71] and the 
benzoyl
[34a] protecting group in methanolic ammonia in order to have a pure 
compound for analysis. With ESI mass spectrometry and 
1H NMR spectroscopy it 
was found that not the desired nucleoside 69, but the dialkylated compound 5 
iodo (3′,3N dicyanoethyl) 2′ deoxycytidine  was  formed  (see  mass  spectrum  in 
figure 19). The explanation for this may be that the formamidino group is only 
metastable and partially cleaved off during the Michael reaction. As a result of 
this, the exocyclic amino function may be cyanoethylated as well as the 3′ Synthesis of reversible terminators for SBS                                                                          
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hydroxy  function.  In  order  to  avoid  the  dialkylation,  the  solubility  of  the 
starting material was enhanced by addition of DMF as co solvent (see scheme 
23a). Besides that, we limited the reaction time to a maximum of 3 h and used 
only a few milliliters of tert butanol/DMF. The purification of Michael adduct 
69  was  always  complicated  caused  by  the  cleavage  of  the  base labile 
protecting  groups  during  column  chromatography.  In  some  cases,  we 
deprotected  crude  product  69  directly  after  the  Michael  reaction  and 
characterized the nucleoside after purification. Both the formamidino and the 
benzoyl  group  could  be  removed  simultaneously  in  saturated  methanolic 
ammonia,  giving  5 iodo 3′ O (2 cyanoethyl) 2′ deoxycytidine  70  in  moderate 
yield (see scheme 23c). 
This  compound  was  difficult  to  purify  on  silica  gel  column  due  to  its  high 
polarity  caused  by  the  free  5′ hydroxyl  and  the  4 amino  function.  As  an 
alternative  to  column  chromatography  the  product  was  crystallized  from 
ethanol which caused lower yields, but delivered the product in higher purity. 
The  Sonogashira  reaction  for  the  introduction  of the propargylamine  moiety 
was carried out with an excess triethylamine, TFA protected propargylamine 
and a ratio of palladium(0) catalyst/copper iodide 1/2 mol equiv in dry DMF as 
already described
[73]. 
 
 
Scheme 23c: Final synthetic steps until the third key compound 72  
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After concentration of the reaction mixture, product 71 was extracted with 
methylene chloride and washed with an aqueous 5 % disodium EDTA solution for 
removal of the metal cations. Concentration of the organic layer revealed only 
a minor product containing fraction; most of it was still diluted in the aqueous 
layer. It was found that 2 butanone was an excellent extraction solvent for this 
highly  polar  product,  which  finally  made  it  possible  to  extract  the  major 
fraction  from  the  aqueous  phase  efficiently.  The  TFA  group  could  also  be 
removed under alkaline conditions
[85] without formation of any by products and 
finally key compound 72 was obtained. 
 
4.3.9  Synthesis of 5 [3 amino prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ 
deoxyuridine 
 
The preparation of the key compound for the preparation of the T terminator is 
comparable  to  the  synthesis  of  nucleoside  72.  In  this  case,  the  starting 
material 5 iodo 2′ deoxyuridine 73 was commercially available so that no extra 
steps for the introduction of iodine into the 5 carbon position were necessary.  
 
 
Scheme 24a: Synthetic strategy for enabling 3′-O-selective introduction of the CE function 
 
As it is shown in scheme 24a, the 5′ hydroxy function was benzoylated in low Synthesis of reversible terminators for SBS                                                                          
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selectivity:  Apart  from  the  expected  product  74,  the  corresponding  3′ 
benzoylated as well as the dibenzoylated nucleoside was formed. The selective 
N3 protection could be achieved by using the transient protection method
[86] 
employing trimethylchlorosilane as intermediate 3′ hydroxyl protection. After 
deblocking  the  3′ hydroxyl  function  of  intermediate  75  with  TFA,  the 
dibenzoylated  product  76  was  obtained  in  high  yield  and  purity.  The  CE 
function  was  introduced  selectively  on  the  3′ position  by  using  the  already 
described  Michael  reaction
[57a].  Here,  the  yield  of  46  %  product  77  after 
purification was moderate. As it is also the case for the cytidine analog, the 
benzoyl groups were partially cleaved off during purification of the product on 
column  chromatography.  Therefore  reliable  spectroscopic  analysis  was  only 
possible after complete removal of both benzoyl groups. 
The deprotected nucleoside 78 was formed by stirring the starting material 77 
in  a  mixture  of  methanol  and  concentrated  ammonia.  The  propargylamine 
moiety (see  scheme 24b) could be introduced via Sonogashira coupling
[73] in 
satisfying yield: In this case the same ratio of palladium catalyst to copper 
iodide was employed (1/2 molequiv Pd catalyst/CuI) like it was already used 
for  the  preparation  of  the  key  compound  5 [3 (trifluoroacetamido) prop 1 
ynyl] 3′ O (2 cyanoethyl) 2′ deoxycytidine. 
 
 
Scheme 24b: Final steps for obtaining the fourth key compound 80 
 
The  trifluoroaceto  group  of  nucleoside  79  was  quantitatively  removable  in 
diluted ammonia/methanol delivering the key compound 80.  
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5 5    Monophosphates as model compounds 
 
5.1  Cleavage experiment in a heterogeneous system 
 
As our reversible terminators possess a 3′ O capping group like either the (2 
cyanoethoxy)methyl (CEM) function or the 2 cyanoethyl (CE) function, it is of 
high interest studying and comparing the cleavability of both functions. There 
are two possibilities to check the cleavability of this group: One possibility is 
the incorporation of a terminal nucleotide bearing the 2 cyanoethyl function 
into  an  oligomer  and  subsequent  cleavage  experiments.  As  a  simpler 
alternative  to  that  the  cleavage  experiments  can  be  carried  out  by  using a 
stable  and  simple  model  compound,  e.g.  3′ O (2 cyanoethyl) 2′ deoxy 
thymidine 5′ phosphate. In this case, the monophosphate moiety attached to 
the 5′ end lowers the solubility of the nucleotide in organic solvents like in THF 
or acetonitrile. This heterogenous environment simulates well the solubility of 
oligonucleotides  in  organic  solvents  enabling  simple  cleavage  experiments 
without consumption of DNA templates.  
 
5.2  Synthesis of 3′ modified monophosphates 
 
5.2.1  Synthesis of 3′ O (2 cyanoethoxy)methyl 2′ deoxythymidine 5′ 
phosphate 
 
The first two steps of the preparation of the CEM wearing model compound are 
known in literature
[34a] (see scheme 26). The Pummerer rearrangement
[87] is the 
method  of  choice  here  for  introducing  the  methylthio  function  on  the  3′ 
hydroxy group. The mechanism
[88] of this reaction, which can be regarded as 
inner  redox  reaction,  is  shown  in  scheme  25:  Similar  to  ketones,  the 
dimethylsulfoxide can tautomerize enabling the attack of its oxygen atom to 
the  carbonyl  function  of  acetic  anhydride  with  release  of  one  proton.  An 
instable intermediate is formed then, which is stabilized after cleavage of the 
acetate moiety. The resulting compound is a sulfonium ylide that can react in  Monophosphates as model compounds                                                                           
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two different ways: Option 1 in scheme 25 shows the possibility of a conjugated 
addition by an added alcohol to the electrophilic carbon of the sulfonium ylide. 
With  the  nucleophilic  attack  of  the  hydroxyl  function,  another  aliquot  of 
acetate  is  released  associating  a  proton  in  acidic  environment  (i.  e. 
regeneration of acetic acid as catalyst). This reaction pathway leads to the 
methylthiomethylether as it is the case if compound 82 is used as substrate
[34a].  
 
 
Scheme 25: Mechanism of the Pummerer rearrangement
[88] 
 
Another possibility (option 2 in scheme 25) is the nucleophilic attack of the 
alcohol’s oxygen atom to the sulfur of the ylide forming equilibrium between 
acetate bound and alcohol bound ylide. The latter one of both intermediates is 
less stable and decomposes under oxidation of the alcohol to an aldehyde. This 
reaction  pathway  does  not  take  place  in  our  case,  but  might  be  dominant 
depending  on  the  conditions  and  the  nature  of  the  alcohol
[88,89].  As  it  is 
reported by Hovinen et al., the reagents DMSO, acetic anhydride and acetic 
acid are not deployed in stoichiometric amounts but in excess and a defined 
volume  ratio.  With  this  simple  procedure,  stirring  nucleoside  82  at  room 
temperature for 24 h in this reaction mixture, the desired methylthiomethyl 
ether 83 could always be obtained in reliable yield (here 83 % as expected from 
literature
[34a]).  This nucleoside served as starting material for the introduction 
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motif  can  be  substituted  with  halogens  like  elementary  bromine
[34a],  N 
bromosuccinimide
[34a,90]  or,  like  in  our  case,  with  sulfuryl  chloride
[91]  (see 
scheme  26).  One  has  to  be  aware  of  the  stability  of  intermediate  84: 
Triethylamine as scavenger for hydrogen chloride, which was generated during 
the  activation  with  sulfuryl  chloride,  prevented  the  decay  of  the  activated 
chloro species. 
 
 
Scheme 26: Synthesis of 3′ O CEM dTMP part 1 
 
Nucleophilic substitution of the chloro function with 3 hydroxypropionitrile in 
the next step led directly to formacetal nucleoside 85 in moderate yield. Here, 
also other nucleophiles could be added instead of this substrate giving a variety 
of  different  3′ modified  products
[34a,90,91].  The  removal  of  the  5′ protecting 
group gave nucleoside 86 ready for the final steps as shown in scheme 27. One 
big obstacle in obtaining desired nucleotide 88 was the metastable CEM group 
itself:  By  employing  the  Yoshikawa  method
[92]  first,  we  did  not  isolate  the 
product. Looking for alternative phosphorylation methods in order to get the 
desired monophosphate 88 in good yield, no convenient procedure was found in 
literature.  For  this  reason  we  decided  to  look  for  a  published  conventional 
triphosphate synthesis such as the Ludwig Eckstein procedure
[93] and modify it 
as a monophosphate synthesis.  Monophosphates as model compounds                                                                           
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Scheme 27:   Synthesis of 3′ O CEM dTMP part 2 
 
 
Scheme 28a: Mechanism of two step phosphorylation method part 1
[94] 
 
One possibility described by Gold et al.
[94] and Sun et al.
[95] is the two step 
procedure  based  on  the  Ludwig Eckstein  phosphorylation  as  first  step  with 
subsequent  hydrolysis  by  addition  of  water  as  second  step  yielding 
quantitatively  the  H phosphonate  87  (see  schemes  28a  and  28b).  This  H 
phosphonate is activated with an excess of trimethylchlorosilane in pyridine 
then facilitating the oxidation with iodine in pyridine. Subsequent addition of  Monophosphates as model compounds                                                                           
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water would complete the formation of the phosphate (see scheme 28b). The 
proposed mechanism of this two step phosphorylation method is explained by 
Sun  et  al.
[95]:  The  activation  with  TMSCl  is  claimed  to  convert  the  H 
phosphonate  I  into  a  silyl H phosphonate  IIa  or  more  reactive  bis silyl 
phosphate  IIb  (see  scheme  28b).  The  authors  could  prove  the  presence  of 
similar  intermediates  like  IIa  and  IIb  because  they  analyzed  the  reaction 
mixture  with  mass  spectroscopy  and 
31P  NMR:  Significant  changes  in  the 
chemical shift of the phosphorus atom after TMSCl addition as well as after 
iodine oxidation indicated that such intermediates must have been formed
[95]. 
The subsequent addition of elemental iodine in pyridine would rapidly oxidize 
the P(III) species  IIb  in situ and generate the reactive pyridinium phosphor 
amidate III (P(V) species)
[96]. 
 
 
Scheme 28b: Mechanism of two step phosphorylation method part 2 with proposed  
intermediates
[94,95] 
 
This intermediate could be transformed then into the desired phosphate IV by 
nucleophilic substitution with water. As shown in scheme 27, we applied this 
method which finally led to the desired model compound 88 in good purity, but 
low yield. Analysis with ESI mass spectroscopy obtained after RP FPLC and RP 
HPLC purification showed that the obtained fractions consisted of dimers as 
well  as  higher  phosphates.  The  minor  product,  sufficiently  pure  for  CEM 
cleavage tests, was precipitated as sodium salt for facile handling and storage. 
The  ESI mass  spectrum  of  the  H phosphonate  87  formed  as  intermediate  is  Monophosphates as model compounds                                                                           
88 
shown in figure 20, the 
31P NMR and ESI( ) mass spectra of phosphate 88 are 
shown in figures 21 and 22.  
 
  
Figure 20: ESI( ) mass spectrum of H phosphonate 87 
 
 
Figure 21: ESI( ) mass spectrum of phosphate 88 
 
 
Figure 22: 
31P NMR spectrum of phosphate 88  Monophosphates as model compounds                                                                           
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In both mass spectra signals at 136.4/136.6 and 198.6/198.7 appear, which are 
in  accordance  with  the  calculated  mass  of  the  hydrolyzed  phosphorylating 
agent 2 hydroxybenzoic acid (136.6 g/mol) and its corresponding pyridinium , 
Na
+  and K
+ salts. These impurities weren’t completely removable even with 
RP HPLC, so it was decided to precipitate the monophosphate as sodium salt 
sufficiently pure for the deprotection tests. 
 
5.2.2  Synthesis of 3′ O (2 cyanoethyl) 2′ deoxythymidine 5′ phosphate 
 
The synthesis starts with the already described one flask transient protection 
of  both  hydroxyl functions  at  the  pentose moiety  of  2′ deoxythymidine  (see 
scheme  29a).  Following  Sekine′s  procedure
[86],  2.5  equiv  TMSCl  were  added 
under alkaline conditions and after 30 min a slight excess of benzoyl chloride 
could be added to the reaction mixture. During the aqueous work up, the silyl 
protection was removed quantitatively and 3 nitrogen protected nucleoside 90 
was obtained in excellent yield after column chromatography. The tritylation 
of the 5′ hydroxyl group under standard conditions
[57b,57c] led to nucleoside 91 
which  underwent  a  Michael  addition
[57a]  reaction  for  introducing  the  CE 
function at the 3′ end (see scheme 29a). 
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The MMT protecting group of compound 92 could be removed quantitatively 
using  para toluenesulfonic  acid.  Without  further  purification,  the  crude 
product 93 could be concentrated under reduced pressure and dissolved again 
in methanol and aqueous ammonia (see scheme 29b). 
 
 
Scheme 29b: Preparation of the monophosphate 95 and the phosphoramidite 96 
 
Stirring at room temperature yielded 5′ O deprotected compound 94 without 
affecting the CE function, which means that this group was stable during both 
deprotection  steps.  The  preparation  of  monophosphate  95  was  simple, 
although the workup procedure appeared to be time demanding due to product 
purification on semipreparative HPLC. We chose the  conventional Yoshikawa 
method
[92]  for  preparation  of  the  monophosphate.  The  mechanism  of  this 
reaction is shown in scheme 30.  
In  literature  it  is  described  that  the  use  of  trialkyl  phosphates  as  solvents 
shortens the reaction time of the phosphorylation
[92,97]. This may be caused by 
the formation of a highly reactive “Vilsmeyer Haack” type complex made from 
phosphorus  oxychloride  and  trimethyl  phosphate  which  selectively 
phosphorylates the 5′ hydroxy group (see scheme 30). In some cases, 1,8 bis 
(dimethylamino)naphthalene is used as proton sponge
[98]. When we applied this  Monophosphates as model compounds                                                                           
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method for conversion of nucleoside 94 into nucleotide 95, we also added the 
proton sponge, but quenched the reaction with aqueous TEAB buffer in order to 
form the monophosphate. 
 
 
Scheme 30: Mechanism of the Yoshikawa phosphorylation
[97,98]  
 
The 5′ hydroxyl function of nucleoside 94 was phosphorylated selectively in a 
moderate yield of roughly 52 % obtained after purification (see scheme 29b). 
Spectroscopic  analysis  via 
31P NMR  shows  the  singulett  signal  of  the  desired 
compound,  but  as  well  peak  patterns  that  belong  to  a  diphosphate  and  a 
triphosphate moiety. 
As is mentioned in literature
[98], a minor part of the product always contained 
those two by products which could hardly be completely separated from the 
monophosphate on HPLC. We assume that the proton sponge also might support 
the  formation  of  those  di   and  triphosphates  built  by  repeated  addition  of 
reactive “Vilsmeyer Haack” complexes to the 5′ hydroxy function of nucleoside 
94. The obtained monophosphate 95 was precipitated as sodium salt after RP  
HPLC furnishing a colorless crystalline product, which is easier to handle and to  Monophosphates as model compounds                                                                           
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store than glassy oil containing the anionic compound with undefined counter 
ions such as triethylammonium, magnesium or sodium cations in various ratios.  
One  fraction  of  nucleoside  94  was  converted
[69]  into  its  corresponding 
phosphoramidite 96 for incorporation into a short DNA sequence (8 mer) for the 
CE deprotection test from an oligomer. The desired compound was obtained in 
moderate purity as can be seen from the 
31P NMR spectrum below (see figure 
23): Two isomers of phosphoramidite 96 were formed and give one singulett 
signal each at 148.8 and 148.2 ppm, while the signal at 13.3 ppm indicates the 
presence of the H phosphonate of compound 94. 
   
 
Figure 23: 
31P NMR spectrum of phosphoramidite 96 after purification 
 
The integral ratio of both phosphoramidites together to H phosphonate is 6/1, 
which means that the product consists of roughly 85   86 % of compound 96 and 
in 14 – 15 % amount of H phosphonate and other impurities. 
Besides  the  commercial  availability  of  2′ deoxythymidine 5′ phosphate,  2′ 
deoxythymidine  81  served  as  test  compound  for  evaluation  of  efficient 
selective  5′ O phosphorylation  (see  scheme  31).  Applying  the  Yoshikawa 
method
[92] without using the proton sponge not only proved to be the easiest 
way for obtaining the desired monophosphate 97 in moderate yield, but was 
also very selective with di or triphosphates only present in traces (see 
31P NMR 
of compound 97).   Monophosphates as model compounds                                                                           
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Scheme 31: Phosphorylation of 2′ deoxythymidine 81 as reference material 
 
 
Figure 24: 
31P NMR spectrum of nucleotide 95 after purification 
 
 
Figure 25: 
31P NMR spectrum of nucleotide 97 after purification  Monophosphates as model compounds                                                                           
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The 
31P NMR spectra (see  figures 24 and  25) of both nucleotides  95 and 97 
demonstrate  that  the  chemical  shifts  of  the  α phosphorus  from  both 
compounds do not differ much. As can be seen from the 
31P NMR spectrum of 
compound 95, the Yoshikawa method carried out with a proton sponge favored 
the formation of the corresponding triphosphate as minor side product (roughly 
20    25 % determined by signal integration). Carrying out the phosphorylation 
for  the  second  time,  1,8 bis(dimethylamino)naphthalene  was  not  added  in 
order to avoid the formation of the by product. 
 
5.2.3  Synthesis of 3′ O (2 cyanoethyl) 2′ deoxyadenosine 5′ phosphate 
 
Starting  with commercially  available  2′ deoxyadenosine,  the exocyclic amino 
function was protected first for preventing the side product formation in the 
next steps. Here, the formamidino protecting group seemed to be an optimal 
choice for selective and efficient protection
[59a] (see scheme 32a). This reaction 
gave the desired product 99 in good yield after roughly 3 h reaction time with 
excess formamidino acetal in DMF at 55 °C.  
 
 
Scheme 32a: Synthesis of 3′ O CE dAMP part 1 
 
The following benzoylation of the 5′ hydroxy function didn’t work selectively 
first:  Employing  methylene  chloride  as  solvent  for  benzoyl  chloride,  the  Monophosphates as model compounds                                                                           
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reaction  delivered  dibenzoylated  product  as  main  fraction  and  the 
monobenzoylated product 100 in 20 % yield only after purification. The yield 
increased  significantly  by  using  pyridine  as  single  solvent  and  diluent  for 
benzoyl  chloride.  In  that  case  81  %  of  the  5′ protected  nucleoside  100  was 
achieved.  After  this  step,  the  nucleoside  underwent  the  Michael  reaction 
performed  at  already  known  conditions,  but  with  a  higher  excess  of 
acrylonitrile (50 equiv) delivering 3′ O cyanoethylated product 101 in moderate 
yield. 
After  removal  of  the  exocyclic  protecting  group  as  well  as  of  the  benzoyl 
moiety (see scheme 32b), the well dried nucleoside 102 was converted into its 
corresponding  nucleotide  104  by  employing  the  two step  phosphorylation 
method
[94,95]  already  used  for  the  preparation  of  model  compound  88:  The 
nucleoside was phosphorylated first and the intermediate quenched by addition 
of  water,  quantitatively  yielding  the  H phosphonate.  The  formation  of  H 
phosphonate  103  was  confirmed  by  ESI mass  spectroscopy  as  shown  in  its 
spectrum in figure 26. This intermediate product was dried well and oxidized 
with iodine after activation with trimethylsilyl chloride, furnishing the desired 
monophosphate 104.  
 
 
Figure 26: ESI( ) mass spectrum of H phosphonate 103 
 
The crude product 104 was purified in two steps then: First, the oily residue 
was taken up in a few milliliters of water and put on RP FPLC after syringe 
filtration. In this purification step, excess of phosphorylator, inorganic salts and 
rests of starting material were separated from the product containing fraction. 
The product was purified further on RP HPLC in order to remove impurities and 
higher phosphates like dimers etc. as found by ESI mass spectroscopy.  Monophosphates as model compounds                                                                           
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Scheme 32b: Synthesis of 3′ O CE dAMP part 2 
 
 
Figure 27: 
31P NMR spectrum of compound 104 
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Figure 28: ESI( ) mass spectrum of compound 104 
 
Both 
31P NMR  and  mass  spectra  taken  after  RP HPLC  purification  show 
impurities  from  the  phosphorylating  agent  as  well  as  signals  from  other 
undefined phosphorus species (see figures 27 and 28). Nevertheless the purity 
of phosphate 104 was sufficient for a few CE cleavage tests. For this purpose, 
the  nucleotide  could  easily  be  stored and handled  after  its  precipitation  as 
sodium salt. 
 
  
5.3  Cleavability of the 3′ modified monophosphates 
 
5.3.1  Cleavage of the CEM function using 3′ O CEM dTMP 
 
The cleavage tests performed with all three model compounds were carried out 
in  the  same  experimental  setup  as  shown  in  figure  29.  This  setup  enables 
tempering and stirring of the reaction mixture, also samples can be taken out 
easily. Before its use, the apparatus was well dried with heating in vacuum and 
flushed with argon in order to create a water free environment. 
For each cleavage experiment, a certain amount of monophosphate 88, 95 or 
104 as sodium salt (in case of 3′ O CEM dTMP 1 mg) was suspended under argon 
in THF, acetonitrile or any other solvent (0.5 – 1 ml) and heated up to a given 
temperature. Treatment with one of the various cleavage reagents and taking 
out  aliquots  (80  µl)  from  the  reaction  mixture  after  certain  time  periods 
enabled monitoring of the reaction progress. These samples were quenched on 
demineralized water (120 µl) and injected into RP HPLC directly. The detailed  Monophosphates as model compounds                                                                           
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method and buffers are listed in the experimental part. As reference material 
for the cleavage tests done with model compound 88, commercially available 
2′ deoxythymidine 5′ phosphate 97 was coinjected (see figure 30). 
 
   
Figure 29: Deprotection experiment setup with detailed view on reaction vessel 
 
The  resulting  chromatogram  shown  in  figure  30  displays  both  signals  and 
retention times of 2′ deoxythymidine 5′ phosphate 97 (7.93 min) and 3′ O (2 
cyanoethoxy)methyl 2′ deoxythymidine 5′ phosphate  88  (11.64  min).  It  is 
obvious that both compounds are well distinguishable and allow monitoring of 
the CEM cleavage reaction. 
 
 
Figure 30: RP HPLC chromatogram of model compound 88 and reference phosphate 97 
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The  results  of  all  deprotection  experiments  using  model  compound  88  are 
shown in chart 2. 
 
Exper. 
No. 
Reagent(s)/ 
 solvent 
Equiv. 
[mol %] 
Temp. 
[°C] 
Time [min] for 
quantitative 
CE cleavage 
 T_CEM_1  1 M 
TBAF/THF  40  40  6 
 T_CEM_2  0.5 M 
AcOH/water 
         
  ~87000  60  No cleavage 
 T_CEM_3  TFA/aceto 
nitrile  200  60  No cleavage 
 T_CEM_4  0.2 M 
KOH/water  40  60  35 
 T_CEM_5  TEA*3HF/ 
acetonitrile  10  60  No cleavage 
Chart 2: Conditions for CEM cleavage experiments using monophosphate 88 
 
The CEM group is known as stable 2′ protecting group for RNA synthesis
[99] and 
2′ O CEM derivatized ribonucleotides are reported to be cleavage with 0.1 M 
acetic  acid  at  90  °C
[100].  In  case  of  employing  our  model  compound  88 
possessing the CEM function as 3′ protecting group we obtained an unexpected 
result:  The  CEM  group  was  found  to  be  remarkably  stable  under  acidic 
conditions,  while it was  removed  under  alkaline  conditions:  Treatment  with 
high excess of acetic acid (pH 2) at 60 °C neither led to CEM removal nor to 
nucleotide decomposition (see stacked chromatograms in figure 31). 
 
 
Figure 31: Stacked RP HPLC chromatograms of cleavage experiment T_CEM_2 
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Figure 32: Stacked RP HPLC chromatograms of cleavage experiment T_CEM_4 
 
In contrast to that, dissolving the nucleotide in aqueous potassium hydroxide 
led to cleavage of the CEM group (see stacked chromatograms in figure 32). In 
the  heterogeneous  system  nucleotide/TBAF/THF,  the  substrate  was  only 
suspended in THF, but cleavage of the CEM group was even more effective than 
before. From these results we made the following conclusion: The dependency 
of the CEM removal on alkaline environment is caused by the mechanism of the 
cleavage,  which  is  similar  to  the  mechanism  for  the  1 (2 cyanoethoxy)ethyl 
(CEE) cleavage
[101]: The removal of the CEM group is supposed to be a β H 
elimination  as  shown  in  scheme  33.  Only  small  bases  that  can  abstract  β 
hydrogens induce CEM decomposition and its removal. 
 
 
Scheme 33: Proposed mechanism of the CEM cleavage 
 
Under  acidic  conditions,  this  reaction  cannot  take  place,  but  either  in 
heterogeneous or homogeneous alkaline environment. We also assume that the 
smaller  and  more  electronegative  the  base  is,  the  more  effective  the 
elimination reaction is. We already published the results from the first CEM 
cleavage tests made on an oligomer which is in accord with the results from the 
CEM cleavage tests of the monomer 88
[102].  Monophosphates as model compounds                                                                           
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5.3.2   Cleavage of the CE function using 3′ O CE dTMP 
 
As  we  were  even  more  interested  in  the  behavior  of  the  CE  group,  we 
investigated further in CE  than in CEM  cleavage tests. Thus we synthesized 
monophosphates 95 and 97 which were used as reference materials for the 
following cleavage experiments. The RP HPLC chromatogram of both starting 
material  (model  compound)  and  deprotected  monophosphate  are  shown  in 
figure 33, while the commercially available phosphate 97 was coinjected for 
calibration of the method (see chromatogram in the background of figure 33). 
The stacked chromatograms in figure 33 show that the model compound after 
CE cleavage, which is assumed to be 2′ deoxythymidine 5′ phosphate 97, is well 
separable  from  the  starting  material  by  the  RP HPLC  method  we  have 
developed. The deprotected nucleotide  97 elutes significantly (at 7.78 min) 
earlier from the column than the CE protected nucleotide 95 (10.88 min). This 
separation method was also used for the analysis of the cleavage experiment 
probes. 
 
 
Figure 33: RP HPLC chromatogram of model compound 95 and reference phosphate 97 
 
Dry 3′ O (2 cyanoethyl) 2′ deoxythymidine 5′ O phosphate 95 (often 20 mg) was 
suspended in dry solvent and heated up to the desired reaction temperature 
with  stirring.  After  tempering  the  suspension  for  a  few  minutes  on  that 
temperature, the cleaving reagent was added in one lot and the stop watch 
started. After certain time periods, a sample (100 or 200 µl) was taken out of 
the  reaction  chamber  and  quenched  on  500  µl  demineralized  water.  These 
probes were filled after syringe filtering into small vials and given to analytical 
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model compound 95 are shown in scheme (chart 3). No cleavage was observed 
in acidic environment as can be seen from experiment no. T_CE_5 in chart 3.  
The stacked chromatograms of this experiment are shown in figure 34 revealing 
that the CE group is stable under acidic conditions and not cleavable with the 
acidic  fluoride  species  hydrogen  fluoride.  The  CE  deprotection was  also  not 
induced  by  employing  the  phase transfer  catalyst  18 crown 6 dicyclohexano 
ether in combination with potassium fluoride as base
[103]. 
 
Exper.  
No. 
Reagent(s)/ 
solvent 
Equiv. 
[mol %] 
Temp. 
[°C] 
Time [min] 
for quant. CE 
cleavage 
T_CE_1  1 M TBAF/THF  40  25  60 
T_CE_2  1 M TBAF/THF  80  37  60 
T_CE_3  1 M TBAF/THF  80  66  3 
T_CE_4  1 M TBAF/THF  40  60  6 
T_CE_5  TEA*3HF/ 
acetonitrile  10  60  No cleavage 
T_CE_6  1 M TBAF/THF  10000  60  Not 
determined 
T_CE_7  1 M solid 
TBAF/THF  40  60  10 
T_CE_8  KOH/water  40  60  30 
T_CE_9 
Dicyclohexano 
18 crown 
6/KF/THF 
0.1 
crown 
ether /2 
KF 
60  No cleavage 
T_CE_10  1 M TBAF/THF  5  60  >20 
T_CE_11  1 M TBAF/THF  20  60  10 
T_CE_12 
1 M 
TBAF/THF/DMF 
(THF/DMF 1/1) 
40  60  1.5 
T_CE_13 
1 M 
TBAF/THF/DMSO 
(THF/DMSO 1/1) 
40  60  1 
T_CE_14 
1 M 
TBAF/THF/DMF 
(THF/DMF 1/1) 
40  40  12 
T_CE_15 
1 M 
TBAF/THF/DMSO 
(THF/DMSO 1/1) 
40  40  3 
T_CE_16  TASF/DMF  15  25  No cleavage 
Chart 3: Conditions for CE cleavage experiments using model compound 95 
 
These  results  support  the  assumption  that  the  CE  cleavage  follows  a  β H 
elimination  mechanism  similar  to  the  CEM  cleavage  mechanism,  which  is  Monophosphates as model compounds                                                                           
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strongly dependent on the pH value of the reaction, the temperature and the 
nature and amount of base (see scheme 34). 
 
 
Scheme 34: Proposed mechanism of the CE cleavage  
 
The elimination products acrylonitrile and the 3′ deprotected nucleotide 97 are 
still reactive if the reaction is not quenched properly and base B
  is still present 
in  the  reaction  mixture.  The  reversibility  of  the  elimination  became  more 
obvious when we carried out the cleavage tests with the purine analog 104 of 
the model compound 97 (see next chapter). 
We  also  carried  out  one  deprotection  test  with  the  fluoride  species 
tris(dimethylamino)sulfonium  difluorotrimethylsilicate  (i.  e.  TASF,  entry  no. 
T_CE_16 in chart 3) which is known as a mild reagent for silicon protecting 
group  removal
[104].  This  reagent  could  also  not  remove  the  2 cyanoethyl 
function, so finally we came to the following conclusion: The CE function is 
cleaved in an alkaline environment with strong and charged bases like fluoride; 
the  cleavage  rate  is  significantly  improved  at  elevated  temperatures,  for 
example at 60 °C. Furthermore, the cleavage efficiency also depends on the 
solvent and TBAF amount. As a result of deprotection tests, the cleavage in the 
model compound is enhanced by addition of polar solvents like DMF or DMSO to 
1 M TBAF/THF standard solution (see entries no. T_CE_12, T_CE_13, T_CE_14 
and  T_CE_15  in  chart  3).  The  stacked  chromatograms  shown  in  figure  35 
illustrate  the  enhanced  CE  cleavage  by  addition  of  DMF  to  the  TBAF/THF 
reaction mixture. 
After  3  minutes,  the  heterogeneous  solvent/substrate  system  turns  into  a 
nearly homogeneous mixture and most of the starting material is consumed.  Monophosphates as model compounds                                                                           
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Figure 34: Stacked RP HPLC chromatograms of CE cleavage experiment T_CE_5 
 
 
Figure 35: Stacked RP HPLC chromatograms from CE cleavage experiment T_CE_14 
 
Based  on  these  promising  results  from  the  effective  CE  cleavage  by  using 
monophosphates  as  model  compounds,  we  investigated  further  in  the  CE 
cleavage from an oligomer. Due to the results from the polymerase acceptance 
tests, where 3′ O CE dTTP revealed better incorporation properties than 3′ O 
CEM dTTP, we focused only on the CE cleavage.  
 
5.3.3  Cleavage of the cyanoethyl function using 3′ O CE dAMP 
 
After  evaluation  of  quantitative  CE  cleavage  using  the  pyrimidine  model 
compound 97, we transferred our knowledge gained from these cleavage tests 
to  the  CE  cleavage  tests  employing  the  purine  model  compound  3′ O (2 
cyanoethyl) 2′ deoxyadenosine 5′ phosphate 104. 
The cleavage reactions were carried out in the same apparatus as described 
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or  1  mg)  was  suspended  in  a  given  solvent  and  heated  up  to  the  desired 
temperature. The cleaving agent was added and after certain time periods, 
aliquots (80 µl) were taken out, quenched on demineralized water (120 µl) and 
injected  directly  into  analytical  RP HPLC  (method  and  buffers  described  in 
detail  in  the  experimental  section).  The  chromatogram  of  both  model 
compound  104  and  commercially  available  2′ deoxyadenosine 5′ phosphate 
(dAMP), which is supposed to be identical with the model compound after CE 
deblocking, is shown in figure 36. 
 
 
Figure 36: RP HPLC chromatogram of model compound 104 and reference phosphate dAMP 
 
Here,  both  nucleotides  are  also  well  distinguishable:  The  deprotected 
nucleotide dAMP elutes significantly earlier (at 9.4 min) than the CE protected 
nucleotide 104 (at 12.68 min). The results from the CE cleavage experiments 
are  summarized  in  chart  4.  The  first  two  experiments  A_CE_1  and  A_CE_2 
didn’t reveal any unexpected results: As we already know, the CE function is 
cleavable with TBAF in THF by using minimum 40 equiv. TBAF at 40 °C for 
roughly complete CE removal (chart 4, experiment no. A_CE_1). 
In  contrast  to  that,  the  CE  function  is  stable  under  acidic  conditions  as 
experiment  no.  A_CE_2  shows:  An  excess  of  acetic  acid  (pH  2)  could  not 
remove  the  3′ blocking  group.  Therefore  the  next  experiments  A_CE_3  and 
A_CE_4  were  performed  under  already  known  conditions  at  elevated 
temperature (60 °C) and by using a higher amount of TBAF in THF. In case of 
experiment A_CE_3 we had an unexpected result as is obvious in the stacked 
chromatograms  shown  in  figure  37:  During  the  first  3  min  of  the  cleavage 
experiment, the protected starting material was consumed in favor of dAMP  Monophosphates as model compounds                                                                           
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formation.    
 
Exper. 
No. 
Reagent(s)/ 
solvent 
Equiv. 
[mol %] 
Temp. 
 [°C] 
Time [min] for 
quant. CE 
cleavage 
A_CE_1  1 M TBAF/THF  40  40  >8 
A_CE_2  0.5 M 
AcOH/water    217  40  No cleavage 
A_CE_3  1 M TBAF/THF  40  60 
Cleavage 
proceeds but with 
side reaction 
A_CE_4 
1 M 
TBAF/THF/n 
propylamine 
(TBAF/n 
propylamine 
20/1) 
80  60 
Cleavage 
complete after 3 
without side 
reaction 
Chart 4: Conditions for CEM cleavage experiments using model compound 104 
 
After the first 3 min, the reaction appeared to be reversible: A peak pattern 
with similar retention times like the one for model compound 104 increased 
even  more  during  the  next  6  min  and  didn’t  disappear  even  after  10  min 
complete reaction time.   
 
 
Figure 37: Stacked RP HPLC chromatograms of cleavage experiment A_CE_3 
 
This  observation  is  in  accord  with  the  mechanism  of  the  reaction  which  is 
supposed  to  be  a  reversible  β H  elimination.  We  assume  that  the  cleavage 
product  acrylonitrile  is  still  reactive  by  absence  of  excess  protons  but  in 
presence of active fluoride anions. This alkene still can act as Michael acceptor 
and alkylate the free 3′ hydroxy function or the exocyclic amino group of the  Monophosphates as model compounds                                                                           
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purine base. The observation of the product reversion was not made in case of 
CE cleavage experiment T_CE_4 (see chart 3) using the model compound 95. 
 
 
Figure 38: Stacked RP HPLC chromatograms of cleavage experiment A_CE_4 
 
This  nucleotide  lacks  any  exocyclic  Michael  donor  like  the  exocyclic  amino 
function  on  the  purine  base  moiety  of  104  so  that  we  assume  the  Michael 
acceptor acrylonitrile being added to the exocyclic amino group in the majority 
of cases. 
In  order  to  prevent  any  back  reaction  caused  by  reactive  acrylonitrile  n 
propylamine was added as scavenger (see chart 4, entry no. A_CE_4). This trick 
was already applied by Saneyoshi et al. in order to enable quantitative 2′ O CE 
blocking group removal
[105] in RNA synthesis and appeared to be effective in our 
case, too: The starting material was deblocked after 3 min without formation 
of alkylated by products or back reaction. The stacked chromatograms in figure 
38 illustrate the effective CE cleavage with absence of any peak patterns at 12 
to 13 min retention but presence of 3′ deprotected compound dAMP. 
 
5.3.4  Cyanoethyl cleavage on an oligomer 
 
Based on the results from the monomeric model compound 3′ O CE dTMP 97, 
we applied the optimized deblocking conditions to a short DNA oligomer (8mer) 
bearing the 2 cyanoethyl function on the 3′ terminus. For the evaluation of the 
CE cleavage on an oligodeoxynucleotide (ODN), we selected the sequence of 
the terminal region of the template oligomer from the polymerase acceptance  Monophosphates as model compounds                                                                           
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tests  consisting  of  8  nucleotides  (DNA  template  sequence  see  chapter  2.2.: 
Polymerase  Acceptance  Tests).  First  we  synthesized  the  corresponding  DNA 
8mer without cyanoethyl function as a reference oligomer. After purification 
on  anion  exchange  HPLC  and  desalting,  the  ODN  could  be  obtained  in  high 
purity  as  depicted  in  the  MALDI mass  spectrum  below  (see  figure  39).  The 
modified DNA 8mer consisting of the same sequence like the unmodified ODN 
was then synthesized bearing the CE function on the 3′ terminus. The resulting 
oligomer  was  purified  in  the  same  manner  like  the  unmodified  reference 
material  giving  the  pure  DNA  8mer  ready  for  the  cleavage  experiment  (see 
figure 40). 
The cleavage test was then carried out in the following manner: The modified 
DNA 8mer was treated with a high excess (7500 equiv) of TBAF in THF/DMF 2/3 
(v/v) and incubated for 15 min at 45 °C (see experimental section for details) 
with gentle shaking. The reaction was stopped by addition of water and the 
solvents were evaporated under reduced pressure (SpeedVac or freeze drying). 
After  desalting  the  crude  product,  OD  measurement,  purification  on  anion 
HPLC and second desalting the sample was characterized via MALDI( ) TOF mass 
spectroscopy.  
 
 
Figure 39: MALDI MS spectrum of the unmodified DNA 8mer 
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Figure 40: MALDI MS spectrum of the modified DNA 8mer with 3′ O CE terminus 
 
The  resulting  MALDI MS  spectrum  is  shown  in  figure  41.  The  mass  of  the 
obtained peak is identical with the one of the unmodified reference DNA 8 mer 
which  proves  the  efficient  CE  cleavage  employing  TBAF  in  THF/DMF.  By 
comparing  the  result  of  the  oligo  cleavage  test  to  the  results  from  the 
monomer  cleavage  tests  it  is  obvious  that  a  significantly  higher  amount  of 
cleaving agent is needed in case of the oligomer. 
 
 
Figure 41: MALDI MS spectrum of the modified DNA 8mer after CE cleavage 
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6 6    Summary 
 
 
The polymerase acceptance tests done at Fermentas’ lab using both 3′ O CEM 
dTTP  and  3′ O CE dTTP  showed  that  the  latter  nucleotide  was  better 
incorporated than the first one. Based on this knowledge all four reversible 
terminators  containing  the  2 cyanoethyl  motif  attached  to  the  3′ end  were 
synthesized within the Array SBS project. In order to enable the attachment of 
a  dye linker  system     an  issue  that  is  crucial  for  our  SBS  approach     the 
iodobases  of  the  pyrimidines  as  well  as  of  the  pyrrolo[2,3 d]pyrimidines,  as 
displayed in the first row of figure 42, had to be synthesized. 
  
 
Figure 42: The iodobases and the modified key compounds needed for the synthesis of  
reversible terminators useful for our SBS approach 
 
This PhD thesis reports the successful preparation of the three iodobases 4 
amino 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]pyrimi 
dine  31,  5 iodo 2′ deoxycytidine  66  and  2 amino 7 [2 deoxy β D erythro 
pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one  54.  For  the  prepara 
tion  of  both  pyrrolo[2,3 d]pyrimidine  nucleobases,  the  glycosylation  was  an                    Summary                                                                                                                              
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essential  step:  In  both  cases  the  best  yield  of  the  desired  nucleoside  was 
obtained  when  the  glycosylation  was  carried  out  with  sodium  hydride  in 
acetonitrile.  Another  issue  in  the  preparation  of  these  nucleosides  was  the 
synthesis of the pyrrolo[2,3 d]pyridine moieties that form the second building 
block of the nucleoside. For the synthesis of iodobase 31, two synthetic routes 
were used. The first route yielded the desired heterocycle 19 (see chapters 
4.3.1 and 4.3.2) in 7 % yield over five steps. The second route, which consists 
of six steps based on Davoll’s protocol
[56], turned out to be the more efficient 
one and gave 19 % of heterocycle  19. After glycosylation, deprotection and 
reconversion  of  the  chlorine masked  4 amino  function,  nucleoside  31  was 
obtained in sufficient amount for further synthetic steps. 
In contrast to that, the preparation of the pyrimidine base 66 was short and 
effective due to the fact that the non iodinated nucleoside was commercially 
available.  The  5 carbon selective  iodination  was  achieved  by  using  Bobek’s 
method
[83b], furnishing nucleoside 66 in a good yield of 68 % over three steps. 
The iodobase 5 iodo 2′ deoxyuridine 73 was commercially available from the 
beginning, so it was procured in sufficient amount for the elaboration of the T 
terminator synthesis.  
The synthesis of the iodobase 2 amino 7 [2 deoxy β D erythro pentofuranosyl] 
5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one  54  was  the  most  difficult  one:  The 
first  attempts  to  prepare  this  nucleobase  following  already  published 
protocols
[68a,68c,75,76]  were  not  successful.  Finally  a  complex  multi step 
strategy
[82] with masking of both the 4 hydroxy as well as the 2 amino function 
of the heterocycle with subsequent glycosylation led to the desired nucleoside, 
but in poor yield due to big loss of material during the reconversion of the 2 
amino function. In order to have enough starting material for further synthetic 
steps we had to acquire 2 grams of this expensive material.  
With  these  four  iodobases  as  starting  material,  the  four  key  compounds 
possessing  the  2 cyanoethyl  group  as  the  3′ tag  were  synthesized  and 
spectroscopically characterized. Hence this thesis reports a novel application of 
the  2 cyanoethyl  group  as  3′ O modification  for  deoxynucleosides.  For  this 
purpose a smart protecting group strategy for each nucleobase enabling the 3′ 
selective  introduction  of  the  2 cyanoethyl  group  had  been  designed  and 
evaluated. The Michael addition reported by Sekine
[57a] who already used this                    Summary                                                                                                                              
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method for the preparation of 2′ O (2 cyanoethyl) nucleotides, was the method 
of  choice  for  the  alkylation  of  the  3′ hydroxyl  function.  This  method  was 
applied for all four fully protected iodo nucleobases and delivered good yields 
of each 3′ O cyanoethylated product. In order to enable the attachment of a 
dye linker system, the iodo function of three nucleobases was transformed into 
a propargyl moiety following a standard protocol of the Sonogashira reaction. 
After  liberation  of  the  propargylamino  function  in  methanolic  aqueous 
ammonia, the three key compounds 38, 72 and 80 were obtained in moderate 
yield.  
The fourth key compound 62 did not need the propargylamine moiety for the 
next synthetic steps
[55b], but still required the CE function bound to the 3′ end: 
Therefore  we  invented  a  novel  synthetic  strategy  for  the  3′-O-selective 
introduction of the CE group by using 2′ deoxyguanosine, as presented within 
this  PhD  work.  The  elaborated  protecting  group  strategy  was  successfully 
transferred to the preparation of 2 amino 7 [3 O (2 cyanoethyl) 2 deoxy β D 
erythro pento furanosyl] 5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one  62.  These 
four 3′ O (2 cyanoethyl) bearing key compounds (see second row in figure 42) 
were  further  transformed  into  their  corresponding  complete  reversible 
terminators
[55b].  
Besides the synthesis of the four building blocks needed for the preparation of 
the complete reversible terminators, the cleavability of the CE function had to 
be evaluated. As mentioned previously, quantitative removal of the 3′ blocking 
group  is  essential  for  our  SBS approach. In  order  to  discover the  conditions 
needed for the quantitative 3′ deblocking, three 3′ modified monophosphates 
as displayed in figure 43 were designed as model compounds. 
  
 
Figure 43: The three monophosphates used for kinetic cleavage tests 
 
These previously unknown model compounds were successfully synthesized for                    Summary                                                                                                                              
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mimicking  the  properties  of  small  oligonucleotides  in  kinetic  cleavage 
experiments.  For  each  of  the  three  monophosphates  an  efficient  synthetic 
strategy has been developed. In case of the CE bearing monophosphates 95 and 
104, the synthetic route of both compounds was quite similar to the ones used 
for the modification of the iodobases 31 and 73. The synthetic strategy for the 
preparation  of  the  CEM bearing  monophosphate  88  we  have  already 
published
[102]  and  it  is  also  reported  in  my  diploma  thesis
[106].  A  modified 
Ludwig Eckstein triphosphate synthesis was used as effective phosphorylating 
method giving monophosphate 104 in moderate yield, monophosphate 88 in 
lower  yield.  For  the  preparation  of  monophosphate  95,  the  conventional 
Yoshikawa method
[92] was used. These three newly invented nucleotides have 
been purified and characterized by NMR, RP HPLC and mass spectrometry.    
With  these  three  monomers  as  model  compounds  in  hand,  several  kinetic 
cleavage experiments were carried out that led to the identification of proper 
cleavage conditions for both 3′ modifications. In case of the CE cleavage tests, 
the  cleavage  conditions  were  optimized  by  variation  of  solvents,  reaction 
temperature and the amount of cleaving agent in order to be applicable in an 
SBS experiment. Furthermore, we compared both the CE and the CEM group 
regarding  their  stability:  Contrary  to  our  assumption  the  CEM  function  was 
found  to  be  cleavable  under  very  similar  conditions  like  the  CE  group. 
Quantitative  cleavage  of  these  3′ tags  was  achieved  when  TBAF  in  THF  was 
used in an excess of minimum 40 equiv, preferably at 40 °C or 60 °C. In case of 
the CE group, which was more interesting regarding our complete reversible 
terminators,  the  cleavage  efficiency  could  be  enhanced  by  addition  of  co 
solvents like DMSO of DMF. Both 3′ blocking groups, the CE as well as the CEM 
group, were found to be remarkably stable under acidic conditions, but only 
metastable in an alkaline environment like in aqueous ammonia at elevated 
temperature  or  in  aqueous  potassium  hydroxide.  These  observations  suggest 
that the cleavage mechanism of both groups is quite similar and proceeds as β 
H elimination. 
An  additional  CE  cleavage  test  performed  with  a  short  oligomer  revealed 
further results that are in accord with the results from the cleavage tests of 
the  monomers.  One  big  difference  in  the  cleavage  efficiency  between  the 
monomers and the oligomer is the demanded amount of cleaving agent. In case                    Summary                                                                                                                              
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of the oligomer, 7500 equiv of TBAF in THF are needed, compared to 40 to 80 
equiv for the monomer, for quantitative CE removal at 45 °C. Based on this 
observation it can be assumed that the solubility of the oligomer as well as the 
concentration  of  TBAF  plays  a  very  important  role  in  the  CE cleavage 
efficiency. This was also demonstrated by Saneyoshi et al. who affirmed that 
the 2′-CE cleavage from RNA dimers and oligomers is prolonged depending on 
the size of the oligomer
[104].      
However, the CE cleavage experiment employing the DNA 8mer proved that the 
CE function is quantitatively removable with TBAF in THF without destruction 
of the oligomer. Moreover, the results from the kinetic experiments carried out 
in strong alkaline environment confirmed the reversibility of the 2 cyanoethyl 
and the (2 cyanoethoxy)methyl function as 3′ blocking groups. As a result of the 
extensive  tests  run  with  the  monophosphate  97  we  released  a  publication 
covering  the  monophosphate  synthesis  and  the  results  of  the  CE  cleavage 
experiments
[107]. The CE cleavage conditions used for the DNA 8mer cleavage 
test are now applied to our SBS proof of principle using array bound hairpin 
shaped templates and are at the stage of being optimized.     Zusammenfassung                                                                                                            
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6 6  Zusammenfassung 
 
 
In  Fermentas‘  Polymerase Akzeptanztests,  die  sowohl  jeweils  mit  3′ O CEM 
dTTP als auch mit 3′ O CE dTTP als Substrat durchgeführt wurden, zeigte sich, 
dass letzteres der beiden Nukleotide besser eingebaut wurde als ersteres. Auf 
diesem Wissen basierend wurden alle vier reversiblen Terminatoren, welche die 
Cyanoethyl Gruppe  am  3′ Ende  besitzen,  im  Rahmen  des  Array SBS Projekts 
synthetisiert. Um die – für unseren SBS Ansatz essentielle – Verknüpfung mit 
einem Farbstoff Linker System zu ermöglichen, mussten die jodierten Nukleosi 
de der Pyrimidine als auch die der Pyrrolo[2,3 d]pyrimidine, wie in Abbildung 
42 in der oberen Reihe gezeigt, hergestellt werden. 
 
 
Abbildung 42: Die jodierten Basen und die modifizierten Schlüsselverbindungen, die zur  
Synthese  reversibler  Terminatoren  für  den  Einsatz  in  einem  SBS  Ansatz 
notwendig sind 
 
Die vorliegende Doktorarbeit beschreibt die erfolgreiche Darstellung der drei 
jodierten  Basen  4 Amino 7 [2 desoxy β D erythro pentofuranosyl] 5 jod 7H 
pyrrolo[2,3 d]pyrimidin 31, 5 Jod 2′ desoxycytidin 66 und 2 Amino 7 [2 desoxy   Zusammenfassung                                                                                                            
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β D erythro pentofuranosyl] 5 jod 7H pyrrolo[2,3 d]pyrimidin 4 on  54.  Die 
Glykosylierung  war  von  zentraler  Bedeutung  in  der  Herstellung  der  beiden 
Pyrrolo[2,3 d]pyrimidino Nukleoside:  In  beiden  Fällen  wurde  die  beste 
Ausbeute  an  gewünschtem  Nukleosid  erzielt,  wenn  die  Reaktion  mit 
Natriumhydrid in Acetonitril durchgeführt wurde. Ein weiterer wichtiger Punkt 
in  der  Darstellung  dieser  Nukleoside  war  die  Synthese  der  Pyrrolo[2,3 
d]pyrimidin Einheit, die dem zweiten Bestandteil der Nukleinsäuren entspricht. 
Für die Synthese von Verbindung 31 wurden zwei Syntheserouten verifiziert. 
Syntheseroute  1  lieferte  den  gewünschten  Heterozyklen  19  in 7  %  Ausbeute 
über fünf Stufen. Syntheseroute 2, die über sechs Stufen verlief und auf der 
Veröffentlichung von Davoll
[56] basierte, lieferte 19 % des Heterozyklen 19 und 
war  damit  die  erfolgreichere  der  beiden  Synthesestrategien.  Nach  der 
Glykosylierung, Entschützung und Rücktransformation der mit Chlor maskierten 
Aminogruppe in 4 Position wurde das Nukleosid 31 in ausreichender Menge für 
die nächsten Syntheseschritte erhalten.  
Im Gegensatz dazu war die Darstellung der Pyrimidinbase 66 kurz und effizient 
aufgrund der Tatsache, dass die nichtjodierte Nucleobase käuflich zu erwerben 
war.  Die  C5 selektive  Jodierung  wurde  unter  Verwendung  der  Methode  von 
Bobek
[83b] erzielt, die das Nukleosid 66 in guter Ausbeute von 68 % lieferte. Die 
jodierte Base 5 Jod 2′ desoxyuridin war von Anfang an käuflich zu erwerben, 
daher stand sie uns im ausreichenden Maße zur Verfügung, um die Synthese des 
T Terminators auszuarbeiten.  
Die  Synthese  der  jodierten  Base  2 Amino 7 [2 desoxy β D erythro pento 
furanosyl] 5 jod 7H pyrrolo[2,3 d]pyrimidin 4 on  war  die  schwierigste:  Erste 
literaturbekannte  Ansätze  zur  Synthese  dieses  Nukleosids  blieben  zunächst 
erfolglos
[68a,68c,75,76].  Letztendlich  führte  eine  komplexe  mehrstufige 
Strategie
[82],  die  auf  der  Maskierung  der  4 Hydroxyl   als  auch  der  2 Amino 
Gruppe des Heterozyklen mit anschließender Glykosylierung basiert, zum Erfolg 
und  lieferte  das  erwünschte  Nukleosid,  jedoch  in  sehr  niedriger  Ausbeute 
aufgrund  des  hohen  Substanzverlusts  bei  der  Rücktransformation  der  2 
Aminogruppe. Um genügend Startmaterial für die weiteren Syntheseschritte zu 
besitzen, mussten 2 Gramm dieser teuren Substanz erworben werden. 
Mit  diesen  vier  jodierten  Basen  als  Ausgangsverbindungen  wurden  die  vier 
Schlüsselverbindungen, die die Cyanoethyl Funktion als 3′ blockierende Gruppe   Zusammenfassung                                                                                                            
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besitzen,  synthetisiert  und  spektroskopisch  charakterisiert.  Demzufolge 
beschreibt  die  vorliegende  Dissertation  eine  neuartige  Anwendung  der 
Cyanoethyl Gruppe  als  3′ O Modifikation  für  Desoxynukleotide.  Zu  diesem 
Zweck ist eine clevere Schutzgruppenstrategie, die die 3′ selektive Einführung 
der Cyanoethyl Gruppe an dem jeweiligen Nukleosid ermöglicht, entworfen und 
durchgeführt worden. Die Michael Addition, welche von Sekine
[57a] publiziert 
und  zur  Herstellung  von  2′ O (2 Cyanoethyl) Nukleotiden  genutzt  wurde,  war 
hierbei  die  Methode  der  Wahl  zur  Alkylierung  der  3′ Hydroxyfunktion.  Diese 
Methode  wurde  für  alle  komplett  geschützten  Jodnukleoside  verwendet  und 
lieferte das jeweilige gewünschte 3′ O Cyanoethyl gelabelte Produkt in guter 
Ausbeute. Um die Anbindung eines Fluorophor Linker Systems zu ermöglichen 
wurde die jeweilige Jodfunktion der drei Nukleobasen mittels Standardmethode 
der  Sonogashira  Reaktion  in  eine  Propargylamineinheit  umgewandelt.  Nach 
Freisetzung der Propargylamino Gruppe in wässrig methanolischer Ammoniak 
lösung  wurden  die  drei  Schlüsselverbindungen  38,  72  und  80  in  mäßiger 
Ausbeute erhalten. 
Die vierte Schlüsselverbindung 62 benötigte für die weiteren Syntheseschritte 
keine  Propargylamin Funktion
[55b],  jedoch  war  die  Cyanoethyl Gruppe  am  3′ 
Ende notwendig: Hierzu entwickelten wir eine neuartige Synthesestrategie zur 
3′ O selektiven Einführung der Cyanoethyl Gruppe unter der Verwendung von 
2′ Desoxyguanosin. Die erarbeitete Schutzgruppenstrategie konnte anschließend 
in die Synthese zur Herstellung von 2 Amino 7 [3 O cyanoethyl 2 desoxy β D 
erythro pentofuranosyl] 5 jod 7H pyrrolo[2,3 d]pyrimidin 4 on 62 übernommen 
werden.  Diese  vier  3′ O (2 Cyanoethyl) blockierten  Schlüsselverbindungen 
(siehe  zweite  Reihe  in  Abbildung  42)  wurden  dann  in  die  entsprechenden 
vollständigen reversiblen Terminatoren umgesetzt
 [55b]. 
Neben  der  Synthese  der  vier  grundlegenden  Bausteine  zur  Herstellung  der 
kompletten  reversiblen  Terminatoren  war  auch  die  Spaltbarkeit  der 
Cyanoethyl Funktion  zu  prüfen.  Wie  schon  vorher  erwähnt  wurde,  ist  die 
quantitative  Abspaltung  der  3′ Modifikation  für  unseren  SBS  Ansatz 
unabdingbar.  Um  die  Bedingungen,  die  zur  quantitativen  Abspaltung  der  3′ 
blockierenden  Gruppe  notwendig  sind,  herauszufinden,  wurden  die  drei  in 
Abbildung  43  gezeigten  3′ modifizierten  Monophosphate  entworfen.  Diese 
bislang  unbekannten  Modellverbindungen,  welche  die  Eigenschaften  kleiner   Zusammenfassung                                                                                                            
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Oligonukleotide  in  kinetischen  Spaltungstests  nachahmen  sollten,  wurden 
erfolgreich hergestellt. 
 
  
Abbildung 43: Die drei für die kinetischen Spaltungstests verwendeten Monophosphate 
 
Für jedes dieser drei Monophosphate wurde eine effiziente Synthesestrategie 
entwickelt.  Im  Falle  der  CE gelabelten  Monophosphate  95  und  104  war  die 
jeweilige  Syntheseroute  den  Synthesestrategien  ähnlich,  die  schon  zur 
Modifikation  der  beiden  jodierten  Basen  31  und  73  verwendet  wurden.  Wir 
veröffentlichten bereits die Darstellung
[102] des CEM gelabelten Monophosphats 
88, die auch in meiner Diplomarbeit
[106] beschrieben ist. Eine Abwandlung der 
Ludwig Eckstein  Triphosphatsynthese  wurde  als  wirkungsvolle  Phosphorylier 
ungsmethode eingesetzt, die Monophosphat 104 in mäßiger, Monophosphat 88 
in niedrigerer Ausbeute lieferte. Zur Herstellung des Monophosphats 95  wurde 
die  konventionelle  Methode  nach  Yoshikawa
[92]  angewandt.  Diese  drei 
neuentwickelten  Nukleotide  wurden  aufgereinigt  und  mittels  RP HPLC,  NMR  
und Massenspektrometrie charakterisiert.  
Mit  den  drei  Monomeren  in  Händen  wurden  mehrere  kinetische  Spaltungs 
experimente  durchgeführt,  die  zu  der  Bestimmung  passender  Spaltungs 
bedingungen  für  beide  3′ Modifikationen  führte.  Im  Falle  der  Cyanoethyl 
Spaltungstests  konnten  die  Spaltungsbedingungen  für  die  Cyanoethyl Gruppe 
sogar  optimiert  werden,  indem  das  Lösungsmittel,  die  Reaktionstemperatur 
sowie  die  eingesetzte  Menge  an  Spaltungsreagenz  variiert  wurde,  um  die 
Bedingungen für ein SBS Experiment anwendbar zu machen. 
Darüber  hinaus  verglichen  wir  die  CE Gruppe  mit  der  CEM Gruppe  bezüglich 
ihrer  Stabilitäten:  Entgegen  unserer  Annahme  zeigte  sich,  dass  die  CEM 
Funktion  unter  sehr  ähnlichen  Bedingungen  wie  die  CE Gruppe  gespalten 
wurde.  Eine  quantitative  Spaltung  dieser  3′ blockierenden  Gruppen  wurde 
durch  die  Verwendung  von  40  bis  80  Äquivalenten  als  Mindestüberschuss  an   Zusammenfassung                                                                                                            
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TBAF  in  THF  erzielt,  vorzugsweise  bei  40  °C  oder  60  °C.  Im  Falle  der 
Cyanoethyl Gruppe, die bezüglich der kompletten reversiblen Terminatoren die 
interessantere  Gruppe  war,  konnte  die  Effizienz  der  Spaltbarkeit  durch  den 
Einsatz von Cosolventien wie DMSO oder THF noch gesteigert werden. Sowohl 
die  CE   als  auch  die CEM Gruppe  waren  erstaunlich  stabil  im  sauren  Milieu, 
allerdings nur metastabil im basischen wie z.B. in  wässrig ammoniakalischer 
Lösung  bei  erhöhten  Temperaturen  oder  in  wässriger  Kaliumhydroxidlösung. 
Diese Beobachtungen suggerieren, dass der Spaltungsmechanismus der beiden 
Gruppen sehr ähnlich sein und nach einer β H Eliminierung verlaufen muss.  
Ein  zusätzliches  Cyanoethyl Spaltungsexperiment,  das  mit  einem  kurzen 
Oligomer durchgeführt wurde, lieferte weitere Resultate, die mit den aus den 
Spaltungstests  der  Monomere  gewonnenen  übereinstimmen.  Ein  großer 
Unterschied  zwischen  den  Monomeren  und  dem  Oligomer  bezüglich  der 
Spaltungseffizienz ist die benötigte Menge an Spaltungsreagenz. Im Falle des 
Oligomers werden 7500 Äquivalente benötigt, um die Cyanoethyl Gruppe bei 45 
°C  vollständig  zu  entfernen.  Im  Gegensatz  dazu  werden  im  Falle  des 
Monophosphats  nur  40  bis  80  Äquivalente  benötigt.  Basierend  auf  dieser 
Beobachtung kann man annehmen, dass sowohl die Löslichkeit des Oligomers 
als auch die TBAF Konzentration eine entscheidende Rolle in der Effizienz der 
CE Spaltung spielt. Dies wurde auch schon von Saneyoshi et al. demonstriert, 
der postulierte, dass im Falle der RNA die Abspaltung der Cyanoethyl Gruppe 
vom 2′ Ende in Abhängigkeit von der Größe des Oligomers verzögert wird
[104]. 
Trotzdem konnte mit dem CE Spaltungsexperiment, welches mit dem kurzen 
Oligomer durchgeführt wurde, gezeigt werden, dass die CE Gruppe mit TBAF in 
THF  quantitativ  abspaltbar  ist,  ohne  das  Oligonukleotid  zu  zerstören. 
Darüberhinaus wurde die Spaltbarkeit und damit Reversiblität der CEM  und der 
CE Gruppe als 3′ blockierende Gruppen bestätigt. Als Resultat der Erkenntnisse 
aus  den  intensiven  Spaltungstests,  die  mit  Monophosphat  97  durchgeführt 
wurden,  veröffentlichten  wir  eine  Publikation,  welche  die  Monophosphat 
synthese und die Ergebnisse aus den CE Spaltungsexperimenten beinhaltet
[107]. 
Die  Bedingungen  aus  dem  CE Oligo Spaltungstest  werden  derzeit  in  unserem 
SBS „Proof of Principle“,  welches  mit  Hairpin Templaten  auf  einem  Array 
durchgeführt wird, angewandt und optimiert.  Experimental part                                                                                                                
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7 7    Experimental part 
 
7.1   Chromatography 
 
7.1.1  Preparative Column Chromatography 
 
Column  chromatography  was  performed  at  atmospheric  pressure  using  Silica 
Gel 60 from Roth. 
7.1.2  Thin Layer Chromatography (TLC) 
 
Thin  layer  chromatography  was  carried  out  on  Silica  Gel  60  F254 coated 
aluminum sheets from Merck. The separated compounds were visualized by UV 
absorption at λ = 254 nm (Camag UV lamp). 
 
7.1.3  Fast Protein Liquid Chromatography (FPLC) 
 
FPLC  purification  of  the  monophosphates  was  performed  on  a  Pharmacia 
reversed phase FPLC system consisting of LCC 500 Plus controller, two P 500 
pumps and one single path UV Monitor UV 1. The monophosphate sample was 
loaded on a column packed with octadecyl functionalized silica gel from Sigma 
Aldrich  with  peristaltic  pump  P1,  fractions  were  collected  with  a  fraction 
collector RediFrac. Further purification of the monophosphates was performed 
on RP HPLC. 
 
7.1.4  Buffers and methods for RP FPLC 
 
Preparative purification of the monophosphates was done at 4°C. The following 
method for the purification of the monophosphates was used: 
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Method FPLC 3: 
 
Buffer A: demineralized water 
Buffer B: ACN 
 
Volume [ml]  Function  Value 
0.00  CONC %B  0.0 
0.00  ML/MIN  4.00 
0.00  CM/ML  0.10 
0.00  ML/MARK  20 
0.00  CLEAR DATA   
0.00  MONITOR  1 
0.00  LEVEL %  0.5 
0.00  VALVE.POS  1.1 
0.00  PORT.SET  6.1 
0.00  PORT.SET  3.1 
0.00  VALVE.POS  1.1 
450.00  CONC %B  10.0 
500.00  CONC %B  50.0 
550.00  CONC %B  100 
560.00  CONC %B  0.0 
560.00  PORT.SET  3.0 
560.00  PORT.SET  6.0 
560.00  INTEGRATE  1 
560.00  PRT PK  1.20 
561.00  CONC %B  0.0 
561.00  ML/MIN  0.30 
561.00  HOLD   
 
7.1.5  Reversed phase High Performance Liquid Chromatography (RP HPLC) 
 
Preparative HPLC purification of all monophosphates after synthesis was done 
on reversed phase using semipreparative column Phenomenex Jupiter 4µ Proteo 
90 Ångstrøm (250 x 15 mm) (at 300 K in Thermotechnic products Jetstream plus 
column thermostat) on a Jasco RP HPLC system consisting of Jasco interface 
LC NetII/ADC,  Jasco  intelligent  HPLC  pump  PU 2080  Plus,  Jasco  intelligent 
UV/vis  detector  UV 2075  Plus,  Jasco  ternary  gradient  unit  LG 2080 02  and  Experimental part                                                                                                                
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Jasco 3 line degasser DG 2080 53. The crude monophosphates as well as the 
samples from the deprotection tests were filtered with syringe filters Spartan 
13/0,45 RC (0.45 µm) from Whatman before injection. Analysis of the samples 
from cleavage tests was performed on analytical column Phenomenex Jupiter 
4µ Proteo 90 Ångstrøm (250 x 4.6 mm) with the same Jasco HPLC system as 
described above. Samples were loaded by direct injection or autosampler Jasco 
intelligent sampler AS 950 10.  
 
7.1.6  Buffers and methods for RP HPLC 
 
For analysis of the samples from cleavage experiments (loaded by auto sampler 
or direct injection) as well as for characterization of the monophosphates the 
following method was used: 
 
Method A: 
Buffer A: 1 M TEAA aqueous solution 
Buffer B: demineralized water 
Buffer C: ACN 
Initial conditions: Flow: 1 ml/min; 10% A, 90% B, 0% C 
Autosampler: Normal injection mode, Number of flush: 1 
UV Detector: wavelength 254 nm 
Time table for gradient: 
Time 
[min] 
Flow 
[ml/min]  %A  %B  %C 
20.00  1.000  10.0  60.0  30.0 
21.00  1.000  0.0  0.0  100.0 
25.00  1.000  0.0  0.0  100.0 
26.00  1.000  10.0  90.0  0.0 
30.00  1.000  10.0  90.0  0.0 
 
For preparative purification of monophosphate 95 the following method was 
applied: 
 
Method B: 
Buffer A: 1 M TEAA aqueous solution 
Buffer B: demineralized water 
Buffer C: ACN  Experimental part                                                                                                                
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Initial conditions: Flow: 7 ml/min; 5% A, 95% B, 0% C 
UV Detector: wavelength 254 nm 
Time table for gradient: 
Time 
[min] 
Flow 
[ml/min]  %A  %B  %C 
20.00  7.000  5.0  65.0  30.0 
21.00  7.000  0.0  0.0  100.0 
25.00  7.000  0.0  0.0  100.0 
26.00  7.000  5.0  95.0  0.0 
30.00  7.000  5.0  95.0  0.0 
 
For preparative purification of monophosphate 97 the following method was 
used: 
 
Method C: 
Buffer A: 1 M TEAA aqueous solution 
Buffer B: demineralized water 
Buffer C: ACN 
Initial conditions: Flow: 7 ml/min; 5% A, 92% B, 3% C 
UV Detector: wavelength 254 nm 
Time table for gradient: 
Time 
[min] 
Flow 
[ml/min]  %A  %B  %C 
20.00  7.000  5.0  80.0  15.0 
22.00  7.000  5.0  0.0  95.0 
27.00  7.000  5.0  0.0  95.0 
29.00  7.000  5.0  95.0  0.0 
35.00  7.000  5.0  95.0  0.0 
 
For  preparative  purification  of  monophosphates  88  and  104  method  C  was 
used: 
 
Method D: 
Buffer A: 1 M TEAA aqueous solution 
Buffer B: demineralized water 
Buffer C: MeOH 
Initial conditions: Flow: 6 ml/min; 5% A, 95% B, 0% C 
UV Detector: wavelength 254 nm 
Time table for gradient: 
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Time 
[min] 
Flow 
[ml/min]  %A  %B  %C 
15.00  6.000  5.0  65.0  30.0 
18.00  5.000  0.0  0.0  100.0 
25.00  5.000  0.0  0.0  100.0 
28.00  5.000  5.0  95.0  0.0 
30.00  6.000  5.0  95.0  0.0 
 
7.1.7  Anion exchange High Performance Liquid Chromatography 
 
The synthesized oligomers (octamers) were purified on semipreparative anion 
exchange HPLC consisting of Dionex DNA Pac © PA 100 column (9 x 250 mm), 
Jasco intelligent UV vis detector UV 970, Jasco intelligent HPLC pump PU 980, 
Jasco  ternary  gradient  unit  LG 980 02,  Jasco  3 line  degasser  DG 980 50  and 
Jasco interface LC NetII/ADC. 
 
7.1.8  Buffers and method for anion exchange HPLC 
 
The  oligonucleotides  were  purified  on  semipreparative  anion exchange  HPLC 
using the following method: 
 
Method E: 
Buffer A: demineralized water 
Buffer B: 0.25 M Tris Cl aqueous solution (pH = 8) 
Buffer C: 1 M NaCl aqueous solution 
Initial conditions: Flow: 5 ml/min; 85% A, 10% B, 5% C 
UV Detector: wavelength 254 nm 
Time table for gradient: 
Time 
[min] 
Flow 
[ml/min]  %A  %B  %C 
20.00  5.000  65.0  10.0  25.0 
23.00  5.000  0.0  0.0  100.0 
25.00  5.000  0.0  0.0  100.0 
27.00  5.000  85.0  10.0  5.0 
30.00  5.000  85.0  10.0  5.0 
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7.1.9  Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
NMR spectra (
1H and 
13C) of nucleosides and other compounds were recorded in 
CDCl3 or DMSO d6 on a Bruker AM 250 spectrometer operating at 250.132 MHz. 
NMR spectra (
1H, 
13C, 
31P and two dimensional spectra) of the monophosphate, 
triphosphate and phosphoramidite were measured in D2O or acetone d6 on a 
Bruker Avance 400 spectrometer operating at 400.132 MHz (161.984 MHz for 
coupled 
31P NMR, measured against 85 % phosphoric acid as external standard). 
Chemical  shifts  (δ)  are  given  in  ppm  downfield  from  tetramethylsilane  and 
coupling constants (J) in Hz. All spectra were measured at 300 K. Peak patterns 
of each signal are characterized with the following abbreviations: s for singlet, 
d for doublet, dd for double doublet, t for triplet, ψt for pseudo triplet, q for 
quartet and m for multiplet. 
 
7.1.10  Mass spectrometry 
 
Mass spectra were recorded on a Fisons MALDI VG time of flight (Tofspec) mass 
spectrometer  in  positive  or  negative  mode  using  ATT  matrix  or  on  a  Fisons 
Electrospray(ES) VG Platform II mass spectrometer. 
 
7.1.11  Elementary analysis 
 
Elementary  analyses  were  performed  on  a  CHN O Rapid  analyzer  from  Foss 
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7.1.12  List of chemical reagents 
7.1.12.1  Chemicals for Synthesis 
 
   Acetic acid, glacial p.a.; C2H4O2 [60.05], bp 118 °C, d = 1.05, Merck    
   Acetic acid anhydride, 99 % p.a.; C4H6O3 [102.09], bp 139 °C, d = 1.08,  
Grüssing 
   Acetone, p.a.; C3H6O [58.08], bp 56.1 °C, d = 0.791, Acros Organics 
   Acetone d6, H2O+D2O < 0.02 %; euriso top 
   Acetonitrile, abs. over molecular sieves ≥99.5 %; C2H3N [41.05], bp 81   82  
°C, d = 0.786, Fluka 
   Acetonitrile, HPLC Gradient grade Far UV, C2H3N [41.05], bp 81   82 °C, d =  
0.786, Fisher Scientific 
   Acetyl chloride, 98 %; C2H3ClO [78.5], bp 51 °C, d = 1.1, Acros Organics 
   Acrylonitrile, puriss., ≥99.5 %; C3H3N [53.06], bp 77°C, d = 0.806, Fluka 
   2 Amino 6 hydroxy 4 mercapto pyrimidine monohydrate, 98 %; C4H5N3OS  
[161.18], mp > 300 °C, Sigma Aldrich 
   Ammonia, 25 % aqueous solution; H3N [17.03]; d = 0.88; Grüssing  
   Ammonia, 32 % aqueous solution; H3N [17.03]; d = 0.88; VWR 
   Ammonium acetate, ≥99.0 %; C2H7NO2 [77.08]; mp 110 – 112 °C; Fluka 
   p Anisylchlorodiphenylmethane, 97 %; C20H17ClO [308.80]; Acros Organics 
   Argon, Quality 4.6 (99.996 Vol. %) 
   Benzoyl chloride, 99 %; C7H5ClO [140.57], bp 68 °C, d = 1.21; Acros  
Organics 
   1,8 bis (dimethylamino) naphthalene, ≥99.0 %; C14H18N2 [214.31], mp 45 –  
48 °C; Fluka 
   N,O Bis (trimethylsilyl) acetamide, purum ≥95.0 %; C8H21NOSi2 [203.43], bp  
71   73°C, d = 0.832, Fluka 
   Bromoacetaldehyde diethyl acetal, techn. ≥90 %; C6H13BrO [197.08]; bp 170  
  172°C, d = 1.27; Fluka 
   tert Butanol, p.a. ACS ≥99.7 %; C4H10O [74.12]; bp 82   83°C, d = 0.79;  
Fluka 
   2 Butanone; C4H8O [72.11]; bp  80°C, d = 0.805; Fluka 
   Carbon tetrachloride; CCl4 [153.82]; bp 76 – 77 °C, d = 1.594; Merck  Experimental part                                                                                                                
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   Celite® 500; Fluka 
   Cesium carbonate, 99.9 % (metal basis); CCs2O3 [325.82]; Alfa Aesar 
   3 Chloroperoxybenzoic acid, 50 – 55 % in water; C7H5ClO3 [172.57]; mp 93 –  
95 °C; Alfa Aesar 
   Chloroform d1, 99.80 % D; stabilized with silver foil, H2O < 0.01 %; euriso  
top 
   Copper iodide, pure; CuI [190.45]; mp 605 °C; Riedel de Haёn 
   (2 Cyanoethyl) di(N,N diisopropyl)phosphine, ≥98.0 %; C15H32N3OP [301.41];  
bp 100°C, d = 0.949; Fluka 
   5 Deaza 2′ deoxy 5 iodo guanosine; C11H13IN4O4 [392.15]; ChemBiotech 
   2′ Deoxyadenosine; C10H13N5O3 [251.24]; Pharma Waldhof  
   2′ Deoxycytidine hydrochloride; C9H13N3O4 HCl [263.68]; Pharma Waldhof 
   2′ Deoxyguanosine; C10H13N5O4 [267.24]; Pharma Waldhof 
   2 Deoxy D ribose, ≥99.0 %; C5H10O4 [134.13]; mp 89   90°C; Fluka 
   2′ Deoxythymidine; C10H14N2O5 [242.23]; Pharma Waldhof 
   Deuterium oxide, 99.9 %; Deutero GmbH 
   2,4 Diamino 6 hydroxypyrimidine, purum ≥98 %; C4H6N4O [126.18]; mp 286 –  
288°C; Fluka 
   1,2 Dichloroethane, abs. over molecular sieve ≥99.5 %; C2H4Cl2 [98.96]; bp  
83°C, d = 1.256; Fluka 
   Dichloromethane, abs. over molecular sieve ≥99.5 %; CH2Cl2 [84.93]; bp  
40°C, d = 1.325; Fluka 
   4,5 Dicyanoimidazole, purum, ≥97 %; C5H2N4 [118.10]; mp 174 – 178°C;  
Fluka 
   Dicyclohexyl 18 crown 6, purum ≥97.0 %; C20H36O6 [372.50]; bp 47 – 50 °C;  
Fluka 
   Diethyl ether, p.a.; Merck; C4H10O [74.12]; bp 34.6 °C, d = 0.71; Merck 
   Diisopropylethylamine, purum ≥98 %; C8H19N [129.25]; bp 126   128°C, d =  
0.755; Fluka 
   N,N Dimethylaniline, 99 %; C8H11N [121.18]; bp 193°C, d = 0.95; Acros  
Organics 
   4 Dimethylaminopyridine, ≥99.0 %; C7H10N2 [122.17]; bp 190 – 192 °C, d =  
1.01; Fluka 
   N,N Dimethyl formamide, abs. over molecular sieve ≥99.8 %; C3H7NO   Experimental part                                                                                                                
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[73.09]; bp 153°C, d = 0.944; Fluka 
   N,N Dimethyl formamide dimethyl acetal, purum ≥95.0 %; C5H13NO2  
[119.16]; bp 102 – 103°C, d = 0.897; Fluka 
   Dimethyl sulfoxide, abs. over molecular sieve ≥99.5 %; C2H6OS [78.13]; bp  
189°C, d = 1.10; Fluka 
   Dimethyl sulfoxide d6, H2O < 0.02 %; euriso top 
   1,4 Dioxane, abs. over molecular sieve ≥99.5 %; C4H8O2 [88.11]; bp 100 –  
102°C, d = 1.034; Fluka 
   Dowex 50W x 8 (200 – 400 mesh), p.a., H
+ form; Fluka 
   Ethanol, ≥ 99.8 %; C2H6O [46.07]; bp 78 °C, d = 0.79; Roth 
   Ethyl cyanoacetate, purum ~ 99 %; C5H7NO2 [113.12]; bp 207   210°C, d =  
1.061; Fluka 
   Ethylenediamine tetraacetic acid disodium salt, analytical grade;  
C10H14N2O8Na2 2H2O [372.3]; Serva 
   n Hexane, p.a.; C6H14 [86.18]; bp 69 °C, d = 0.66; Grüssing  
   Hydrochloric acid, p.a. 37 %; HCl [36.46]; bp > 100 °C, d = 1.19; Merck  
   3 Hydroxypropionitrile, 98 %; C3H5ON [71.08]; bp 227 228°C, d = 1.041; Alfa  
Aesar 
   Iodic acid, p.a. ≥ 99.5 %; HIO3 [175.91]; Fluka 
   Iodine; I2 [253.81]; mp 184 °C; Fluka 
   Iodomethane, 99 % stabilized; CH3I [141.94]; bp 41 – 43°C, d = 2.28; Acros  
Organics 
   5 Iodo 2′ deoxyuridine; C9H11IN2O5 [354.10]; Pharma Waldhof 
   N iodosuccinimide, ≥97 %; C4H4INO2 [224.98]; Fluka 
   Magnesium sulfate, pure 99 %; MgSO4 [120.37]; Grüssing 
   Methanol, abs. over molecular sieve ≥99.5 %; CH4O [32.04]; bp 64.7°C, d =  
0.791; Fluka 
   Molecular sieve 3 Å; Riedel de Haёn 
   Phosphorus oxychloride, ≥99 %; POCl3 [153.33]; bp 105   110°C, d = 1.67;  
Riedel de Haёn 
   Pivaloyl chloride, purum ≥98.0 %; C5H9ClO [78.13]; bp 105   106°C, d =  
0.980; Fluka 
   Potassium fluoride, 99.99 % (metal basis); KF [58.10]; mp 859°C; Alfa Aesar 
   Potassium bis(trimethylsilyl)amide, 95 %; C6H18KNSi2 [199.49]; Sigma Aldrich  Experimental part                                                                                                                
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   Potassium hydroxide, p.a. 99 %; KOH [56.11]; mp 361 °C; Grüssing 
   Potassium iodide, puriss.; KI [166.00]; mp 681 °C; Riedel de Haёn 
   n Propylamine, ≥99 %; C3H9N [59.11]; bp 48 °C; Sigma Aldrich  
   Pyridine, abs. over molecular sieve ≥99.8 %; C5H5N [79.10]; bp 115°C, d =  
0.978; Fluka 
   Pyridine, 99.5 %; C5H5N [79.10]; bp 115°C, d = 0.978; Grüssing 
   syn 2 Pyridinealdoxime, 99+ %; C6H6N2O [122.12]; Sigma Aldrich 
   Nickel Aluminum, Raney type, Ni/Al 50/50 wt %, aqueous suspension; Acros  
Organics 
   Sodium acetate, anhydrous, powder extra pure; C2H3NaO2 [82.03]; mp > 300  
°C; Riedel de Haёn  
   Sodium carbonate, extra pure, anhydrous; Na2CO3 [105.99]; mp 851 °C;  
Merck  
   Sodium chloride, ≥99.5 %; NaCl [58.44]; mp 801 °C; Fluka 
   Sodium dihydrogen phosphate monohydrate, ACS; NaH2PO4 H2O [137.99];  
mp 100 °C ( H2O); Merck 
   Sodium ethoxide, 96 %, pure; C2H5NaO [68.04]; mp >300 °C; Acros Organics 
   Sodium hydride, 57 – 63 % oil dispersion; NaH [24.00]; mp 800 °C; Lancaster 
   Sodium hydrogen carbonate, pure 99 %; NaHCO3 [84.01]; Grüssing  
   Sodium hydroxide, 99 %, p.a.; NaOH [40.00]; mp 318 °C; Grüssing 
   Sodium methoxide, purum ≥97 %; CH3NaO [54.02]; mp >300 °C; Fluka 
   Sodium perchlorate; NaClO4 [122.44]; mp 468 °C; Sigma Aldrich  
   Sulfuryl chloride, 97 %; SO2Cl2 [134.97]; bp 69 °C, d = 1.68; Acros Organics 
   Tetra n butylammonium fluoride trihydrate 98 %; C16H36FN 3H2O [315.52];  
mp 55 – 57 °C; Alfa Aesar 
   Tetra n butylammonium fluoride 1.0 M solution in THF; C16H36FN [261.47];  
d = 0.903; Sigma Aldrich 
   1,1,3,3 Tetra isopropyl 1,3 dichloro disiloxane; Wacker 
   1,1,3,3 Tetramethylguanidine 99 %; C5H13N3 [115.18]; bp 52 – 54 °C, d =  
0.917; Lancaster 
   Tetrakis(triphenylphosphine)palladium, ≥97 %, pure; C72H60P4Pd [1155.56];  
Fluka  
   Tetrahydrofuran, abs. over molecular sieve (H2O ≤ 0.005 %); C4H8O [72.11];  
bp 65 – 67 °C, d = 0.889; Fluka  Experimental part                                                                                                                
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   Thiourea, p.a. ACS reagent ≥99.0 %; CN2H4S [76.12]; mp 174 – 177 °C;  
Sigma Aldrich 
   Toluene, p.a. 99.5 %; C7H8 [92.14]; bp 110 – 111 °C, d = 0.865; Grüssing 
   p Toluenesulfonic acid monohydrate, puriss. ≥98.5 %; C7H8O3S H2O [190.22];  
mp 102   105°C, Fluka 
   p Toluoyl chloride, 98 %; C8H7ClO [154.60]; bp 95 – 96 °C, d = 1.16; Acros  
Organics 
   Triethylamine, p.a. ≥99.5 %; C6H15N [101.19]; bp 88   89°C, d = 0.727; Fluka 
   Triethylamine trihydrofluoride, purum ~ 37 % HF; C6H15N 3HF [161.21]; bp  
70°C; d = 0.99; Fluka 
   Trifluoroacetic acid, 99 %; CF3CO2H [114.02]; bp 72 – 73 °C, d = 1.48; Alfa  
Aesar 
   Trimethyl phosphate, purum ≥97 %; C3H9O4P [140.08]; bp 192   194°C, d =  
1.213; Fluka 
   Trimethylsilyl chloride, puriss. ≥99.0 %; C3H9ClSi [108.64]; bp 57°C, d =  
0.856; Fluka 
   Tris(dioxa 3,6 heptyl)amine, 95 %, C15H33NO6 [323.42]; bp d = 1.01; Acros  
Organics 
7.1.12.2  Chemicals for Oligonucleotide Synthesis 
 
Oligonucleotide synthesis was performed on a DNA synthesizer Expedite Nucleic 
Acid Synthesis System from Perseptive Biosystems.  
   Acetonitrile  for  DNA  synthesis  and  as  amidite  diluents,  Perseptive 
Biosystems 
   Activator, Proligo Biochemie 
   Capping Reagents (Cap A and Cap B), Proligo Biochemie 
   DNA synthesis columns (1 µmol dT 500 Å CPG) from Applied Biosystems 
   3′ phosphoramidites from Pharmacia Biotech 
   5′ phosphoramidites for the inverse synthesis (direction 5′ to 3′) from Glen 
Research 
   Deblocking solution, Perseptive Biosystems 
   Desalting columns PD 10 columns (prepacked with Sephadex
TM G 25 M) from 
GE Healthcare 
   Oxidizer, Biosolve Experimental part                                                                                                                
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7.1.13  List of synthesized compounds 
 
   4 Amino 5 [3 amino prop 1 ynyl] 7 [3 O (2 cyanoethyl) 2  
deoxy β D erythro pentofuranosyl) 7H pyrrolo[2,3 d]pyrimidine 38 
   2 Amino 7 (2 deoxy β D erythro pentofuranosyl) 5 iodo 7H pyrrolo[2,3  
d]pyrimidin 4 one 54 
   6 Amino 5 (2,2 diethoxyethyl) 4 hydroxy 2 mercaptopyrimidine 22 
   6 Amino 4 hydroxy 2 methylthiopyrimidine 15 
   2 Amino 4 hydroxy pyrrolo[2,3 d]pyrimidine 40 
   4 Amino 7 [3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl] 5  
iodo 7H pyrrolo[2,3 d]pyrimidine 36 
   4 Amino 7 [3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl] 5 (3  
trifluoroacetamido prop 1 ynyl) 7H pyrrolo[2,3 d]pyrimidine 37 
   4 Amino 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]  
pyrimidine 31 
   5 [3 Amino prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxycytidine 72 
   5 [3 Amino prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxyuridine 80 
   5′ O Benzoyl 3′ O [(2 cyanoethoxy)methyl] 2′ deoxythymidine 85 
   7 [5 O Benzoyl 3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl]  
4N (N,N dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidine 
35 
   3N Benzoyl 7 [3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl] 2N  
(N,N dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one 
61 
   3N Benzoyl 7 [3 O (2 cyanoethyl) 2 deoxy 5 O (4 monomethoxytrityl) β D  
erythro pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H 
pyrrolo[2,3 d]pyrimidin 4 one 60 
   3N Benzoyl 3′ O (2 cyanoethyl) 2′ deoxy 5′ O (4 monomethoxytrityl)  
thymidine 92 
   3N Benzoyl 3′ O (2 cyanoethyl) 2′ deoxythymidine 93 
   7 [5 O Benzoyl 2 deoxy β D erythro pentofuranosyl] 4N (N,N  
dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidine 34 
   5′ O Benzoyl 2′ deoxy 3′ O (methylthiomethyl)thymidine 83  Experimental part                                                                                                                
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   3N Benzoyl 7 [2 deoxy 5 O (4 monomethoxytrityl) β D erythro  
pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H  
pyrrolo[2,3 d]pyrimidin 4 one 59 
   3N Benzoyl 2′ deoxy 5′ O (4 monomethoxytrityl)thymidine 91 
   3N Benzoyl 7 [2 deoxy 3,5 O (tetraisopropyldisiloxane 1,3 diyl) β D  
erythro pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H  
pyrrolo[2,3 d]pyrimidin 4 one 57 
   3N Benzoyl 2′ deoxythymidine 90 
   5′ O Benzoyl 2′ deoxythymidine 82 
   3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 3′ O (2 cyanoethyl) 2′  
deoxy 5′ O (4 monomethoxytrityl)guanosine 10a 
   3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 2′ deoxyguanosine 8 
   3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 2′ deoxy 5′ O (4  
monomethoxytrityl)guanosine 9a 
   3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 2′ deoxy 3′,5′ O  
(tetraisopropyldisiloxane 1,3 diyl)guanosine 7 
   4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro  
pentofuranosyl] 5 iodo 2 methylthio 7H pyrrolo[2,3 d]pyrimidine 51 
   4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 5  
iodo 2 pivaloylamino 7H pyrrolo[2,3 d]pyrimidine 46 
   4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 5 iodo 
7H pyrrolo[2,3 d]pyrimidine 29 
   4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 2  
methylthio 7H pyrrolo[2,3 d]pyrimidine 49 
   4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 7H  
pyrrolo[2,3 d]pyrimidine 28 
   4 Chloro 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d]  
  pyrimidine 30 
   4 Chloro 5 iodo 2 methylthio pyrrolo[2,3 d]pyrimidine 48 
   4 Chloro 5 iodo pyrrolo[2,3 d]pyrimidine 19 
   4 Chloro 2 methylthio pyrrolo[2,3 d]pyrimidine 47 
   4 Chloro pyrrolo[2,3 d]pyrimidine 18 
   3′ O [(2 Cyanoethoxy)methyl] 2′ deoxythymidine 86 
   3′ O [(2 Cyanoethoxy)methyl] 2′ deoxythymidine 5′ phosphate 88  Experimental part                                                                                                                
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   3′ O (2 Cyanoethyl) 2′ deoxyadenosine 102 
   3′ O (2 Cyanoethyl) 2′ deoxyadenosine 5′ phosphate 104 
   7 [3 O (2 Cyanoethyl) 2 deoxy 5 O β D erythro pentofuranosyl] 5 iodo 7H  
pyrrolo[2,3 d]pyrimidin 4 one 62 
   3′ O (2 Cyanoethyl) 2′ deoxyguanosine 11 
   3′ O (2 Cyanoethyl) 2′ deoxythymidine 94 
   3′ O (2 Cyanoethyl) 2′ deoxythymidine 5′ (N,N diisopropyl)phosphoramidite  
96 
   3′ O (2 Cyanoethyl) 2′ deoxythymidine 5′ phosphate 95 
   2′ Deoxy (3′,5′ O diacetyl)cytidine 64 
   7 [2 Deoxy β D erythro pentofuranosyl] 2N (N,N  
dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one 58 
   2 Deoxy 3,5 di O p toluoyl α D erythro pentofuranosyl chloride 27 
   7 [2 Deoxy 3,5 O (tetraisopropyldisiloxane 1,3 diyl) β D erythro  
pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H  
pyrrolo[2,3 d]pyrimidin 4 one 56 
   7 [2 Deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 5 iodo 2  
methylthio 7H pyrrolo[2,3 d]pyrimidin 4 one 52 
   7 [2 Deoxy β D erythro pentofuranosyl] 4N (N,N 
dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidine 33 
   2′ Deoxythymidine 5′ phosphate 97 
   4N (N,N Dimethylaminomethylidenyl) 5′ O benzoyl 3′ O (2 cyanoethyl) 2′  
deoxyadenosine 101 
   4N (N,N Dimethylaminomethylidenyl) 5′ O benzoyl 2′ deoxyadenosine 100 
   4N (N,N Dimethylaminomethylidenyl) 2′ deoxyadenosine 99 
   2N (N,N Dimethylaminomethylidenyl) 2′ deoxy 3,5′ O (dibenzoyl)guanosine  
9b 
   2N (N,N Dimethylaminomethylidenyl) 2′ deoxyguanosine 2 
   2N (N,N Dimethylaminomethylidenyl) 2′ deoxy 5′ O (4  
monomethoxytrityl)guanosine 3 
   2N (N,N Dimethylaminomethylidenyl) 2′ deoxy 3′,5′ O  
(tetraisopropyldisiloxane 1,3 diyl)guanosine 6 
   2,2 Dimethyl N (4 chloro 5 iodo pyrrolo[2,3 d]pyrimidin 2 yl) propionamide  
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   2,2 Dimethyl N (4 chloro pyrrolo[2,3 d]pyrimidin 2 yl) propionamide 44 
   2,2 Dimethyl N (4 hydroxy 5 iodo pyrrolo[2,3 d]pyrimidin 2 yl)  
propionamide 42 
   2,2 Dimethyl N (4 hydroxy pyrrolo[2,3 d]pyrimidin 2 yl) propionamide 41 
   Ethyl (2,2 diethoxyethyl) cyanoacetate 21 
   4 Hydroxy 2 mercapto pyrrolo[2,3 d]pyrimidine 23 
   4 Hydroxy 2 methylthio pyrrolo[2,3 d]pyrimidine 16 
   4 Hydroxy pyrrolo[2,3 d]pyrimidine 17 
   5 Iodo 5′ O benzoyl 2′ deoxyuridine 74 
   5 Iodo 3′ O (2 cyanoethyl) 2′ deoxycytidine 70 
   5 Iodo 3′ O (2 cyanoethyl) 2′ deoxy (5′ O,3N dibenzoyl)uridine 77 
   5 Iodo 3′ O (2 cyanoethyl) 2′ deoxyuridine 78 
   5 Iodo 2′ deoxycytidine 66 
   5 Iodo 2′ deoxy (5′ O,3N dibenzoyl)uridine 76 
   5 Iodo (3′,5′ O diacetyl) 2′ deoxycytidine 65 
   5 Iodo 4N (N,N dimethylaminomethylidenyl) 5′ O benzoyl 3′ O (2  
cyanoethyl) 2′ deoxycytidine 69 
   5 Iodo 4N (N,N dimethylaminomethylidenyl) 5′ O benzoyl 2′ deoxycytidine  
68 
   5 Iodo 4N (N,N dimethylaminomethylidenyl) 2′ deoxycytidine 67 
   5 [3 Trifluoroacetamido prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxycytidine  
71 
   5 [3 Trifluoroacetamido prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxyuridine  
79 
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7.2  Synthesis and analytical data of all compounds 
 
2N (N,N Dimethylaminomethylidenyl) 2′ deoxyguanosine 
 
 
To a suspension of 2.67 g (10 mmol) 2′ deoxyguanosine 1 in 60 ml MeOH 5.3 ml 
(40  mmol)  of  N,N dimethylformamide  dimethyl  acetal  were  added.  The 
reaction mixture was agitated for 60 h at room temperature within which the 
crystalline product precipitated. The colorless crystals were then filtered off, 
washed with MeOH and dried in vacuum. The product was sufficiently pure for 
further synthetic use. 
 
Yield:   2.45 g (7.6 mmol, 76 %) 
TLC:   Rf = 0.07 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 11.31 (br s, 1H, NH3), 8.55 (s, 1H, formamidino CH), 8.03 
(s, 1H, H6), 6.25 (dd, 1H, H1′, J = 6.11 and J = 7.83), 4.38 (m, 1H, 
H3′), 3.83 (m, 1H, H4′), 3.54 (m, 2H, H5′), 3.16 (s, 3H, formamidino 
CH3), 3.03 (s, 3H, formamidino CH3), 2.64 – 2.18 (m, 2H, H2′). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm]  = 158.0  (C4),  157.3  (formamidino C=N),  153.9  (C2),  149.6 
(C7a), 136.6 (C6), 119.7 (C4a), 87.7 (C4′), 82.8 (C1′), 70.9 (C3′), 61.8 
(C5′), 40.6 (formamidino CH3), 37.9 (C2′), 34.6 (formamidino CH3). 
 
ESI(+) MS:   m/z  323.0 [M + H
+] 
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2N (N,N Dimethylaminomethylidenyl) 2′ deoxy 5′ O (4 
monomethoxytrityl)guanosine 
 
 
2.4 g (7.45 mmol) of compound 2 was dried at 40 °C over two days in vacuum 
and suspended in 50 ml abs. pyridine under argon. The suspension was treated 
with 2.76 g (8.93 mmol) p anisylchlorodiphenylmethane and stirred for 24 h at 
room temperature within which it turned into a yellow solution. The reaction 
was stopped by the addition of 1 ml MeOH and the mixture concentrated under 
reduced pressure. The yellow oily residue was taken up in 100 ml methylene 
chloride, washed once with 50 ml 2 % aqueous sodium carbonate solution and 
once with 100 ml brine. The organic layer was dried over MgSO4, filtered and 
concentrated  again.  The  yellow  foamy  product  was  purified  via  column 
chromatography using CH2Cl2/MeOH (0.5 – 5 % MeOH) as eluent. 
 
Yield:   3.72 g (6.26 mmol, 84 %) 
TLC:   Rf = 0.26 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 9.54 (br s, 1H, NH3), 8.50 (s, 1H, formamidino CH), 7.70 
(s, 1H, H6), 7.41   7.15 (m, 12H, MMT), 6.78 (ψd, 2H, MMT, J = 9.39), 
6.39 (ψt, 1H, H1′, J = 6.26 and J = 7.04), 4.64 (m, 1H, H3′), 4.17 (m, 
1H, H4′), 3.75 (s, 3H, MMT OCH3), 3.39 – 3.26 (m, 2H, H5′), 3.02 (s, 
3H, formamidino CH3), 2.99 (s, 3H, formamidino CH3), 2.55 (m, 2H, 
H2′). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 158.8 (MMT C OCH3), 158.3 (formamidino C=N), 158.2 (C4), 
156.9 (C2), 150.4 (C7a), 144.2 (MMT), 144.1 (MMT), 136.1 (C6), 135.3 
(MMT), 130.4 (MMT), 128.5 (MMT), 128 (MMT), 127.2 (MMT), 120.3  Experimental part                                                                                                                
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(C4a), 113.3 (MMT), 86.9 (MMT), 85.9 (C4′), 83.1 (C1′), 72.5 (C3′), 
64.4  (C5′),  55.4  (MMT OCH3),  41.4  (formamidino CH3),  40.7  (C2′), 
35.2 (formamidino CH3). 
 
ESI(+) MS:   m/z  595.4 [M + H
+] 
 
 
2N (N,N Dimethylaminomethylidenyl) 2′ deoxy 3′,5′ O (tetraisopropyldisiloxane 
1,3 diyl)guanosine 
 
 
802 mg (3 mmol) of 2′ deoxyguanosine 1 were coevaporated three times with 
dry pyridine and dried in vacuum overnight. After suspending the nucleoside in 
10  ml  dry  pyridine,  1.06  ml  (3.3  mmol)  1,1,3,3 tetraisopropyldisiloxane 1,3 
dichloride were added at 0 °C. The mixture was stirred for a few minutes on 
cooling, then for 24 h at room temperature. After complete conversion of the 
starting material the reaction was stopped by addition of 10 ml MeOH. The 
mixture was concentrated, the residual syrup coevaporated with toluene and 
suspended in 20 ml methanol again. The slightly acidic reaction mixture was 
neutralized with triethylamine, then 2 ml (15 mmol) N,N dimethylformamide 
dimethylacetal were added to the solution which was stirred further for 24 h at 
room  temperature.  After  solvent  removal  the  resulting  crude  product  was 
purified on silica gel column using CH2Cl2/MeOH 95/5 as eluent. 
 
Yield:   1.4 g (2.5 mmol, 83 %) 
TLC:   Rf = 0.49 (CH2Cl2/MeOH 9/1) 
 
1H NMR:  (400 MHz, CDCl3)  Experimental part                                                                                                                
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δ [ppm] = 9.35 (br s, 1H, NH3), 8.47 (s, 1H, formamidino CH), 7.69 
(s, 1H, H6), 6.14 (dd, 1H, H1′, J = 3.66 and J = 6.59), 4.58 (q, 1H, 
H3′, J = 7.68), 3.96 – 3.84 (m, 2H, H5′), 3.75 (m, 1H, H4′), 3.07 (s, 
3H, CH3), 2.99 (s, 3H, CH3), 2.48 – 2.44 (m, 2H, H2′), 0.98 – 0.91 (m, 
28H, TIPDS H). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm]  = 158  (C4),  157.9  (formamidino C=N),  156.8  (C2),  149.5 
(C7a), 135.4 (C6), 120.3 (C4a), 85 (C4′), 81.7 (C1′), 70 (C3′),  61.8 
(C5′), 41.2 (formamidino CH3), 40.2 (C2′), 35 (formamidino CH3), 17.4 
– 16.8 (iso propyl CH3), 13.3 – 12.4 (iso propyl CH CH3). 
 
ESI(+) MS:   m/z   565.4 [M + H
+] 
 
 
3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 2′ deoxy 3′,5′ O 
(tetraisopropyldisiloxane 1,3 diyl)guanosine 
 
 
1.13 g (2 mmol) of compound 6 was dissolved in 10 ml dry pyridine and cooled 
down to 0°C. In a syringe, 348 µl (3 mmol) of benzoyl chloride were diluted in 
0.6  ml  dry  methylene  chloride  and  added  dropwise  under  argon  to  the 
nucleoside. The mixture was stirred for 30 min on cooling, then 4 h at room 
temperature. Another portion of 232 µl (2 mmol) benzoyl chloride in 0.6 ml 
methylene  chloride  were  added  at  0  °C,  then  the  reaction  was  allowed  to 
proceed overnight at room temperature. The solvent was removed, the residue 
taken up in 100 ml methylene chloride and washed with each 50 ml of sat. 
NaHCO3 solution,  brine  and  water.  The  organic  layer  was  dried  over  MgSO4, 
filtered and concentrated. The oily residue was purified on silica gel column 
(CH2Cl2/MeOH, 2 – 5 % MeOH) to give the pure compound as yellowish foam.  Experimental part                                                                                                                
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Yield:   912 mg (1.36 mmol, 68 %) 
TLC:   Rf = 0.68 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.48 (s, 1H, formamidino CH), 7.88 (ψd, 2H, benzoyl HA, J 
= 7.83), 7.84 (s, 1H, H6), 7.56 (ψt, 1H, benzoyl HC, J = 7.83), 7.42 
(ψt, 2H, benzoyl HB, J = 7.83), 6.28 (m, 1H, H1′), 4.72 (m, 1H, H3′), 
4.03 (m, 2H, H5′), 3.89 (m, 1H, H4′), 3.08 (s, 3H, formamidino CH3), 
2.69 (s, 3H, formamidino CH3), 2.58 (m, 2H, H2′), 1.07 – 0.84 (m, 
28H, TIPDS  H). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 171.1 (benzoyl C=O), 157.4 (C4), 156.6 (formamidino C=N), 
155.5  (C2),  148.1  (C7a),  134.9  (C6),  134.0  (benzoyl CC),  132.9 
(benzoyl Cquart), 130.3 (benzoyl CA), 128.9 (benzoyl CB), 120.4 (C4a), 
85.6 (C4′), 82.8 (C1′), 70.4 (C3′), 62.1 (C5′), 41.2 (formamidino CH3), 
39 (C2′), 35.1 (formamidino CH3), 17.3 – 16.8 (iso propyl CH3), 13.6 – 
12.7 (iso propyl CH CH3). 
 
ESI(+) MS:   m/z   669.4 [M + H
+] 
 
 
 
3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 2′ deoxyguanosine 
 
 
Under argon, 850 mg (1.27 mmol) of the nucleoside 7 were dissolved in 10 ml 
dry THF. Subsequently 723 µl of triethylamine tris hydrofluoride were added in 
one lot and the mixture was stirred for 1.5 h at room temperature. The solvent 
was  then  evaporated  and  the  yellow  oily  residue  purified  on  column  with 
CH2Cl2/MeOH 9/1 as eluent giving the pure product as glassy oil. 
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Yield:   532 mg (1.25 mmol, 98 %) 
TLC:   Rf = 0.1 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.58 (s, 1H, formamidino CH), 8.18 (s, 1H, H6), 7.81 (ψd, 
2H, benzoyl HA, J = 7.32), 7.70 (ψt, 1H, benzoyl HC, J = 7.32), 7.55 
(ψt, 2H, benzoyl HB, J = 7.68), 6.32 (dd, 1H, H1′, J = 6.59 and J = 
7.32), 5.34 (d, 1H, 3′ OH, J = 4.03), 4.96 (t, 1H, 5′ OH, J = 5.49), 4.41 
(m, 1H, H3′), 3.86 (m, 1H, H4′), 3.57 (m, 2H, H5′), 3.09 (s, 3H, CH3), 
2.63 (s, 3H, CH3), 2.67   2.26 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 171.2 (benzoyl C=O), 157 (formamidino C=N), 156.6 (C4), 
155.1  (C2),  149.4  (C7a),  137.6  (C6),  134.4  (benzoyl CC),  132.9 
(benzoyl Cquart),  129.6  (benzoyl CA),  129.2  (benzoyl CB),  128.1 
(benzoyl C), 118.7 (C4a), 87.9 (C4′), 82.9 (C1′), 70.9 (C3′), 61.7 (C5′), 
40.7 (formamidino CH3), 39.9 (C2′), 34.4 (formamidino CH3). 
 
ESI( ) MS:   m/z  425.0 [M – H
+] 
 
 
3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 2′ deoxy 5′ O (4 
monomethoxytrityl)guanosine 
 
 
1.06 g (2.49 mmol) of starting material 8 were dissolved under argon in 15 ml 
dry pyridine and treated with 1.0 g (3.24 mmol) p anisylchlorodiphenylmethane 
and 30 mg (0.25 mmol) N,N dimethylaminopyridine. The yellow solution was 
stirred at room temperature and quenched after 24 h reaction time by addition 
of 3 ml MeOH. The solvent was removed and the oily  residue coevaporated 
three  times  with  toluene  and  purified  via  column  chromatography  using 
CH2Cl2/MeOH (2 – 5 % MeOH) as eluent.  Experimental part                                                                                                                
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Yield:   909 mg (1.3 mmol, 52 %) 
TLC:   Rf = 0.25 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.49 (br s, 1H, formamidino CH), 7.72 (br s, 1H, H6), 7.86   
6.8 (m, 19H, MMT  and benzoyl H), 6.4 (ψt, 1H, H1′), 4.65 (m, 1H, 
H3′), 4.18 (m, 1H, H4′), 3.77 (s, 3H,  OCH3), 3.33 (m, 2H, H5′), 2.99 
(s, 3H, formamidino CH3), 2.67 (s, 3H, formamidino CH3), 2.54 (m, 
2H, H2′). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm]  = 170.9  (benzoyl C=O),  158.8  (MMT C OMe),  157.5  (C4), 
156.9  (formamidino C=N),  155.5  (C2),  148.8  (C7a),  144.3  (MMT), 
144.2  (MMT),  135.3  (C6),  134.1  (benzoyl CC),  130.4  (MMT),  130.2 
(benzoyl CA),  128.9  (benzoyl CB),  128.5  (MMT),  128  (MMT),  127.2 
(MMT), 118.3 (C4a), 113.3 (MMT), 86.9 (MMT), 86.1 (C4′), 83.2 (C1′), 
72.5 (C3′), 64.5 (C5′), 55.4 (MMT OCH3), 41.2 (C2′), 35 (formamidino 
CH3), 31 (formamidino CH3). 
 
ESI(+) MS:   m/z   699.4 [M + H
+] 
 
 
2N (N,N Dimethylaminomethylidenyl) 2′ deoxy 3,5′ O (dibenzoyl)guanosine 
 
 
Under argon, 2.0 g (4.69 mmol) of compound 8 were dissolved in 25 ml dry 
pyridine and cooled down to –20°C. Freshly distilled benzoyl chloride (606 µl, 
5.16  mmol)  was  taken  up  in  1.5  ml  dry  methylene  chloride  and  injected 
dropwise  to  the  nucleoside  via  syringe  through  a  septum.  The  reaction  was 
allowed to proceed for 3.5 h at –20°C and stopped by the addition of 3 ml 
MeOH. After solvent removal, the residue was coevaporated with toluene and 
purified on silica gel column using CH2Cl2/MeOH 9/1.  Experimental part                                                                                                                
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Yield:   2.13 g (4.02 mmol, 86 %) 
TLC:   Rf = 0.27 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.62 (s, 1H, formamidino CH), 8.1 (s, 1H, H6), 8.01   7.36 
(m, 10H, benzoyl), 6.38 (ψt, 1H, H1′, J = 6.95), 4.57 (m, 1H, H4′), 
4.45 (m, 2H, H5′), 4.35 (m, 1H, H3′), 3.06 (s, 3H, formamidino CH3), 
2.62 (s, 3H, formamdidino CH3), 2.88   2.41 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 171.2 (benzoyl C=O), 165.6 (benzoyl C=O), 157 (C4), 156.7 
(formamidino C=N),  154.9  (C2),  149.3  (C7a),  138.1  (C6),  134.4 
(benzoyl CC′),  133.5  (benzoyl CC),  132.9  (benzoyl Cquart),  131.6 
(benzoyl),  129.6  (benzoyl CA′),  129.4  (benzoyl CA),  129.2  (benzoyl 
CB′), 128.8 (benzoyl CB), 118.5 (C4a), 84.3 (C4′), 83 (C1′), 70.7 (C3′), 
64.4 (C5′), 40.7 (formamidino CH3), 34.4 (C2′). 
 
ESI(+) MS:   m/z   531.5 [M + H
+] 
 
 
3N Benzoyl 2N (N,N dimethylaminomethylidenyl) 3′ O (2 cyanoethyl) 2′ deoxy 
5′ O (4 monomethoxytrityl)guanosine 
 
In an Erlenmeyer flask with triangle stirrer bar, 250 mg (0.36 mmol) of the 
nucleoside 9a were dissolved under argon in 4 ml tert butanol and 471 µl (7.2 
mmol) freshly distilled acrylonitrile. After a few minutes, 117 mg (0.36 mmol) 
of cesium carbonate were added in one lot and the suspension was vigorously 
agitated  at  room  temperature  for  3.5  h.  After  consumption  of  the  starting 
material, the suspension was taken up 100 ml methylene chloride and filtered 
over Celite. The filtrate was concentrated, the residue purified on a short silica 
gel column using CH2Cl2/MeOH 95/5 as eluent furnishing the pure product.  Experimental part                                                                                                                
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Yield:   218 mg (0.29 mmol, 81 %) 
TLC:   Rf = 0.25 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm]  = 8.51  (s,  formamidino CH),  7.87  (d,  2H,  benzoyl HA,  J  = 
7.33), 7.73 (s, 1H, H6), 7.87 (t, 1H, benzoyl HC, J = 7.33), 7.42   6.83 
(m, 16H, trityl  and benzoyl H), 6.35 (dd, 1H, H1′, J = 5.56 and J = 
8.59), 4.23 (m, 2H, H3′, H4′), 3.79 (s, 3H,  OCH3), 3.69 (t, 2H,  O 
CH2, J = 6.06), 3.38  (m, 2H, H5′), 3.04 (s, 3H, formamidino CH3), 
2.69 (s, 3H, formamidino CH3), 2.62 (t, 2H,  CH2CN, J = 6.06), 2.54 
(m, 2H, H2′). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm]  = 170.8  (benzoyl C=O),  158.7  (MMT C OMe),  157.5  (C4), 
156.9  (formamidino C=N),  155.5  (C2),  148.9  (C7a),  144.3  (MMT), 
144.2  (MMT),  135.3  (C6),  134.1  (benzoyl CC),  130.5  (MMT),  130.2 
(benzoyl CA), 128.8 (benzoyl CB), 128.5 (MMT), 127.6 (MMT), 127.2 
(MMT), 119.3 (CN), 113.3 (MMT), 86.7 (MMT), 83.5 (C4′), 82.7 (C1′), 
80.6  (C3′),  63.7  ( O CH2),  63.5  (C5′),  55.0  (MMT OCH3),  40.4 
(formamidino CH3),  40.9  (C2′),  34.6  (formamidino CH3),  18.8  ( 
CH2CN). 
 
ESI(+) MS:   m/z   752.6  [M + H
+] 
 
Elemental analysis:  calculated:  C, 68.69; H, 5.50; N, 13.04; O, 12.77 
        Found:    C, 68.85; H, 5.76; N, 12.81 
 
 
3′ O (2 Cyanoethyl) 2′ deoxyguanosine 
 
 
In a well dried sealable Erlenmeyer flask with magnetic triangle stirrer bar, 1.6 
g  (3.02  mmol)  of  compound  9b  were  dissolved  in  4  ml  (60.4  mmol)  freshly 
distilled acrylonitrile and 8 ml tert butanol under inert atmosphere. 984 mg  Experimental part                                                                                                                
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(3.02 mmol) of cesium carbonate were added in one lot and the pale yellow 
suspension  was  vigorously  stirred  for  about  3  h  at  room  temperature.  The 
mixture was diluted with 100 ml methylene chloride then, filtered over Celite, 
concentrated and purified on a silica gel column using CH2Cl2/MeOH (2 – 10 % 
MeOH).  The  resulting  700  mg  (1.2  mmol)  of  crude  compound  10b  were 
dissolved in a mixture of 30 ml MeOH, 10 ml methylene chloride and 20 ml 32 % 
aq. ammonia.  The  solution  was  stirred  for  24  h  at  room temperature  while 
monitoring the reaction on TLC, then the solvent was evaporated. The residue 
was purified on column chromatography using CH2Cl2/MeOH 9/1 as eluent to 
give product 11 as colorless crystals. 
 
Yield:   230 mg (0.72 mmol, 24 % over two steps) 
TLC:   Rf = 0.02 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 10.82 (br s, 1H, NH3), 7.83 (s, 1H, H6), 6.58 (br s, 2H, 
NH2), 6.15 (dd, 1H, H1′, J = 8.05, J = 2.56), 4.24 (m, 1H, H4′), 4.18 
(m, 1H, H3′), 3.67 (t, 2H,  O CH2, J = 5.86), 3.45 (m, 2H, H5′), 2.79 
(t, 2H, CH2CN, J = 5.86), 2.74 – 2.32 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 156.8 (C4), 153.7 (C2), 150.8 (C7a), 135.2 (C6), 119.1 (CN), 
116.3 (C4a), 85.5 (C4′), 82.7 (C1′), 79.8 (C3′), 63.9 ( O CH2), 61.6 
(C5′), 37.4 (C2′), 18.2 (CH2CN). 
 
ESI(+) MS:   m/z   321.0 [M + H
+] 
 
 
6 Amino 4 hydroxy 2 methylthiopyrimidine 
 
 
16.4 g (100 mmol) of 6 amino 4 hydroxy 2 mercaptopyrimidine monohydrate 14  Experimental part                                                                                                                
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and 4.4 g (110 mmol) sodium hydroxide were dissolved in 200 ml water to form 
a clear pale yellow solution. The mixture was treated with 6.8 ml (110 mmol) 
of  methyl  iodide  and  stirred  for  4  h  at  room  temperature.  The  product 
precipitated as a thick cristalline mass which was filtered off, washed with 50 
ml cold water and dried in vacuum for 2 days at 60 °C.  
 
Yield:   13.3 g (84.6 mmol, 85 %) 
TLC:   Rf = 0.22 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 11.50 (br s, 1H, H3), 6.44 (br s, 2H, NH2), 4.9 (s, 1H, H5), 
2.41 (s, 3H, SCH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 164.3 (C4), 163.6 (C6), 162.8 (C2), 81.2 (C5), 12.6 (CH3). 
 
ESI(+) MS:   m/z   157.6 
 
 
4 Hydroxy 2 methylthio pyrrolo[2,3 d]pyrimidine 
 
 
A mixture of 2.9 ml (18 mmol) bromoacetaldehyde diethylacetal 20, 0.47 ml 37 
% hydrochloric acid and 9.3 ml water was heated up to 90 °C for 30 min, then 
the clear pale yellow solution was allowed to cool down to room temperature 
and treated with 1.74 g (21 mmol) sodium acetate. In another flask (250 ml) a 
suspension of 2.5 g (16 mmol) of compound 15 and 1.08 g (13 mmol) sodium 
acetate in 100 ml water was heated up to 70 – 85 °C. After having reached this 
temperature range, the mixture from the first flask was added in one portion 
with vigorous stirring and heating at 80 °C continued for further 3.5 h. Progress 
of the reaction was obvious as the suspension turned into a solution first and,  Experimental part                                                                                                                
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after  roughly  1  h,  product  precipitation  occurred.  The  crude  mixture  was 
cooled down to 0 °C for 24 h for completion of the product precipitation, then 
the dark yellow crystals were filtered off and washed with 100 ml water and 
100 ml cold acetone. The crude product was dried in vacuum overnight and 
purified further on silica gel column using CH2Cl2/MeOH 9/1 as eluent. 
 
Yield:   1.34 g (7.4 mmol, 46 %) 
TLC:   Rf = 0.46 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 12.03 (br s, 1H, H3), 11.76 (br s, 1H, H7), 6.91 (dd, 1H, 
H6, J = 3.28 and J = 2.53), 6.36 (dd, 1H, H5, J = 3.28 and J = 2.02), 
2.52 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 158.9  (C4),  154.2  (C2),  148.3  (C7a),  119.3  (C6),  104.2 
(C4a), 102 (C5), 12.8 (SMe). 
 
ESI(+) MS:   m/z   181.7 
 
 
4 Hydroxy pyrrolo[2,3 d]pyrimidine 
 
 
Method A: 
5.0 g (30 mmol) of compound 23 were suspended in 200 ml water and 15 ml of 
28 % aqueous ammonia. 15.0 g Raney nickel (aqueous suspension) were added 
and the black mixture was allowed to react under reflux for 2.5 h. The dark 
solution was filtered while hot through Celite and the filter cake was washed 
with 100 ml hot water. The clear filtrate was concentrated then until pale pink 
crystalline product precipitated. These crystals were filtered off, washed with 
water and dried in vacuum at 60 °C over 2 days.  Experimental part                                                                                                                
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Yield: 3.92 g (29 mmol, 97 %) 
 
Method B: 
5.43 g (30 mmol) of compound 16 were suspended in 250 ml EtOH and treated 
with 30.0 g Raney nickel. The black suspension was heated up to reflux for 3 h 
and filtered quickly while hot through Celite for separation from the nickel. 
After washing the filter cake with hot water, the slightly cloudy filtrate was 
concentrated  until  the  product  precipitated.  The  crystals  were  filtered  off, 
washed with cold water and dried in vacuum at 60 °C over 2 days. 
 
Yield:   1.49 g (11 mmol, 37 %) 
TLC:   Rf = 0.32 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 11.86 (br s, 1H, H3), 11.43 (br s, 1H, H7), 7.82 (s, 1H, H2), 
7.02 (d, 1H, H6, J = 3.48), 6.43 (d, 1H, H5, J = 3.48). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm]  = 158.5  (C4),  149.5  (C2),  148.1  (C7a),  120.3  (C6),  102.0 
(C4a), 85.3 (C5). 
 
ESI(+) MS:   m/z   135.7 
 
 
4 Chloro pyrrolo[2,3 d]pyrimidine 
 
 
Method A: 
1.0 g (7.3 mmol) of well dried heterocycle 17 was suspended in 15 ml (160 
mmol) phosphorus oxychloride and heated up to reflux for 45 min. The excess 
POCl3  was  distilled  off  and  the  reaction  mixture  poured  on  ice  with  strong  Experimental part                                                                                                                
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stirring. The pH value was adjusted to 4 by addition of 10 % aqueous ammonia, 
the  aqueous  layer  extracted  five  times  with  50  ml  CH2Cl2  each  and  the 
combined  organic  layers  were  dried  over  MgSO4.  After  filtration,  solvent 
removal and recrystallization in ethyl acetate the pure product was obtained. 
 
Method B: 
Under argon, 1.0 g (7.3 mmol) of dry heterocycle 17 was suspended in 14 ml 
(146 mmol) phosphorus oxychloride and 1.4 ml (11 mmol) N,N dimethylaniline. 
The reaction mixture was heated up to reflux for 4.5 h, then the excess POCl3 
was distilled off and the same work up procedure as described for method A 
was applied for obtaining the product as colorless crystals. 
 
Yield:  Method A: 568 mg (3.7 mmol, 51 %) 
Method B: 563 mg (3.6 mmol, 50 %) 
 
TLC:   Rf = 0.61 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, CDCl3) 
δ [ppm] = 10.69 (s, 1H, H7), 8.7 (s, 1H, H2), 7.42 (dd, 1H, H6, J = 
2.21 and J = 3.48), 6.68 (dd, 1H, H5, J = 2.21 and J = 3.48). 
 
13C NMR:  (63 MHz, CDCl3) 
δ [ppm]  = 152.5  (C4),  150.7  (C2),  150.5  (C7a),  129.3  (C6),  117.1 
(C4a), 99.1 (C5). 
 
ESI(+) MS:   m/z   153.5 
 
 
4 Chloro 5 iodo pyrrolo[2,3 d]pyrimidine 
 
 
1.0 g (6.4 mmol) of dry compound 18 was dissolved in 100 ml dry methylene  Experimental part                                                                                                                
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chloride, followed by the addition of 1.59 g (7 mmol) N iodosuccinimide and 
stirring  for  1  h  at  room  temperature  under  argon  atmosphere.  The  product 
precipitated as a colorless solid which was filtered off then and recrystallized 
in ethyl acetate. Further purification was achieved by column chromatography 
using CH2Cl2/MeOH 9/1 as eluent. 
 
Yield:   1.59 g (5.7 mmol, 89 %) 
TLC:   Rf = 0.64 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 12.95 (s, 1H, H7), 8.59 (s, 1H, H2), 7.94 (d, 1H, H6). 
  
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm]  = 151.4  (C4),  150.6  (C2),  150.4  (C7a),  133.8  (C6),  115.7 
(C4a), 51.5 (C5). 
 
MALDI(+) MS:  m/z   279.30 
 
 
Ethyl (2,2 diethoxyethyl) cyanoacetate 
 
 
1.83 g (120 mmol) of sodium iodide, 28.05 g (200 mmol) anhydrous potassium 
carbonate and 31.5 ml (200 mmol) bromoacetaldehyde diethylacetal 20 were 
suspended in 108 ml  (1 mol) ethylcyano acetate in a dry 250  ml flask  with 
magnetic stirrer, reflux cooling and heating. The orange mixture was heated up 
to  130  –  150  °C  for  6  h  within  which  CO2 gas  was  generated  (after 
approximately 1.5 h the generation of CO2 gas stopped). The dark red solution 
was allowed to cool down to room temperature, diluted in 160 ml water and 
extracted with 200 ml of diethyl ether. The aqueous layer was extracted again 
twice with 200 ml diethyl ether each and the combined organic layers were 
dried over sodium sulfate. The diethyl ether was evaporated, the residual dark  Experimental part                                                                                                                
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red solution distilled under reduced pressure to give the product as a colorless 
liquid. 
 
Fraction/substance  bp at 15 mbar  Yield 
Fraction 1: 1,1 diethoxyethene (by product from 
elimination)  47 – 68 °C  2.93 g 
Fraction 2: ethylcyano acetate (reagent and solvent)  70 – 75 °C  65.34 g 
Fraction 3: α cyano α (2,2 diethoxyethyl)  
acetate (product) 
120 – 124 °C  29.07 g 
 
Yield:   29.07 g (127 mmol, 63 %) 
 
1H NMR:  (250 MHz, CDCl3) 
δ [ppm] = 4.65 (t, 1H, O H4 O), 4.21 (q, 2H, ester CH2), 3.72 – 3.42 
(m,  5H,   O CH2(acetal),  H2),  2.19  (m,  2H,  H3,  CH2),  1.28  (t,  3H, 
ester CH3), 1.16 (m, 6H, acetal CH3). 
 
13C NMR:  (63 MHz, CDCl3) 
δ [ppm]  = 165.9  (C1),  116.3  (CN),  99.9  ( O C4 O),  62.8  ( O 
CH2(acetal)), 62.6 ( O CH2(ester)), 33.6 (C3), 33.5 (C2), 15.2 (acetal 
CH3), 15.2 (acetal CH3), 13.9 (ester CH3). 
 
ESI( ) MS:   m/z   227.9 [M – 2H
+] 
 
 
6 Amino 5 (2,2 diethoxyethyl) 4 hydroxy 2 mercaptopyrimidine 
 
 
7.61 g (100 mmol) of thiourea were dissolved under argon in 50 ml abs. EtOH, 
treated with 7.1 g (100 mmol) sodium ethoxide and stirred at 45 °C for 5 min 
at  room  temperature.  Subsequently  22.93  g  (100  mmol)  of  compound 
21, dissolved  in  100  ml  abs.  EtOH  were  added  to  the  ethoxide/thiourea 
solution and the mixture was heated up to reflux for about 4 h. After solvent 
removal the residue was diluted in 100 ml water and washed twice with 70 ml  Experimental part                                                                                                                
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diethyl ether. The addition of 5.8 ml (100 mmol) glacial acetic acid caused 
precipitation  of  the  colorless  crystalline  product  from  the  aqueous  layer. 
Filtering and washing the product with 50 ml cold water and 100 ml diethyl 
ether gave the pure compound 22. 
 
Yield:   18.74 g (72 mmol, 72 %) 
TLC:   Rf = 0.19 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 11.70 (br s, 2H, H3, H1), 6.08 (br s, 2H, NH2), 4.49 (t, 1H, 
 O CH O, J = 5.56), 3.66 – 3.33 (m, 4H, acetal CH2), 2.42 (d, 2H, 
CH2, J = 5.56), 1.07 (t, 6H, acetal CH3, J = 7.07). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 172.9 (C2), 161.9 (C4), 152.1 (C6), 101.8 ( O C(acetal) 
O), 85.7 (C5), 61.7 (acetal CH2), 28 (C5 CH2), 15.3 (acetal CH3). 
 
ESI(+) MS:   m/z   259.9 
 
 
4 Hydroxy 2 mercapto pyrrolo[2,3 d]pyrimidine 
 
 
12.96 g (50 mmol) of compound 22 were suspended in 750 ml (150 mmol) 0.2 M 
hydrochloric  acid  solution  and  the  mixture  was  vigorously  agitated  at  room 
temperature for 24 h. The colorless crystalline product was filtered off then, 
washed with 100 ml cold water and dried in vacuum at 60 °C over 2 days. 
 
Yield:   7.96 g (47.6 mmol, 95 %) 
TLC:   Rf = 0.17 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
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H7), 6.71 (d, 1H, H6, J = 3.16), 6.33 (d, 1H, H5, J = 3.16). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 158.8 (C2), 158.7 (C4), 145.4 (C7a), 117.5 (C6), 102.2 (C5), 
102 (C4a). 
 
ESI(+) MS:   m/z   167.7 
 
 
2 Deoxy 3,5 di O (4 toluoyl) α D erythro pentofuranosyl chloride 
 
 
To a solution of 10.0 g (74.5 mmol) 2 deoxy D ribose 24 in 120 ml abs. MeOH, 
20 ml of a 1 % methanolic hydrochloric solution (prepared by adding 1.7 ml of 
acetyl chloride to 100 ml MeOH) were added. The reaction mixture was stirred 
at room temperature for 25 minutes and neutralized by addition of 4 g solid 
NaHCO3.  After  filtration,  the  solvent  was  evaporated  and  the  oily  residue 
coevaporated three times with 50 ml dry pyridine each. The yellowish syrup 
was dissolved in 60 ml abs. pyridine, cooled down to 0 °C and 22 ml (160 mmol) 
of p toluoyl chloride were added dropwise within 1 h. The reaction was allowed 
to  proceed  overnight  under  argon  atmosphere  at  room  temperature.  The 
reaction mixture was diluted in 150 ml cold water then and extracted three 
times with 100 ml methylene chloride each. The combined organic layers were 
washed with 100 ml each of saturated sodium hydrocarbonate solution, 2 N 
hydrochloric acid and water and dried over solid sodium hydrogencarbonate. 
After filtration, the solvent was removed giving an oily residue. This colored  Experimental part                                                                                                                
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syrup was dissolved in 40 ml glacial acetic acid and cooled down to 0 °C. In an 
Erlenmeyer  flask,  a  saturated  hydrochloric  acid  solution  was  prepared  by 
adding 4 ml of water to well cooled 81 ml glacial acetic acid. On cooling, 16.3 
ml of acetyl chloride were added in a few portions to this mixture within 5 
minutes. 63 ml of this cooled saturated HCl solution were quickly filled into an 
ice bath  cooled  flask  with  magnetic  stirrer.  The  diluted  sugar  was  poured 
dropwise  into  the  saturated  HCl solution  with  only  little  stirring  until  a 
colorless  crystalline  precipitation  occurred.  The  thick  crystalline  mass  was 
quickly filtered off then, washed with roughly 700 ml ice cold dry diethyl ether 
for  removing  acid  residues  and  dried  in  vacuum  overnight.  The  crystalline 
product was stored under argon at 0 °C. 
 
Yield:   11.68 g (30 mmol, 40 %) 
TLC:   Rf = 0.1 (n hexane/ethyl acetate: 4/1)  
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.03 (d, 2H, toluoyl HA, J = 8.05), 7.93 (d, 2H, toluoyl HA, J 
= 8.05), 7.26 (m, 4H, toluoyl HB), 6.47 (d, 1H, H1′, J = 5.12), 5.56 
(dd, 1H, H3′, J = 2.56 and J = 6.95), 4.86 (q, 1H, H4′, J = 3.29), 4.73 – 
4.55 (m, 2H, H5′), 2.93 – 2.74 (m, 2H, H2′), 2.42 (s, 3H, CH3), 2.41 (s, 
3H, CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm]  = 166.5  (toluoyl C=O),  166.2  (toluoyl C=O),  144.4  (toluoyl 
CC),  144.2  (toluoyl CC),  130  (toluoyl CA),  129.8  (toluoyl CA),  129.4 
(toluoyl CB),  129.3  (toluoyl CB),  126.9  (toluoyl C COO),  126.8 
(toluoyl C COO),  95.4  (C1′),  84.8  (C4′),  73.7  (C3′),  63.6  (C5′),  44.7 
(C2′), 21.9 (CH3) , 21.8 (CH3). 
 
ESI(+) MS:   m/z   388.0    
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4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 7H 
pyrrolo[2,3 d]pyrimidine 
 
 
Under argon, 1.0 g (6.4 mmol) of the starting material 18 was dissolved in 80 
ml dry acetonitrile. 0.91 g (16.2 mmol) of solid potassium hydroxide and 0.22 
ml (0.64 mmol) TDA 1 were added and the mixture was stirred for 15 min at 
room  temperature.  2.65  g  (6.8  mmol)  of  2 deoxy 3,5 di O (4 toluoyl) α D 
erythro pentofuranosyl chloride  27  were  added  in  one  lot  and  the  reaction 
mixture  was  stirred  for  20  min  at  room  temperature.  After  filtration,  the 
solvent was evaporated and the residue purified by column chromatography (n 
hexane/ethyl acetate = 4/1) to give the product as colorless crystals. 
 
Yield:   1.98 g (3.9 mmol, 61 %) 
TLC:   Rf = 0.28 (n hexane/ethyl acetate: 4/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.65 (s, 1H, H2), 7.97 (d, 1H, H6, overlapped with toluoyl 
HA), 7.97 (d, 2H, toluoyl HA), 7.86 (d, 2H, toluoyl HA, J = 8.08), 7.38 
(d, 2H, toluoyl HB, J = 8.08), 7.32 (d, 2H, toluoyl HB, J = 8.08), 6.77 
(ψt, 1H, H1′), 6.77 (dd, 1H, H1′, overlapped with H5, J = 6.32), 6.75 
(d, 1H, H5, J = 3.79), 5.76 (m, 1H, H3′), 4.68 – 4.48 (m, 3H, H4′, H5′), 
3.18 (m, 1H, H2′), 2.76 (m, 1H, H2′), 2.41 (s, 3H, CH3), 2.38 (s, 3H, 
CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 165.5  (toluoyl C=O),  165.3  (toluoyl C=O),  151.2  (C7a), 
151.0 (C4), 150.8 (C2), 144.1 (toluoyl Cquart), 143.8 (toluoyl Cquart), 
129.5  (toluoyl CA),  129.3  (toluoyl CA),  129.3  (toluoyl CB),  129.3 
(toluoyl CB), 128.8 (C6), 126.6 (toluoyl CC), 126.5 (toluoyl CC), 117.6  Experimental part                                                                                                                
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(C4a), 100.1 (C5), 83.9 (C1′), 81.4 (C4′), 74.9 (C3′), 64.1 (C5′), 36.0 
(C2′), 21.3 (CH3), 21.2 (CH3). 
 
MALDI(+) MS:  m/z   507.39 [M + 2H
+] 
 
 
4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 5 iodo 
7H pyrrolo[2,3 d]pyrimidine 
 
 
Method A: 
Under argon atmosphere, 980 mg (3.5 mmol) of compound 19 were dissolved in 
80 ml dry acetonitrile. To this solution 0.5 g (8.8 mmol) of solid potassium 
hydroxide and 0.11 ml (0.35 mmol) TDA 1 were added and the mixture was 
stirred for 15 min at room temperature. 1.5 g (3.85 mmol) of compound 27 
were added in one portion and the reaction was allowed to proceed for 20 min 
at  room  temperature.  After  filtration,  the  solvent  was  evaporated  and  the 
residual purified on a silica gel column (eluent: n hexane/ethyl acetate = 4/1) 
to give the product as colorless crystals. 
 
Yield:   663 mg (1.05 mmol, 30 %) 
 
Method B: 
430 mg (2 mmol) potassium bis(trimethylsilyl)amide were dissolved under argon 
in 40 ml dry ACN and treated with 44 µl (0.14 mmol) TDA 1. The mixture was 
stirred  for  15  min  at  room  temperature  and  then  381  mg  (1.36  mmol)  of  Experimental part                                                                                                                
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compound 19 were added while stirring continued for another 15 min. After 
the  addition  of  580  mg  (1.5  mmol)  of  27  and  stirring  for  15  min  more  the 
product formed (as monitored by TLC). After filtration and solvent evaporation 
the  crude  product  was  purified  on  column  chromatography  using  n 
hexane/ethyl acetate = 4/1 as eluent. 
 
Yield:  644 mg (1.02 mmol, 51 %) 
 
Method C: 
1.0 g (3.6 mmol) of compound 19 was dissolved under argon in 50 ml dry ACN 
and stirred at 40 – 50 °C until complete solvation occured. Then the mixture 
was  treated  with  155  mg  (3.6  mmol)  sodium  hydride  (60  %  suspension  in 
mineral oil) and stirred for 15 min at room temperature. Subsequently, 1.36 g 
(3.6 mmol) of compound 27 were added and the reaction mixture was stirred 
for  2  h  at  room  temperature.  The  reaction  was  stopped  by  the  addition  of 
Dowex (H
+ form), then the mixture was taken up in 100 ml methylene chloride 
and filtered over Celite. The filtrate was concentrated and the resulting yellow 
foamy  crude  product  purified  on  column  chromatography  (n hexane/ethyl 
acetate 4/1) to give the product as colorless crystals. 
 
Yield:   1.84 g (2.9 mmol, 81 %) 
TLC:   Rf = 0.31 (n hexane/ethyl acetate: 4/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.65 (s, 1H, H2), 8.18 (s, 1H, H6), 7.95 (d, 2H, toluoyl HA, 
J = 8.08), 7.85 (d, 2H, toluoyl HA, J = 8.08), 7.36 (d, 2H, toluoyl HA, 
J = 8.08), 7.31 (d, 2H, toluoyl HA, J = 8.08), 6.76 (dd, 1H, H1′, J = 
6.32, J = 7.58), 5.75 (m, 1H, H3′), 4.69 – 4.38 (m, 3H, H4′, H5′), 3.09 
(m, 1H, H2′), 2.77 (m, 1H, H2′), 2.40 (s, 3H, CH3), 2.38 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 165.4 (toluoyl C=O), 165.2 (toluoyl C=O), 151.3 (C2), 150.8 
(C4), 150.6 (C7a), 144.1 (toluoyl Cquart), 143.8 (toluoyl Cquart), 133.3 
(C6), 129.5 (toluoyl CA), 129.3 (toluoyl CA), 129.3 (toluoyl CB), 129.2 
(toluoyl CB), 126.5 (toluoyl CC), 126.4 (toluoyl CC), 116.8 (C4a), 83.7 
(C1′), 81.6 (C4′), 74.7 (C3′), 63.9 (C5′), 54.1 (C5), 36.2 (C2′), 21.3 
(CH3), 21.2 (CH3). 
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MALDI(+) MS:  m/z  633.15 [M + 2H
+] 
 
 
4 Chloro 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d] 
pyrimidine 
 
 
In a sealable 100 ml flask, 1.26 g (2 mmol) of nucleoside 29 were dissolved in 
30 ml sat. ammonia and 50 ml MeOH, then stirred at room temperature for 20 
h.  After  solvent  removal  the  residue  was  purified  on  silica  gel  column  in 
CH2Cl2/MeOH (2 – 10 % MeOH) to give the product as colorless crystals. 
 
Yield:   752 mg (1.9 mmol, 95 %) 
TLC:   Rf = 0.35 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 8.66 (s, 1H, H6), 8.21 (s, 1H, H2), 6.63 (ψt, 1H, H1′), 5.32 
(d, 1H, 3′ OH,
 J = 4.39), 4.99 (t, 1H, 5′ OH, J = 5.49), 
 4.37 (m, 1H, 
H3′), 3.85 (m, 1H, H4′), 3.56 (m, 2H, H5′), 2.52 (m, 1H, H2′), 2.26 (m, 
1H, H2′). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm]  = 151.1  (C2),  150.6  (C4),  150.4  (C7a),  133.4  (C6),  116.6 
(C4a), 87.7 (C1′), 83.4 (C4′), 70.6 (C3′), 61.5 (C5′), 53.4 (C5), 39.8 
(C2′). 
 
ESI( ) MS:   m/z   393.37  [M   2H
+] 
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4 Amino 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 d] 
pyrimidine 
 
Method A: 
593 mg (1.5 mmol) of nucleoside 30 were suspended in 100 ml 25 % aqueous 
ammonia and filled into a Parr steel bomb. The mixture was stirred at 110 °C 
(4  bar)  for  about  15  h  within  which  the  white  crystalline  starting  material 
completely  dissolved.  The  yellow  solution  was  concentrated  then  and  the 
residue purified by column chromatography in CH2Cl2/MeOH 9/1. 
 
Yield:  480 mg (1.28 mmol, 85 %) 
 
Method B: 
In  a  sealed  microwave  vessel,  440  mg  (1.11  mmol)  of  compound  30  were 
suspended in 40 ml 25 % aqueous ammonia and stirred at 110 °C (2 bar, 150 W) 
for  about  3  h  within  which  the  colorless  crystalline  starting  material  fully 
dissolved. The pale yellow solution was concentrated and the crude product 
purified on column chromatography in CH2Cl2/MeOH 9/1. 
 
Yield:   346 mg (0.92 mmol, 83 %) 
TLC:   Rf = 0.23 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm]  = 8.10  (s,  1H,  H2),  7.65  (s,  1H,  H6),  7.35  (br  s,  1H, 
NH2(exchange)), 6.65 (br s, 1H, NH2(exchange)), 6.48 (ψt, 1H, H1′), 
5.26 (d, 1H, 3′ OH,
 J = 4.05), 5.03 (t, 1H, 5′ OH, J = 5.5), 
 4.33 (m, 
1H, H3′), 3.82 (m, 1H, H4′), 3.54 (m, 2H, H5′), 2.54 – 2.15 (m, 2H, 
H2′). 
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13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 157.2  (C4),  151.9  (C2),  149.7  (C7a),  126.7  (C6),  103.1 
(C4a), 87.4 (C4′), 82.9 (C1′), 70.9 (C3′), 61.8 (C5′), 51.7 (C5), 39.7 
(C2′). 
 
ESI( ) MS:   m/z   374.9 [M   2H
+] 
 
 
7 [2 Deoxy β D erythro pentofuranosyl] 4N (N,N dimethylaminomethylidenyl) 
5 iodo 7H pyrrolo[2,3 d]pyrimidine 
 
 
2.07 g (5.5 mmol) of nucleoside 31 were dissolved under argon in 15 ml dry 
DMF  and  11  ml  (82.5  mmol)  N,N dimethylformamide  dimethylacetal.  The 
mixture was stirred at 55 °C for 2 h and concentrated. The residue was purified 
on silica gel column using CH2Cl2/MeOH (5 – 10 % MeOH) as eluent to furnish the 
product as yellow crystals.  
 
Yield:   1.91 g (4.4 mmol, 80 %) 
TLC:   Rf = 0.28 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.82 (s, 1H, formamidino CH), 8.31 (s, 1H, H2), 7.71 (s, 
1H, H6), 6.53 (dd, 1H, H1′, J = 5.87 and J = 8.07), 4.34 (m, 1H, H3′), 
3.82 (m, 1H, H4′), 3.55 (m, 2H, H5′), 3.22 (s, 3H, formamidino CH3), 
3.18 (s, 3H, formamidino CH3), 2.48 – 2.16 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 160.2  (C4),  156.2  (formamidino C=N),  151.4  (C2),  150.8 
(C7a), 128.5 (C6), 110.2 (C4a), 87.4 (C4′), 83 (C1′), 71 (C3′), 61.9 
(C5′),  53.6  (C5),  40.4  (formamidino CH3),  39.9  (C2′),  34.9 
(formamidino CH3).  Experimental part                                                                                                                
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ESI( ) MS:   m/z   430.1 [M – H
+] 
 
 
 
7 [5 O Benzoyl 2 deoxy β D erythro pentofuranosyl] 4N (N,N 
dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidine 
 
 
1.72 g (4 mmol) of nucleoside 33 was coevaporated three times and dissolved 
in 80 ml dry pyridine. After cooling the yellow solution down to  20 °C, 488 µl 
(4.2 mmol) of benzoyl chloride in 20 ml dry methylene chloride were added 
dropwise via syringe. The mixture was stirred at  20 °C for 1 h and the reaction 
progress monitored via TLC. After completion of the reaction, 5 ml MeOH were 
added and the solvent was removed under reduced pressure. The oily residue 
was coevaporated with toluene and purified on column chromatography with 
CH2Cl2/MeOH (2 – 5 % MeOH) to give the product as yellowish crystals. 
 
Yield:   1.76 g (3.29 mmol, 82 %) 
TLC:   Rf = 0.06 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.81 (s, 1H, formamidino CH), 8.4 (s, 1H, H2), 7.98 (ψd, 
2H, benzoyl HA, J = 7.09), 7.74 (s, 1H, H6), 7.67 (t, 1H, benzoyl HC, J 
= 7.58), 7.54 (t, 2H, benzoyl HB, J = 7.09), 6.58 (ψt, 1H, H1′, J = 
6.85), 4.56 – 4.38 (m, 3H, H3′, H5′), 4.11 (m, 1H, H4′), 3.24 (s, 3H, 
formamidino CH3),  3.22  (s,  3H,  formamidino CH3),  2.71     2.28  (m, 
2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 165.6 (benzoyl C=O), 160 (C4), 156.8 (formamidino C=N), 
151.4 (C2), 150.4 (C7a), 133.4 (benzoyl CC), 129.4 (benzoyl Cquart),  Experimental part                                                                                                                
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129.2 (benzoyl CA), 128.9 (benzoyl CB), 128.2 (C6), 109.9 (C4a), 83.7 
(C4′), 82.7 (C1′), 70.5 (C3′), 64.5 (C5′), 54.8 (C5), 40.6 (formamidino 
CH3), 39 (C2′), 35 (formamidino CH3). 
 
ESI(+) MS:   m/z   536.1 [M + H
+] 
 
 
7 [5 O Benzoyl 3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl] 4N 
(N,N dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidine 
 
 
In an Erlenmeyer flask with triangle stirring bar, 1.34 g (2.5 mmol) of well 
dried nucleoside 34 were dissolved in 10 ml  tert butanol and in 3.3 ml (50 
mmol) freshly distilled acrylonitrile. 814 mg (2.5 mmol) of cesium carbonate 
were added and the mixture was stirred vigorously under argon 3 h at room 
temperature. The mixture was filtered through Celite, the filter cake washed 
with  methylene  chloride  and  the  organic  layer  was  concentrated  then.  The 
residue was purified on a short silica gel column using CH2Cl2/MeOH (5 – 10 % 
MeOH) to give the product as yellowish foam. 
 
Yield:   1.32 g (2.24 mmol, 90 %) 
TLC:   Rf = 0.21 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.75 (s, 1H, formamidino CH), 8.40 (s, 1H, H2), 8.02 (ψd, 
2H, benzoyl HA, J = 7.09), 7.58 (m, 1H, benzoyl HC, J = 7.34), 7.47 
(t, 2H, benzoyl HB, J = 7.09), 7.24 (s, 1H, H6), 6.59 (ψt, 1H, H1′, J = 
6.6), 4.56 (m, 2H, H5′), 4.35 (m, 2H, H3′,H4′), 3.72 (t, 2H,  O CH2, J 
= 6.36), 3.28 (s, 3H, formamidino CH3), 3.16 (s, 3H, formamidino 
CH3), 2.62 (t, 2H,  CH2CN, J = 6.36), 2.57 (m, 2H, H2′). 
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13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 166.4 (benzoyl C=O), 160.5 (C4), 156.1 (formamidino C=N), 
151.9  (C2),  151.2  (C7a),  133.5  (benzoyl CC),  129.7  (benzoyl CA), 
129.6  (benzoyl Cquart),  128.8  (benzoyl CB),  127.7  (C6),  117.5  (CN), 
111.6 (C4a), 84 (C1′), 81.9 (C4′), 80.4 (C3′), 64.5 (C5′), 64.4 (O CH2), 
53.8 (C5), 41 (formamidino CH3), 37.7 (C2′), 35.6 (formamidino CH3), 
19.2 (CH2CN). 
 
ESI(+) MS:   m/z   589.2 [M + H
+] 
 
 
4 Amino 7 [3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl] 5 iodo 7H 
pyrrolo[2,3 d]pyrimidine 
 
 
1.12  g  (2  mmol)  of  nucleoside  35  were  dissolved  in  70  ml  sat.  methanolic 
ammonia and 10 ml 32 % aqueous ammonia. The mixture was stirred at 50 °C 
and concentrated after complete conversion of the starting material (15 h). 
The crystalline product was obtained as colorless crystals after purification on 
a short silica gel column using CH2Cl2/MeOH (10 – 15 % MeOH). 
 
Yield:   644 mg (1.5 mmol, 75 %) 
TLC:   Rf = 0.29 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.10 (s, 1H, H2), 7.68 (s, 1H, H6), 6.68 (br s, 2H, NH2), 
6.44 (dd, 1H, H1′, J = 5.87 and J = 8.56), 5.14 (t, 1H, 5′ OH, J = 5.5), 
4.23 (m, 1H, H3′), 3.96 (m, 1H, H4′), 3.67 (t, 2H,  O CH2, J = 6.11), 
3.55 (m, 2H, H5′), 2.81 (t, 2H, CH2CN, J = 6.11), 2.59 – 2.31 (m, 2H, 
H2′). 
 
13C NMR:  (100 MHz, DMSO d6)  Experimental part                                                                                                                
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δ [ppm] = 157.2 (C4), 152 (C2), 149.8 (C7a), 126.7 (C6), 119.2 (CN), 
103.1  (C4a),  84.6  (C4′),  82.9  (C1′),  79.9  (C3′),  63.4  (O CH2),  61.8 
(C5′), 52.1 (C5), 36.5 (C2′), 18.2 (CH2CN). 
 
ESI(+) MS:   m/z   429.9 [M + H
+] 
 
 
4 Amino 7 [3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl] 5 (3 
trifluoroacetamido prop 1 ynyl) 7H pyrrolo[2,3 d]pyrimidine 
 
 
A  solution  of  350  mg  (0.82  mmol)  of  nucleoside  36  and  567  µl  (4.1  mmol) 
triethylamine in 13 ml dry DMF was degassed three times, then 94 mg (0.082 
mmol) Pd(PPh3)4 and 31 mg (0.164 mmol) of copper iodide were added. The 
mixture was treated with 290  µl (1.63 mmol) TFA protected propargylamine 
and stirred 3 h under argon at room temperature in the dark. After solvent 
evaporation,  the  dark yellow  residue  was  taken  up  in  100  ml  methylene 
chloride and washed twice with 50 ml 5 % aq. disodium EDTA solution. The 
aqueous layer was extracted again with 100 ml 2 butanone, then the combined 
organic layers were dried over MgSO4, filtered and concentrated. The residue 
was purified further on a short flash column using CH2Cl2/MeOH (5 – 10 % MeOH) 
furnishing the product as yellow brownish oil. 
 
Yield:   257 mg (0.57 mmol, 69 %)  Experimental part                                                                                                                
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TLC:   Rf = 0.23 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 10.1 (br t, 1H, TFA NH, J = 5.14), 8.18 (br s, 1H, H2), 7.79 
(s, 1H, H6), 6.85 (br s, 2H, NH2), 6.42 (dd, 1H, H1′, J = 5.87 and J = 
7.83), 5.17 (t, 1H, 5′ OH, J = 5.38), 4.31 (d, 2H, propargyl CH2, J = 
5.38), 4.25 (m, 1H, H3′), 3.98 (m, 1H, H4′), 3.67 (t, 2H,  O CH2, J = 
6.11), 3.55 (m, 2H, H5′), 2.81 (t, 2H, CH2CN, J = 6.11), 2.61 – 2.31 
(m, 2H, H2′). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm]  = 157.4  (C4),  156.6  (TFA C=O),  152.6  (C2),  149.3  (C7a), 
126.5  (C6),  119.2  (CN),  117.6  (CF3),  102.2  (C4a),  94.3  (C5),  86.8 
(propargyl C CH2), 84.7 (C4′), 83.2 (C1′), 79.8 (C3′), 76.1 (propargyl 
C C5), 63.4 (O CH2), 61.8 (C5′), 36.5 (C2′), 30.7 (propargyl CH2), 18.2 
(CH2CN). 
 
ESI(+) MS:   m/z   453.2 [M + H
+] 
 
 
4 Amino 5 [3 amino prop 1 ynyl] 7 [3 O (2 cyanoethyl) 2  
deoxy β D erythro pentofuranosyl) 7H pyrrolo[2,3 d]pyrimidine 
 
 
370 mg (0.82 mmol) of nucleoside 37 were dissolved in a mixture of 10 ml 
MeOH and 5 ml of 32 % aqueous ammonia. The pale yellow solution was stirred 
at  room  temperature  overnight  and  concentrated  after  completion  of  the 
reaction. The brownish oily residue was put on a short silica gel column using 
CH2Cl2/MeOH (10 – 100 % MeOH) as eluent to give the product as glassy oil. 
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Yield:   220 mg (0.617 mmol, 75 %) 
TLC:   Rf = 0.06 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.1 (br s, 1H, H6), 7.69 (s, 1H, H2), 6.78 (br s, 2H, NH2), 
6.42 (dd, 1H, H1′, J = 5.87 and J = 8.07), 5.21 (d, 1H, 5′ OH, J = 
5.14), 4.25 (m, 1H, H3′), 3.97 (m, 1H, H4′), 3.67 (t, 2H,  O CH2, J = 
6.26), 3.55 (m, 2H, H5′), 3.4 (br s, 2H, propargyl CH2), 2.81 (t, 2H, 
CH2CN, J = 6.26), 2.64 – 2.34 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 157.4 (C4), 152.9 (C2), 149.3 (C7a), 125.9 (C6), 119.2 (CN), 
102.1 (C4a), 95.5 (C5), 84.7 (C4′), 83.6 (propargyl C CH2), 83.2 (C1′), 
79.9 (C3′), 75.1 (propargyl C C5), 63.4 (O CH2), 61.9 (C5′), 36.5 (C2′), 
30.7 (propargyl CH2), 18.2 (CH2CN). 
 
ESI(+) MS:   m/z   357.1 [M + H
+] 
 
 
2 Amino 4 hydroxy pyrrolo[2,3 d]pyrimidine 
 
 
A mixture of 42.3 ml (0.26 mol) bromoacetaldehyde diethylacetal 20, 6.8 ml 37 
% hydrochloric acid and 137 ml water were heated up to 90 °C for 30 min with 
stirring.  The  clear  pale  yellow  solution  was  allowed  to  cool  down  to  room 
temperature and treated with 26.5 g (0.32 mol) sodium acetate. In another 
flask  (500  ml),  a  suspension  of  40.0  g  (0.32  mol)  2,4 diamino 6 hydroxy 
pyrimidine  39  and  13.3  g  (0.16  mol)  sodium  acetate  in  294  ml  water  was 
heated up to 70 – 85 °C. Having reached that temperature, the content from 
the first flask was added to the second one. With vigorous stirring, this mixture 
was  heated  up  to  80  °C  for  2  h  within  which  the  suspension  turned  into  a 
solution  first,  followed  by  precipitation  of  purple  crystalline  product.  The 
reaction mixture was cooled down to 0 °C for completion of precipitation. The  Experimental part                                                                                                                
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crystals were filtered off, washed with each 100 ml cold water and acetone and 
dried under reduced pressure. 
 
Yield:   26.8 g (178.5 mmol, 69 %) 
TLC:   Rf = 0.55 (CH2Cl2/EtOH 2/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 10.96 (br s, 1H, H3), 10.26 (s, 1H, H7), 6.60 (dd, 1H, H6, J 
= 2.56 and J = 3.29), 6.18 (dd, 1H, H5, J = 2.56 and J = 3.29), 6.06 
(br s, 2H, NH2).  
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 159.0 (C4), 152.3 (C2), 151.2 (C7a), 116.7 (C6), 101.6 (C5), 
99.9 (C4a). 
 
ESI(+) MS:   m/z   150.7 
 
 
2,2 Dimethyl N (4 hydroxy pyrrolo[2,3 d]pyrimidin 2 yl) propionamide 
 
 
In a preheated flask, 4.54 g (30 mmol) of compound 40 and 13.1 ml (105 mmol) 
pivaloyl  chloride  were  dissolved  in  50  ml  dry  pyridine  under  an  argon 
atmosphere. The violet suspension was heated up to 80 – 90 °C for about 30 
min  while  it  turned  into  a  clear  dark  brown  solution.  The  solvent  was 
evaporated then, the residue dissolved in 30 ml MeOH and treated with 10 % 
aqueous  ammonia  until  pH  4  causing  the  product  precipitating  as  brown 
crystals. The crude product was filtered off, dried under reduced pressure and 
purified on column with CH2Cl2/MeOH (2 – 10 % MeOH). 
 
Yield:   5.16 g (22 mmol, 73 %) 
TLC:   Rf = 0.3 (CH2Cl2/MeOH: 9/1)  Experimental part                                                                                                                
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1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 11.83 (s, 1H, piv NH), 11.57 (s, 1H, H3), 10.79 (s, 1H, H7), 
6.95 (m, 1H, H6), 6.40 (m, 1H, H5), 1.24 (s, 9H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 180.9 (piv C=O), 157.0 (C4), 147.8 (C2), 146.5 (C7a), 119.7 
(C6), 103.9 (C4a), 102.2 (C5), 40.3 (piv C CH3), 26.4 (piv CH3). 
 
ESI(+) MS:   m/z   234.8 
 
 
2,2 Dimethyl N (4 hydroxy 5 iodo pyrrolo[2,3 d]pyrimidin 2 yl) propionamide 
 
 
1.0 g (4.3 mmol) of the heterocycle 41 was dissolved in 20 ml abs. DMF under 
an  argon  atmosphere.  The  solution  was  treated  with  4  ml  (15.4  mmol)  of 
bis(trimethylsilyl)acetamide and stirred for 2 h at 40 °C. After cooling down to 
room temperature, 1.2 g (5.2 mmol) of N iodosuccinimide were added in one 
portion. The solution was protected from light and stirred for another 2 h at 
room temperature. The dark brown solution was poured into 50 ml cold water 
with stirring. After 1 2 h the product precipitated as brown crystals which were 
filtered off, washed with 50 ml cold water and dried in vacuum. 
 
Yield:   929 mg (2.58 mmol, 60 %) 
TLC:   Rf = 0.44 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 11.91 (br s, 1H, piv NH), 11.81 (br s, 1H, H3), 10.83 (br s, 
1H, H7), 7.15 (s, 1H, H6), 1.23 (s, 9H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 180.9 (piv C=O), 156.5 (C4), 147.9 (C2), 146.9 (C7a), 124.9 
(C6), 103.8 (C4a), 54.2 (C5), 40.3 (piv C CH3), 26.3 (piv CH3). 
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MALDI(+) MS:   m/z   361.81 [M + H
+] 
 
 
 
2,2 Dimethyl N (4 chloro pyrrolo[2,3 d]pyrimidin 2 yl) propionamide 
 
 
2.34 g (10 mmol) of the well dried compound 41 were suspended under inert 
atmosphere in 50 ml POCl3 and refluxed for about 2.5 h. Roughly 30 ml POCl3 
were then distilled off and the dark brown residue was poured slowly into 200 
ml of ice water. The pH value of the reaction mixture was adjusted to 4 by 
dropwise  addition  of  10  %  aqueous  ammonia.  The  product  precipitated  as 
yellowish brown crystals which were collected by filtration, washed with cold 
water and dried in vacuum. The aqueous filtrate was extracted three times 
with 100 ml ethyl acetate each and the combined organic layers were washed 
once with brine, dried over MgSO4 and concentrated to give a second fraction 
of the product.  
 
Yield:   2.21 g (8.74 mmol, 87 %) 
TLC:   Rf = 0.65 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 12.34 (br s, 1H, piv NH), 10.04 (br s, 1H, H7), 7.54 (d, 1H, 
H6), 6.53 (d, 1H, H5), 1.24 (s, 9H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 176.0 (piv C=O), 153.0 (C4), 151.6 (C2), 150.8 (C7a), 127.8 
(C6), 113.3 (C4a), 99.1 (C5), 39.3 (piv C CH3), 27.2 (piv CH3). 
 
ESI(+) MS:   m/z   253.0 
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2,2 Dimethyl N (4 chloro 5 iodo pyrrolo[2,3 d]pyrimidin 2 yl) propionamide 
 
 
Method A: 
2.2 g (8.7 mmol) of compound 44 were dissolved in 40 ml abs. DMF and treated 
with 3.4 ml (13 mmol) of bis (trimethylsilyl)acetamide. The mixture was stirred 
for  2  h  at  40  °C  under  argon,  then  cooled  down  to  room  temperature  and 
treated with 2.35 g (10.4 mmol) of N iodosuccinimide. The orange solution was 
stirred for another 2 h in the dark at room temperature and poured into 100 ml 
cold water with stirring in order to quench the reaction. The aqueous layer was 
extracted three times with 150 ml CH2Cl2 each, the combined organic layers 
were  washed  once  with  100  ml  brine,  dried  over  MgSO4,  filtered  and 
concentrated.  The  crude  residue  was  purified  on  a  silica  gel  column  with 
CH2Cl2/MeOH (2 – 10 % MeOH) as eluent to furnish the pure product as yellow 
crystals. 
 
Yield:   2.50 g (6.6 mmol, 76 %) 
 
Method B: 
Under argon, 1.0 g (3.96 mmol) of the starting material 44 was dissolved in 12 
ml dry DMF and treated with 1.12 g (4.95 mmol) of N iodosuccinimide. The 
mixture  was  protected  from  light and  stirred  for  2  h at  room temperature, 
diluted with 150 ml methylene chloride and washed with each 50 ml of brine 
and  Na2S2O3 solution.  The  oily  residue  obtained  after  solvent  removal  was 
purified on column chromatography (CH2Cl2/MeOH, 2 – 10 % MeOH) to furnish 
yellow crystalline product. 
 
Yield:  1.39 g (3.67 mmol, 92 %)     Experimental part                                                                                                                
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TLC:   Rf = 0.7 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 12.71 (br s, 1H, piv NH), 10.12 (br s, 1H, H7), 7.77 (d, 1H, 
H6, J = 2.53), 1.23 (s, 9H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 175.8 (pivaloyl C=O), 152.5 (C4), 151.4 (C2), 150.5 (C7a), 
132.7 (C6), 112.3 (C4a), 51.6 (C5), 39.7 (piv C CH3), 26.8 (piv CH3). 
 
ESI(+) MS:   m/z   378.8 
 
 
4 Chloro 7 (2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 5 iodo 2 
pivaloylamino 7H pyrrolo[2,3 d]pyrimidine 
 
 
Under argon, 757 mg (2 mmol) of compound 45 were dissolved in 15 ml dry 
THF, treated with 90 mg (2.2 mmol) NaH (60 % in mineral oil) and the orange 
solution was stirred for 30 min at room temperature while it turned dark green. 
933 mg (2.4 mmol) of compound 27 were added then and the cloudy mixture 
was stirred for another 1 h at room temperature within which it turned dark 
orange. The reaction was stopped by addition of Dowex (H
+ form), diluted in 
100 ml CH2Cl2, filtered over Celite and concentrated under reduced pressure. 
The residual oil was purified on a silica gel column using CH2Cl2/MeOH (0 – 1 % 
MeOH) as eluent to give the product as yellowish crystals. 
 
Yield:   628 mg (0.86 mmol, 43 %)  Experimental part                                                                                                                
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TLC:   Rf = 0.59 (CH2Cl2) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.18 (br s, 1H, piv NH), 8.02 – 7.28 (m, 8H, toluoyl H), 7.45 
(s, 1H, H6), 6.76 (m, 1H, H1′), 5.82 (m, 1H, H3′), 4.74 (m, 2H, H5′), 
4.61 (m, 1H, H4′), 2.98 – 2.86 (m, 2H, H2′), 2.47 (s, 3H, toluoyl CH3), 
2.46 (s, 3H, toluoyl CH3), 1.38 (s, 9H, piv CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 175.7 (pivaloyl C=O), 166.3 (toluoyl C=O), 166.2 (toluoyl 
C=O),  153  (C2),  151.5  (C4),  144.5  (toluoyl C),  144.3  (toluoyl C), 
131.1  (C6),  130  (toluoyl C),  129.7  (toluoyl C),  129.5  (toluoyl C), 
129.4 (toluoyl C), 126.9 (toluoyl C), 126.6 (C7a), 113.7 (C4a), 84.7 
(C1′), 82.8 (C4′), 75.1 (C3′), 64.1 (C5′), 53.0 (C5), 40.4 (piv C CH3), 
38.2 (C2′), 27.5 (piv CH3), 21.8 (toluoyl CH3). 
 
ESI(+) MS:   m/z   731.4 [M + H
+] 
 
 
4 Chloro 2 methylthio pyrrolo[2,3 d]pyrimidine 
 
 
1.0 g (5.5 mmol) of heterocycle 16 were suspended in 30 ml of phosphorus 
oxychloride  and  heated  up  to  reflux  for  4  h  while  the  starting  material 
completely  dissolved.  Afterwards  the  mixture  was  allowed  to  cool  down  to 
room temperature and quenched on 200 ml ice water with stirring. By addition 
of  aqueous  ammonia  the  pH  value  was  adjusted  to  4  causing  product 
precipitation. The crystalline product was filtered off then and the aqueous 
layer was extracted three times with 200 ml ethyl acetate each. The combined 
organic  layers  were  dried  over  MgSO4  and  evaporated  to  dryness  to  give  a 
second fraction of yellow crystalline product. Both crystalline fractions were 
recrystallized in ethyl acetate, filtered off and dried in vacuum. 
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Yield:   400 mg (2 mmol, 36 %) 
TLC:   Rf = 0.23 (n hexane/ethyl acetate: 4/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 12.39 (br s, 1H, H7), 7.51 (dd, 1H, H6, J = 3.54 and J = 
2.27), 6.51 (dd, 1H, H5, J = 3.54 and J = 1.77), 2.55 (s, 9H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 162.7  (C2),  152.7  (C4),  150.4  (C7a),  126.8  (C6),  113.2 
(C4a), 99.0 (C5), 13.8 (SMe). 
 
ESI(+) MS:   m/z   199.6 
 
 
4 Chloro 5 iodo 2 methylthio pyrrolo[2,3 d]pyrimidine 
 
 
Under argon, 242 mg (1.2 mmol) of compound 47 were dissolved in 50 ml dry 
methylene chloride and treated with 300 mg (1.32 mmol) N iodosuccinimide. 
The reaction mixture was stirred for 3 h until completion of the reaction at 
room temperature. The solvent was removed under reduced pressure and the 
yellowish crystalline product obtained after purification on column chromato 
graphy with CH2Cl2/MeOH (0 – 2 % MeOH) as eluent. 
 
Yield:   260 mg (0.8 mmol, 67 %) 
TLC:   Rf = 0.57 (CH2Cl2/MeOH: 9/1) 
 
1H NMR  (250 MHz, DMSO d6) 
δ [ppm] = 12.73 (br s, 1H, H7), 7.75 (d, 1H, H6), 2.54 (s, 3H, SCH3). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm]  = 163.2  (C2),  152.4  (C4),  150.7  (C7a),  132.3  (C6),  112.5 
(C4a), 52.1 (C5), 13.7 (SMe). 
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4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 2 
methylthio 7H pyrrolo[2,3 d]pyrimidine 
 
 
210 mg (1.05 mmol) of the well dried heterocycle 47 were dissolved in 30 ml 
dry acetonitrile and treated with 50 mg (1.16 mmol) of 60 % sodium hydride in 
mineral oil. The yellow solution was stirred under argon for 30 min at room 
temperature, then 408 mg (1.05 mmol) of compound 27 were added in one lot. 
The cloudy suspension was stirred for 3 h at room temperature for completion 
of the reaction and quenched by the addition of Dowex (H
+ form) then. After 
filtration through Celite, the filtrate was concentrated and purified on column 
chromatography  with  n hexane/ethyl  acetate  4/1  to  give  the  product  as 
colorless foam. 
 
Yield:   419 mg (0.76 mmol, 72 %) 
TLC:   Rf = 0.36 (n hexane/ethyl acetate: 4/1) 
 
1H NMR:  (250 MHz, CDCl3) 
δ [ppm] = 7.94 (m, 4H, toluoyl HA, J = 8.23), 7.26 (m, 4H, toluoyl HB, 
J = 6.86), 7.24 (d, 1H, H6), 6.74 (dd, 1H, H1′, J = 6.04 and J = 7.96), 
6.49 (d, 1H, H5, J = 3.84), 5.75 (m, 1H, H3′), 4.75 – 4.53 (m, 3H, H4′, 
H5′), 2.89 (m, 1H, H2′), 2.75 (m, 1H, H2′), 2.64 (s, 3H, SCH3), 2.44 (s, 
3H, toluoyl CH3), 2.42 (s, 3H, toluoyl CH3). 
 
13C NMR:  (63 MHz, CDCl3) 
δ [ppm]  = 166.3  (C=O),  166.1  (C=O),  165  (C2),  152.2  (C4),  152.1  Experimental part                                                                                                                
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(C7a), 144.6 (toluoyl Cquart), 144.3 (toluoyl Cquart), 129.9 (toluoyl CA), 
129.7  (toluoyl CA),  129.4  (toluoyl CB),  129.2  (toluoyl CB),  126.8 
(toluoyl CC), 126.6 (toluoyl CC), 124.4 (C6), 114.8 (C4a), 101.4 (C5), 
84.3 (C1′), 82.4 (C4′), 75.1 (C3′), 64.3 (C5′), 38.2 (C2′), 21.8 (toluoyl 
CH3), 21.8 (toluoyl CH3). 
 
ESI(+) MS:   m/z   552.2    
 
 
4 Chloro 7 [2 deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 5 iodo 2 
methylthio 7H pyrrolo[2,3 d]pyrimidine 
 
120 mg (0.37 mmol) of the heterocycle 48 were dissolved with heating at 60 °C 
in  20  ml  dry  acetonitrile  within  15  min.  The  solution  was  cooled  down  to 
approximately 30 °C and 17 mg (0.4 mmol) of sodium hydride (60 % in mineral 
oil)  were  added  in  one  lot.  The  mixture  was  stirred  for  15  min  at  room 
temperature,  followed  by  subsequent  addition  of  143  mg  (0.37  mmol)  of 
compound 27. The yellow solution was stirred for 1 h at room temperature and 
the reaction stopped by addition of Dowex (H
+ form). The mixture was diluted 
in 50 ml methylene chloride and filtered through Celite. The residue obtained 
after concentration of the orange clear filtrate was placed atop of a silica gel 
column for purification using n hexane/ethyl acetate 4/1 to give the product as 
colorless crystals. 
 
Yield:   137 mg (0.2 mmol, 55 %)  Experimental part                                                                                                                
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TLC:   Rf = 0.34 (n hexane/ethyl acetate: 4/1) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 7.97 (d, 2H, toluoyl HA, J = 8.08), 7.91 (d, 2H, toluoyl HA, J 
= 8.08), 7.38 (s, 1H, H6), 7.28 (t, 4H, toluoyl HB, J = 8.34), 6.71 (t, 
1H, H1′, J = 6.82), 5.72 (m, 1H, H3′), 4.69 (qd, 2H, H5′, J = 3.54, J = 
12.13 and J = 33.09), 4.59 (m, 1H, H4′), 2.76 (m, 2H, H2′), 2.62 (s, 
3H, SCH3) 2.44 (s, 3H, toluoyl CH3), 2.43 (s, 3H, toluoyl CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 166.3 (toluoyl C=O), 166.1 (toluoyl C=O), 165.2 (C2), 153.8 
(C4), 152.7 (C7a), 144.4 (toluoyl Cquart), 129.9 (C6), 129.8 (toluoyl 
CA), 129.5 (toluoyl CA), 129.3 (toluoyl CB), 126.7 (toluoyl CC), 126.6 
(toluoyl CC), 114.8 (C4a), 84.3 (C1′), 82.8 (C4′), 75.1 (C3′), 64.1 (C5′), 
53.4  (C5),  38.7  (C2′),  21.9  (toluoyl CH3),  21.8  (toluoyl CH3),  14.7 
(SCH3). 
 
ESI(+) MS: calculated:  677.94 
    found:    678.0 
 
 
7 [2 Deoxy 3,5 di O (4 toluoyl) β D erythro pentofuranosyl] 5 iodo 2 
methylthio 7H pyrrolo[2,3 d]pyrimidin 4 one 
 
 
Under argon, 103 mg (0.15 mmol) of nucleoside 51 were dissolved in 4 ml dry 
DMF  and  2.7  ml  1,4 dioxane.  To  this  solution,  92  mg  (0.75  mmol)  of  syn 
pyridinealdoxime  and  105 µl  (0.83  mmol)  1,1,3,3 tetramethylguanidine  were 
added and the mixture was stirred for 24 h at room temperature. After removal  Experimental part                                                                                                                
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of the solvent, the residue was taken up in 100 ml methylene chloride, washed 
with  0.1  M  aqueous  citric  acid  (2  x  50  ml),  water  (100  ml)  and  saturated 
aqueous  NaHCO3  (100  ml),  then  dried  over  MgSO4  and  concentrated  after 
filtration. The yellow crystalline product was purified on a silica gel column 
using a gradient starting with CH2Cl2/ethyl acetate 95/5 to CH2Cl2/MeOH 95/5. 
 
Yield:   88 mg (0.13 mmol, 89 %) 
TLC:   Rf = 0.39 (CH2Cl2/MeOH: 96/4) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 10.76 (br s, 1H, NH), 7.94 (t, 4H, toluoyl HA, J = 8.34), 
7.27 (d, 4H, toluoyl HB, J = 8.08), 7.05 (s, 1H, H6), 6.62 (dd, 1H, H1′, 
J = 6.32 and J = 7.83), 5.69 (m, 1H, H3′), 4.67 (m, 2H, H5′), 4.56 (q, 
1H, H4′, J = 3.03), 2.72 (m, 2H, H2′), 2.64 (s, 3H, SCH3), 2.44 (s, 3H, 
CH3), 2.42 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 166.5 (toluoyl C=O), 165.9 (toluoyl C=O), 159 (C4), 156.5 
(C2),  147.2  (C7a),  144.5  (toluoyl Cquart),  129.9  (toluoyl CA),  129.8 
(toluoyl CA),  129.6  (toluoyl CB),  129.4  (toluoyl CB),  126.7  (toluoyl 
CC),  123.8  (C6),  105.8  (C4a),  84.0  (C1′),  82.6  (C4′),  75  (C3′),  64.1 
(C5′),  55.8  (C5),  38.7  (C2′),  21.9  (toluoyl CH3),  21.8  (toluoyl CH3), 
13.9 (SCH3). 
 
ESI(+) MS:   m/z   660.1 [M + H
+] 
 
 
 
2 Amino 7 [2 deoxy β D erythro pentofuranosyl] 5 iodo 7H pyrrolo[2,3 
d]pyrimidin 4 one 
 
 
220  mg  (0.33  mmol)  of  compound  52  were  dissolved  in  20  ml  methylene  Experimental part                                                                                                                
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chloride  and  cooled  down  to  0  °C.  136  mg  (0.43  mmol)  of  3 chloroperoxy 
benzoic acid (50 – 60 % MCPBA) were added in one lot and the mixture was 
stirred for 15 min at 0 °C, then for 105 min at room temperature. The solvent 
was evaporated and the residue quickly purified on a short silica gel column 
using CH2Cl2/MeOH 96/4 as eluent. The oxidized nucleoside was suspended in 
100 ml of a sat. NH4OH/dioxane solution and filled into a sealable Parr bomb. 
The  mixture  was  heated  for  15  h at  110  °C,  cooled  and concentrated.  The 
brownish oily residue was taken up in 100 ml CH2Cl2, washed with 100 ml sat. 
aq. NaHCO3, dried over MgSO4 and concentrated. The resulting yellow brownish 
oil was suspended in 100 ml of a sat. NH4OH/MeOH solution and filled in the 
Parr autoclave again. The mixture was heated up to 140 °C for 2 h, cooled 
down and concentrated. The oily residue was purified on a silica gel column 
using CH2Cl2/MeOH 9/1 yielding the product as yellow crystals. 
 
Yield:   25 mg (0.06 mmol, 19 %) 
TLC:   Rf = 0.13 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 10.4 (br s, 1H, NH3), 7.11 (s, 1H, H6), 6.32 (br s, 2H, NH2), 
6.26 (dd, 1H, H1′, J = 5.81 and J = 8.59), 5.19 (d, 1H, 3′ OH, J = 
3.54), 4.89 (t, 1H, 5′ OH, J = 5.31), 4.26 (m, 1H, H3′), 3.74 (m, 1H, 
H4′), 3.48 (m, 2H, H5′), 2.31 (m, 1H, H2′), 2.04 (m, 1H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 158.1 (C4), 152.7 (C2), 150.6 (C7a), 121.7 (C6), 99.8 (C4a), 
87.1 (C4′), 82.2 (C1′), 70.9 (C3′), 61.9 (C5′), 55 (C5), 39.8 (C2′). 
 
ESI( ) MS:   m/z   390.9 [M   H
+] 
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 7 [2 Deoxy 3,5 O (tetraisopropyldisiloxane 1,3 diyl) β D erythro 
pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 
d]pyrimidin 4 one 
 
 
1.0  g  (2.55  mmol)  of  nucleoside  54  was  coevaporated  three  times  with 
pyridine, then dissolved in 10 ml dry pyridine and cooled down to 0 °C. 0.88 ml 
(2.81  mmol)  of  1,1,3,3 tetraisopropyldichlordisiloxane  were  added  and  the 
mixture was stirred under argon 30 min at 0 °C first, then for 20 h at room 
temperature. The reaction was stopped by addition of 10 ml MeOH and stirring 
for 15 min. The solvents were removed, the oily residue was dissolved in 15 ml 
dry N,N dimethylformamide again and treated with 1.7 ml (12.8 mmol) N,N 
dimethylformamide dimethylacetal. The yellow solution was stirred for 24 h at 
room temperature under argon while the reaction was monitored by TLC. The 
mixture was concentrated and the crude product purified on a silica gel column 
using CH2Cl2/MeOH (5 – 10 % MeOH) as eluent. 
 
Yield:   1.73 g (2.51 mmol, 98 %) 
TLC:   Rf = 0.2 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 11.11 (br s, 1H, NH3), 8.57 (s, 1H, formamidino CH), 7.12 
(s, 1H, H6), 6.36 (dd, 1H, H1′, J = 3.91 and J = 7.33), 4.67 (m, 1H, 
H3′), 3.9 (m, 2H, H5′), 3.71 (m, 1H, H4′), 3.14 (s, 3H, formamidino 
CH3), 3.02 (s, 3H, formamidino CH3), 2.59   2.36 (m, 2H, H2′), 1.02 
(m, 28H, iso propyl CH3). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm]  = 158.9  (C4),  157.7  (formamidino C=N),  156.3  (C2),  149.2  Experimental part                                                                                                                
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(C7a), 122.6 (C6), 102.7 (C4a), 84 (C4′), 80.4 (C1′), 70.6 (C3′), 61.9 
(C5′),  55.6  (C5),  40.6  (formamidino CH3),  40.2  (C2′),  34.5 
(formamidino CH3),  17.3     16.7  (iso propyl CH3),  12.7  –  12  (iso 
propyl CH CH3). 
 
ESI(+) MS:   m/z   690.3 [M + H
+] 
 
 
3N Benzoyl 7 [2 deoxy 3,5 O (tetraisopropyldisiloxane 1,3 diyl) β D erythro 
pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 
d]pyrimidin 4 one 
 
1.59 g (2.3 mmol) of nucleoside 56 were coevaporated three times with dry 
pyridine, then dissolved in 15 ml abs. pyridine and cooled down to 0 °C. 402 µl 
(3.45 mmol) of benzoyl chloride, diluted in 0.5 ml dry CH2Cl2, were added and 
the mixture was stirred for 30 min at 0 °C, then for 5 h at room temperature. 
After treatment with a second portion of benzoyl chloride (134 µl, 1.15 mmol) 
the reaction was allowed to proceed overnight. The mixture was concentrated, 
the residue taken up in 200 ml CH2Cl2 and washed with each 50 ml of water, 
sat.  aqueous  NaHCO3  and  brine.  The  organic  layer  was  dried  over  MgSO4, 
filtered  and  concentrated.  The  residue  was  purified  on  silica  gel  using  a 
gradient starting with n hexane/ethyl acetate = 5/1 to CH2Cl2/MeOH 95/5. 
 
Yield:   1.4 g (1.76 mmol, 77 %) 
TLC:   Rf = 0.61 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (250 MHz, CDCl3) 
δ [ppm] = 8.49 (s, 1H, formamidino H), 7.85 (ψd, 2H, benzoyl HA, J = 
7.34), 7.55 (ψt, 1H, benzoyl HC, J = 7.34), 7.41 (ψt, 2H, benzoyl HB,  Experimental part                                                                                                                
180 
J = 7.83), 7.0 (s, 1H, H6), 6.47 (dd, 1H, H1′, J = 3.42 and J = 7.34), 
4.71 (q, 1H, H3′, J = 7.58), 4.02 (m, 2H, H5′), 3.82 (m, 1H, H4′), 3.06 
(s, 3H, formamidino CH3), 2.69 (s, 3H, formamidino CH3), 2.53 (m, 
2H, H2′), 1.16   1.04 (m, 28H, iso propyl CH). 
 
13C NMR:  (63 MHz, CDCl3) 
δ [ppm] = 171.4 (benzoyl C=O), 158.8 (C4), 156.3 (formamidino C=N), 
154.3 (C2), 148.3 (C7a), 133.9 (benzoyl CC), 132.8 (benzoyl Cquart), 
130.3 (benzoyl CA), 128.9 (benzoyl CB), 123.1 (C6), 103.9 (C4a), 84.9 
(C4′), 81.2 (C1′), 70.2 (C3′), 61.9 (C5′), 55.8 (C5), 41.2 (formamidino 
CH3),  38.4  (C2′),  35.1  (formamidino CH3),  17.7     17.1  (iso propyl 
CH3), 13.6 – 12.7 (iso propyl CH CH3). 
 
ESI(+) MS:   m/z   794.5 [M + H
+] 
 
 
7 [2 Deoxy β D erythro pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 
5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one 
 
 
397 mg (0.5 mmol) 57 were dissolved in 10 ml dry THF and treated with 285 µl 
(1.75 mmol) of a triethylamine trihydrofluoride solution (approx. 37 % HF). The 
mixture was stirred for 4 h at room temperature, then concentrated and the 
residue purified on a short silica gel column with CH2Cl2/MeOH 9/1 to give the 
product as yellowish glassy crystals. 
 
Yield:   276 mg (0.5 mmol, 100 %) 
TLC:   Rf = 0.27 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 8.58 (s, 1H, formamidino CH), 7.80 (ψd, 2H, benzoyl HA, J 
= 7.09 and J = 8.56), 7.7 (ψt, 1H, benzoyl HC, J = 7.34), 7.55 (ψt, 2H,  Experimental part                                                                                                                
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benzoyl HB, J = 7.34), 7.4 (s, 1H, H6), 6.47 (dd, 1H, H1′, J = 5.87 and 
J = 7.58), 5.29 (d, 1H, 3′ OH, J = 3.91), 4.93 (t, 1H, 5′ OH, J = 5.14), 
4.34 (m, 1H, H3′), 3.81 (m, 1H, H4′), 3.54 (m, 2H, H5′), 3.09 (s, 3H, 
formamidino CH3),  2.61  (s,  3H,  formamidino CH3),  2.44  –  2.13  (m, 
2H, H2′). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm] = 171.7 (benzoyl C=O), 157.8 (C4), 156.5 (formamidino C=N), 
153.8 (C2), 148.7 (C7a), 134.3 (benzoyl CC), 133.1 (benzoyl Cquart), 
129.6 (benzoyl CA), 129.2 (benzoyl CB), 124.2 (C6), 102.1 (C4a), 87.4 
(C4′), 82.4 (C1′), 70.9 (C3′), 61.8 (C5′), 55.7 (C5), 40.6 (formamidino 
CH3), 39.9 (C2′), 34.4 (formamidino CH3). 
 
ESI(+) MS:   m/z   552.0 [M + H
+] 
 
 
3N Benzoyl 7 [2 deoxy 5 O (4 monomethoxytrityl) β D erythro 
pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 
d]pyrimidin 4 one 
 
 
845 mg (1.53 mmol) of the starting material 58 were coevaporated three times 
with pyridine and dissolved in 10 ml abs. pyridine. 19 mg (0.15 mmol) of 4 
dimethylaminopyridine  and  617  mg  (2  mmol)  p monomethoxytrityl  chloride 
were  added  and  the  mixture  was  stirred  under  argon  overnight  at  room 
temperature.  The  reaction  was  stopped  by  addition  of  2  ml  MeOH,  then 
concentrated and the residue taken up in 100 ml CH2Cl2. The organic layer was 
washed with 50 ml water, sat. aq. NaHCO3 and brine each, dried over MgSO4, 
filtered and concentrated. The purification of the crude material on silica gel 
column with CH2Cl2/MeOH (0 – 5 % MeOH) gave the product as yellow foam.  Experimental part                                                                                                                
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Yield:   1.04 g (1.26 mmol, 82 %) 
TLC:   Rf = 0.42 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.51 (s, 1H, formamidino CH), 7.87 (ψd, 2H, benzoyl HA, J 
= 7.68), 7.55 (ψt, 1H, benzoyl HC, J = 7.32), 7.46 – 7.23 (m, 14H, 
benzoyl HB, J = 7.68, MMTr H), 6.93 (s, 1H, H6), 6.86 (ψd, 2H, MMTr 
H, J = 8.78), 6.60 (ψt, 1H, H1′, J = 6.22), 4.56 (m, 1H, H3′), 4.07 (m, 
1H, H4′), 3.81 (s, 3H, OCH3), 3.47   3.27 (m, 2H, H5′), 3.06 (s, 3H, 
formami dino CH3), 2.69 (s, 3H, formamidino CH3), 2.50 – 2.36 (m, 
2H, H2′). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 171.4 (benzoyl C=O), 158.6 (MMT C OMe), 158 (C4), 157.7 
(MMT C), 156.4 (formamidino C=N), 153.7 (C2), 149.4 (MMT C), 148.5 
(C7a), 144.1 (MMT C), 144 (MMT C), 134.8 (MMT C), 134.1 (benzoyl 
CC),  132.9  (benzoyl Cquart),  129.8  (benzoyl CA),  129.4  (benzoyl CB), 
129 (MMT C), 127.9 (MMT C), 127.8 (MMT C), 127.7 (MMT C), 126.7 
(MMT C), 123 (C6), 113.5 (MMT C), 102.1 (C4a), 85.8 (C4′), 82.3 (C1′), 
72.9 (C3′), 64.3 (C5′), 55.7 (C5), 55 (MMT OCH3), 40.5 (formamidino 
CH3), 39.9 (C2′), 34.3 (formamidino CH3). 
 
ESI(+) MS:   m/z   824.7 [M + H
+] 
 
 
3N Benzoyl 7 [3 O (2 cyanoethyl) 2 deoxy 5 O (4 monomethoxytrityl) β D 
erythro pentofuranosyl] 2N (N,N dimethylaminomethylidenyl) 5 iodo 7H 
pyrrolo[2,3 d]pyrimidin 4 one 
 
 
In an Erlenmeyer flask with magnetic stirrer and triangle stirring bar, 1.02 g 
(1.25 mmol) of compound 58 were dissolved in 12 ml tert butanol and 3.3 ml 
(50 mmol) freshly distilled acrylonitrile under argon. The mixture was agitated  Experimental part                                                                                                                
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vigorously for a few minutes at room temperature, then 407 mg (1.25 mmol) of 
cesium  carbonate  were  added  and  vigorous  stirring  continued  for  4  h.  The 
suspension was taken up in 200 ml methylene chloride then, filtered through 
Celite and concentrated. The residue was purified on a silica gel column with 
CH2Cl2 as eluent. The product was obtained as yellow foam. 
 
Yield:   759 mg (0.87 mmol, 69 %) 
TLC:   Rf = 0.69 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.54 (s, 1H, formamidino CH), 7.87 (ψd, 2H, benzoyl HA, J 
= 7.32), 7.55 (t, 1H, benzoyl HC, J = 7.32), 7.44 (t, 2H, benzoyl HB, J 
= 7.68), 7.39   7.23 (m, 12H, MMT), 6.95 (s, 1H, H6), 6.87 (ψd, 2H, 
MMT, J = 8.78), 6.56 (dd, 1H, H1′, J = 5.86 and J = 8.78), 4.18 (m, 
2H, H3′, H4′), 3.81 (s, 3H, OCH3), 3.68 (t, 2H,  O CH2, J = 6.22), 3.41 
–  3.29  (m,  2H,  H5′),  3.06  (s,  3H,  formamidino CH3),  2.69  (s,  3H, 
formami dino CH3), 2.62 (t, 2H, CH2CN, J = 6.22), 2.48 – 2.31 (m, 2H, 
H2′). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm]  = 171.4  (benzoyl C=O),  158.1  (C4),  157.7  (MMT C),  156.5 
(formami dino C=N),  153.8  (C2),  148.7  (C7a),  144.1  (MMT C),  144 
(MMT C), 134.8 (MMT C), 134.1 (benzoyl CC), 132.9 (benzoyl Cquart), 
130.2 (MMT C), 129.9 (benzoyl CA), 129.4 (benzoyl CB), 129 (MMT C), 
127.9 (MMT C), 127.8 (MMT C), 126.8 (MMT C), 123.8 (C6), 119 (CN), 
113.5 (MMT C), 102.2 (C4a), 82.8 (C4′), 82.2 (C1′), 80.7 (C3′), 63.8 
(C5′), 63.6 ( O CH2), 55.9 (C5), 55.1 (MMT OCH3), 40.8 (formamidino 
CH3), 36.7 (C2′), 34.7 (formamidino CH3), 18.9 (CH2CN). 
 
ESI(+) MS:   m/z   877.5 [M + H
+] 
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3N Benzoyl 7 [3 O (2 cyanoethyl) 2 deoxy β D erythro pentofuranosyl] 2N 
(N,N dimethylaminomethylidenyl) 5 iodo 7H pyrrolo[2,3 d]pyrimidin 4 one 
 
 
740 mg (0.84 mmol) of compound 60 were dissolved in 10 ml CH2Cl2/EtOH (1/1) 
and treated with 321 mg (1.69 mmol) p toluenesulfonic acid monohydrate. The 
mixture was stirred for 1.5 h, then concentrated and the residue taken up in 
100  ml  CH2Cl2.  The  organic  layer  was  washed  with  each  50  ml  of  aq.  sat. 
NaHCO3, brine and water, dried over MgSO4 and filtered. After solvent removal 
the crude product was purified on column chromatography using CH2Cl2/MeOH 
98/2 as eluent to give the pure compound as yellow foam. 
 
Yield:   386 mg (0.64 mmol, 76 %) 
TLC:   Rf = 0.22 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 8.57 (s, 1H, formamidino CH), 7.78 (ψd, 2H, benzoyl HA, J 
= 7.09 and J = 8.31), 7.70 (ψt, 1H, benzoyl HC, J = 7.58), 7.55 (ψt, 
2H, benzoyl HB, J = 7.58), 7.42 (s, 1H, H6), 6.43 (dd, 1H, H1′, J = 
6.11 and J = 8.07), 5.1 (t, 1H, 5′ OH, J = 5.14), 4.24 (m, 1H, H3′), 
3.95 (m, 1H, H4′), 3.69 (t, 2H,  O CH2, J = 6.11), 3.56 (m, 2H, H5′), 
3.07 (s, 3H, formamidino CH3), 2.8 (t, 2H, CH2CN, J = 6.11), 2.61 (s, 
3H, formamidino CH3), 2.42 (m, 2H, H2′). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm] = 171.7 (benzoyl C=O), 158 (C4), 156.7 (formamidino C=N), 
154  (C2),  148.9  (C7a),  134.5  (benzoyl CC),  133.1  (benzoyl Cquart), 
129.7 (benzoyl CA), 129.3 (benzoyl CB), 124.2 (C6), 119.5 (CN), 102.2 
(C4a), 84.8 (C4′), 82.5 (C1′), 79.9 (C3′), 63.5 ( O CH2), 61.9 (C5′), 56 
(C5),  40.7  (formamidino CH3),  37.1  (C2′),  34.5  (formamidino CH3), 
18.4 (CH2CN).  Experimental part                                                                                                                
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ESI(+) MS:   m/z   605.2 [M + H
+] 
 
 
7 [3 O (2 Cyanoethyl) 2 deoxy 5 O β D erythro pentofuranosyl] 5 iodo 7H 
pyrrolo[2,3 d]pyrimidin 4 one 
 
 
349 mg (0.58 mmol) of nucleoside 61 were dissolved in 10 ml MeOH and 10 ml 
of  32  %  aq.  ammonia  and  stirred  at  room  temperature  for  24  h.  After 
completion of the reaction, the solvents were evaporated and the residue was 
purified on column chromatography using CH2Cl2/MeOH 9/1 to give the product 
as yellowish crystals. 
 
Yield:   187 mg (0.42 mmol, 72 %) 
TLC:   Rf = 0.25 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 10.46 (br s, 1H, NH3), 7.14 (s, 1H, H6), 6.36 (br s, 2H, 
NH2), 6.22 (dd, 1H, H1′, J = 5.87 and J = 8.80), 5.02 (t, 1H, 5′ OH, J = 
5.38), 4.16 (m, 1H, H3′), 3.9 (m, 1H, H4′), 3.65 (t, 2H,  O CH2, J = 
6.11), 3.51 (m, 2H, H5′), 2.78 (t, 2H, CH2CN, J = 6.11), 2.45 – 2.22 
(m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 158.1 (C4), 152.8 (C2), 150.8 (C7a), 121.7 (C6), 119.4 (CN), 
99.9 (C4a), 87 (C4′), 82.2 (C1′), 80.1 (C3′), 63.5 ( O CH2), 61.9 (C5′), 
55.3 (C5), 39.9 (C2′), 18.3 (CH2CN). 
 
ESI(+) MS:   m/z   446.0 [M + H
+] 
 
  Experimental part                                                                                                                
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2′ Deoxy (3′,5′ O diacetyl)cytidine 
 
 
10 g (37.9 mmol) of 2′ deoxycytidine hydrochloride 63 were suspended in 130 
ml glacial acetic acid and 10.8 ml (152 mmol) of acetyl chloride were added 
dropwise.  The  suspension  was  agitated  overnight  at  room  temperature,  the 
solvent was distilled off and the solid residue recrystallized in EtOH to give the 
product as colorless crystals. 
 
Yield:   11.0 g (35.3 mmol, 93 %) 
TLC:   Rf = 0.18 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm]  = 9.99  (br  s,  1H,  NH2  (exchange)),  8.86  (br  s,  1H,  NH2 
(exchange)), 7.98 (d, 1H, H6, J = 7.96), 6.23 (d, 1H, H5, J = 7.96), 
6.08 (ψt, 1H, H1′, J = 6.59), 5.18 (m, 1H, H3′), 4.30 – 4.21 (m, 3H, 
H4′, H5′), 2.43 (m, 2H, H2′), 2.06 (s, 3H, acetyl CH3), 2.03 (s, 3H, 
acetyl CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 170.1 (acetyl C=O), 170.0 (acetyl C=O), 159.6 (C4), 146.9 
(C2), 144.3 (C6), 94.3 (C5), 86.3 (C1′), 82 (C4′), 73.7 (C3′), 63.5 (C5′), 
36.6 (C2′), 20.7 (acetyl CH3), 20.6 (acetyl CH3). 
 
ESI(+) MS:   m/z   311.9 [M + H
+] 
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5 Iodo (3′,5′ O diacetyl) 2′ deoxycytidine 
 
 
3.5 g (10 mmol) of nucleoside 64 were dissolved in 35 ml tetrachlorocarbon and 
35 ml glacial acetic acid, then treated with 1.52 g (6 mmol) iodine and the dark 
red solution was heated up to 40 °C with stirring. A freshly prepared solution of 
1.58 g (9 mmol) iodic acid in 4 ml water was added and the mixture stirred at 
40 °C for about 4 h while it turned cloudy yellow. After solvent removal, the 
obtained residue was dissolved in 200 ml CH2Cl2 and washed with sat. NaHCO3 
solution  and  water  until  the  filtrate  reached  pH  7.  The  excess  iodine  was 
removed  by  washing  the  organic  layer  with  5  %  aq.  NaHSO3 solution.  After 
drying  the  organic  layer  over  MgSO4,  it  was  filtered  and  concentrated.  The 
yellow  crystalline  product  was  obtained  after  column  chromatography  with 
CH2Cl2/MeOH (3 – 10 % MeOH). 
 
Yield:   3.46 g (7.9 mmol, 79 %) 
TLC:   Rf = 0.31 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 7.94 (s, 1H, H6), 7.91 (br s, 1H, NH2(exchange)), 6.72 (br s, 
1H, NH2(exchange)), 6.11 (ψt, 1H, H1′), 5.17 (m, 1H, H3′), 4.29 – 4.11 
(m, 3H, H4′, H5′), 2.33 (m, 2H, H2′), 2.09 (s, 3H, acetyl CH3), 2.06 (s, 
3H, acetyl CH3). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm] = 170.1 (acetyl C=O), 170.0 (acetyl C=O), 163.7 (C4), 153.6 
(C2), 146.8 (C6), 85.6 (C1′), 81.5 (C4′), 74.2 (C3′), 63.7 (C5′), 57.3 
(C5), 36.8 (C2′), 20.7 (acetyl CH3), 20.7 (acetyl CH3). 
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ESI(+) MS:   m/z   437.9 [M + H
+] 
 
 
5 Iodo 2′ deoxycytidine 
 
 
4.17  g  (9.5  mmol)  of  compound  65  were  dissolved  in  100  ml  of  a  freshly 
prepared  0.5  M  sodium  methoxide/MeOH  solution  and  stirred  at  room 
temperature for 1 h. The mixture was neutralized by the addition of Dowex 
(H
+ form) and concentrated. The yellow crystalline crude product was purified 
on a silica gel column using CH2Cl2/MeOH 8/2 as eluent. 
 
Yield:   3.12 g (8.8 mmol, 93 %) 
TLC:   Rf = 0.17 (CH2Cl2/MeOH: 8/2) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.28 (s, 1H, H6), 7.77 (br s, 1H, NH2(exchange)), 6.58 (br s, 
1H, NH2(exchange)), 6.07 (ψt, 1H, H1′), 5.21 (d, 1H, 3′ OH), 5.11 (t, 
1H, 5′ OH), 4.20 (m, 1H, H3′), 3.77 (m, 1H, H4′), 3.55 (m, 2H, H5′), 
2.19 – 1.92 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 164 (C4), 154.2 (C2), 147.8 (C6), 87.1 (C4′), 85.1 (C1′), 69.7 
(C3′), 60.6 (C5′), 56.5 (C5), 40.5 (C2′). 
 
ESI(+) MS:   m/z   353.8 [M + H
+] 
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5 Iodo 4N (N,N dimethylaminomethylidenyl) 2′ deoxycytidine 
 
 
2.0 g (5.66 mmol) of nucleoside 66 were dissolved in 20 ml dry DMF. Under 
argon, 15 ml (113 mmol) of N,N dimethylformamide dimethylacetal were added 
and the reaction mixture was heated up to 55 °C for 2.5 h. The solvent was 
evaporated and the residue purified on a silica gel column using CH2Cl2/MeOH 
(5 – 10 % MeOH) as eluent to give the product as yellowish crystals. 
 
Yield:   1.43 g (3.5 mmol, 62 %) 
TLC:   Rf = 0.1 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.56 (s, 1H, formamidino CH), 8.46 (s, 1H, H6), 6.09 (t, 
1H, H1′, J = 6.32), 5.22 (d, 1H, H3′), 5.12 (t, 1H, H5′), 4.23 (m, 1H, 
H3′), 3.61 (m, 2H, H5′), 3.20 (s, 3H, CH3), 3.13 (s, 3H, CH3), 2.24 – 
1.96 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 168 (C4), 158.3 (formamidino C=N), 154.2 (C2), 147.3 (C6), 
87.5  (C4′),  85.7  (C1′),  69.8  (C3′),  68.7  (C5),  60.7  (C5′),  41 
(formamidino CH3), 40.9 (C2′), 34.9 (formamidino CH3). 
 
ESI(+) MS:   m/z   409.1 [M + H
+] 
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5 Iodo 4N (N,N dimethylaminomethylidenyl) 5′ O benzoyl 2′ deoxycytidine 
 
 
1.0  g  (2.45  mmol)  of  well dried  nucleoside  67  was  dissolved  in  45  ml  dry 
pyridine and 10 ml dry DMF. The pale yellow solution was cooled down to 0 °C, 
then  385  µl  (3.28  mmol)  benzoyl  chloride  in  4  ml  dry  pyridine  were  added 
dropwise via syringe during 2 h. The reaction was allowed to proceed for 30 
min at room temperature, then the solvents were evaporated and the residual 
oil purified on column using CH2Cl2/MeOH (5   10 % MeOH) furnishing the pure 
crystalline product. 
 
Yield:   750 mg (1.46 mmol, 60 %) 
TLC:   Rf = 0.13 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.56 (s, 1H, formamidino CH), 8.07 (s, 1H, H6), 8.01 (d, 
2H, benzoyl HA, J = 7.33), 7.68 (t, 1H, benzoyl HC, J = 7.33), 7.55 (t, 
2H, benzoyl HB, J = 7.58), 6.14 (ψt, 1H, H1′, J = 6.57), 5.45 (d, 1H, 
3′ OH, J = 4.29), 4.51 (m, 2H, H5′), 4.35 (m, 1H, H3′), 4.16 (m, 1H, 
H4′), 3.21 (s, 3H, CH3), 3.12 (s, 3H, CH3), 2.33 – 2.12 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 168.1 (C4), 165.6 (benzoyl C=O), 158.3 (formamidino C=N), 
154 (C2), 146.5 (C6), 133.5 (benzoyl CC), 129.2 (benzoyl CA), 128.9 
(benzoyl CB), 86.1 (C1′), 84.4 (C4′), 70.5 (C3′), 69.1 (C5), 64.5 (C5′), 
40.9 (formamidino CH3), 40.1 (C2′), 34.9 (formamidino CH3). 
 
ESI(+) MS:   m/z   513.1 [M + H
+] 
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5 Iodo 4N (N,N dimethylaminomethylidenyl) 5′ O benzoyl 3′ O (2 cyanoethyl) 
2′ deoxycytidine 
 
 
In a well dried sealable Erlenmeyer flask with magnetic triangle stirrer bar, 
1.02 g (2 mmol) of nucleoside 68 were dissolved under argon in 2.64 ml (40 
mmol)  freshly  distilled  acrylonitrile,  12  ml  tert butanol and  6  ml  abs.  DMF. 
After 2 min of stirring, 652 mg (2 mmol) of cesium carbonate were added and 
the  pale  yellow  suspension  was  vigorously  agitated  for  about  3  h  at  room 
temperature. The mixture was taken up in 100 ml methylene chloride then and 
filtered over Celite. The filtrate was concentrated and the residue purified on 
a silica gel column using CH2Cl2/MeOH (2 – 10 % MeOH) to give the product as 
yellow foam. 
 
Yield:   1.0 g (1.77 mmol, 88 %) 
TLC:   Rf = 0.26 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.68 (s, 1H, formamidino NH), 8.06 (s, 1H, H6), 8.01 (m, 
2H, benzoyl HA), 7.56 (ψt, 1H, benzoyl HC, J = 7.33), 7.44 (ψt, 2H, 
benzoyl HB, J = 7.57), 6.21 (dd, 1H, H1′, J = 6.06 and J = 7.32), 4.59 
(m, 2H, H5′), 4.42 (m, 1H, H3′), 4.18 (m, 1H, H4′), 3.72 (t, 2H, O CH2, 
J = 6.06), 3.18 (s, 3H, CH3), 3.16 (s, 3H, CH3), 2.61 (t, 2H, CH2CN, J = 
6.06), 2.77 – 2.59 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 168.9 (C4), 166.2 (benzoyl C=O), 158.9 (formamidino C=N), 
155.3  (C2),  146  (C6),  133.6  (benzoyl CC),  129.7  (benzoyl Cquart), 
129.2  (benzoyl CA),  128.8  (benzoyl CB),  117.5  (CN),  87.2  (C1′),  83 
(C4′),  80.3  (C3′),  69.4  (C5),  64.4  (C5′),  64.3  ( O CH2),  41.5  Experimental part                                                                                                                
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(formamidino CH3) , 38.8 (C2′), 35.6 (formamidino CH3), 19 (CH2CN). 
 
ESI(+) MS:   m/z   566.1 [M + H
+]  
 
 
5 Iodo 3′ O (2 cyanoethyl) 2′ deoxycytidine 
 
 
250 mg (0.44 mmol) of nucleoside 69 were dissolved in 50 ml sat. methanolic 
ammonia and stirred in a sealable vessel at room temperature for 2.5 h until 
complete consumption of the starting material. Concentration of the mixture 
gave  the  crude  product  which  was  purified  on  a  silica  gel  column  using 
CH2Cl2/MeOH 95/5 as eluent. 
 
Yield:   147 mg (0.36 mmol, 82 %) 
TLC:   Rf = 0.16 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.24 (s, 1H, H6), 7.82 (br s, 1H, NH(exchange)), 6.62 (br s, 
1H, NH(exchange)), 6.05 (dd, 1H, H1′, J = 6.06 and J = 7.32), 5.18 (t, 
1H, 5′ OH, J = 5.05), 4.12 (m, 1H, H3′), 3.94 (m, 1H, H4′), 3.62 (t, 
2H,  O CH2, J = 6.06) , 3.59 (m, 2H, H5′), 2.77 (t, 2H, CH2CN, J = 
6.06), 2.3 – 2.06 (m, 2H, H2). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 163.7 (C4), 153.8 (C2), 147.2 (C6), 119.2 (CN), 85.3 (C1′), 
84.7 (C4′), 79.1 (C3′), 63.6 ( O CH2), 61.1 (C5′), 56.8 (C5), 37.6 (C2′), 
18.3 (CH2CN). 
 
ESI( ) MS:   m/z   405.1 [M   H
+] 
 
Elemental analysis:  calculated:  C, 35.48; H, 3.72; N, 13.79; O, 15.76  Experimental part                                                                                                                
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        found:    C, 35.35; H, 3.93; N, 13.62 
 
5 [3 Trifluoroacetamido prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxycytidine 
 
 
Under argon, 580 mg (1.43 mmol) of compound 70 were dissolved in 12 ml abs. 
DMF and 992 µl (7.14 mmol) TEA. The mixture was degassed in vacuum three 
times, then 54 mg (0.29 mmol) copper iodide and 165 mg (0.14 mmol) tetrakis 
(triphenylphosphin) palladium  were  added.  At  last,  502  µl  (2.86  mmol)  N 
propargyltrifluoroacetamide was injected via syringe through the septum and 
the mixture stirred in the dark for 24 h under argon. After concentration of the 
crude orange brownish mixture, the residue was diluted in 100 ml CH2Cl2 and 
washed once with 100 ml of a 5 % aq. disodium EDTA solution. The aqueous 
layer  was  extracted  three  times  with  50  ml  2 butanone  for  quantitative 
isolation of the product. The combined organic layers were dried over MgSO4, 
filtered and concentrated again. The residue was purified on a short silica gel 
column using CH2Cl2/MeOH (0 – 10 % MeOH) as eluent, yielding the product as 
yellow glassy oil. 
 
Yield:   522 mg (1.21 mmol, 85 %) 
TLC:   Rf = 0.32 (CH2Cl2/MeOH: 85/15) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 9.96 (br t, 1H, TFA NH, J = 5.05), 8.13 (s, 1H, H6), 7.85 (br 
s, 1H, NH2(exchange)), 6.88 (br s, 1H, NH2(exchange)), 6.08 (ψt, 1H, 
H1′, J = 6.06), 5.17 (t, 1H, 5′ OH, J = 4.55), 4.28 (d, 2H, propargyl 
CH2, J = 5.31), 4.11 (m, 1H, H3′), 3.95 (m, 1H, H4′), 3.62 (t, 2H,  O  Experimental part                                                                                                                
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CH2, J = 6.06), 3.58 (m, 2H, H5′), 2.76 (t, 2H, CH2CN, J = 6.06), 2.33 
– 2.03 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 164.4 (C4), 156 (TFA C=O), 153.4 (C2), 144.4 (C6), 119.2 
(CN), 117.3 (CF3), 104.1 (C5), 90.1 (propargyl C CH2), 85.5 (C1′), 84.9 
(C4′),  79.2  (C3′),  74.5  (propargyl C C5),  63.6  ( O CH2),  61.3  (C5′), 
37.7 (C2′), 30 (propargyl CH2), 18.3 (CH2CN). 
 
ESI(+) MS:   m/z   430.0 [M + H
+] 
 
 
5 [3 Amino prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxycytidine 
 
 
520 mg (1.2 mmol) of compound 71 were dissolved in 20 ml MeOH and 10 ml 25 
% NH4OH. The mixture was stirred at room temperature for 5 h, concentrated 
and the residue purified on a short silica gel column with CH2Cl2/MeOH (10 – 
100 % MeOH) to give the product as yellow glassy oil. 
 
Yield:   343 mg (1.03 mmol, 86 %) 
TLC:   Rf = 0.05 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.07 (s, 1H, H6), 7.76 (br s, 1H, NH2(exchange)), 6.94 (br s, 
1H, NH2(exchange)), 6.09 (dd, 1H, H1′, J = 5.81 and J = 7.33), 5.25 
(br s, 1H, 5′ OH), 4.12 (m, 1H, H3′), 3.96 (m, 1H, H4′), 3.62 (t, 2H,  
O CH2, J = 6.05), 3.60 (m, 2H, H5′), 3.42 (br s, 2H, propargyl CH2 
NH2), 2.77 (t, 2H, CH2CN, J = 6.05), 2.31 – 2.02 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 164.4 (C4), 153.5 (C2), 143.6 (C6), 119.3 (CN), 105.2 (C5),  Experimental part                                                                                                                
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90.2  (propargyl C CH2),  85.4  (C1′),  84.9  (C4′),  79.4  (C3′),  76.7 
(propargyl C C5),  63.7  ( O CH2),  61.3  (C5′),  37.7  (C2′),  30.1 
(propargyl CH2), 18.3 (CH2CN). 
 
ESI(+) MS:   m/z   334.1 [M + H
+] 
 
 
5 Iodo 5′ O benzoyl 2′ deoxyuridine 
 
 
7.72 g (21.8 mmol) of well dried nucleoside 73 were dissolved in 30 ml abs. 
pyridine and cooled down to  20 °C. Under argon, 2.66 ml (23 mmol) of benzoyl 
chloride, diluted in 7.5 ml dry CH2Cl2, were added dropwise within 10 min. 
Conversion of the starting material was complete after stirring the mixture for 
2 h at  20 °C and addition of 3 ml MeOH. The solvent was removed and the 
resulting residue purified on column chromatography using CH2Cl2/MeOH (0 – 10 
% MeOH) to give the pure product as colorless foam. 
 
Yield:   5.06 g (11 mmol, 51 %) 
TLC:   Rf = 0.5 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 11.67 (br s, 1H, N3 H), 8.01 (s, 1H, H6), 7.98 – 7.52 (m, 
5H, benzoyl H), 6.13 (ψt, 1H, H1′), 5.48 (br s, 1H, 3′ OH), 4.49 (m, 
2H, H5′), 4.36 (m, 1H, H3′), 4.1 (m, 1H, H4′), 2.35 – 2.14 (m, 2H, H2′). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm] = 165.6 (benzoyl C=O), 160.4 (C4), 150.1 (C2), 144.5 (C6), 
133.5  (benzoyl CC),  129.3  (benzoyl CA),  128.9  (benzoyl CB),  85.1 
(C4′), 84.1 (C1′), 70.3 (C5′), 69.8 (C3′), 64.4 (C5), 40 (C2′). 
 
ESI( ) MS:   m/z   457.1 [M – H
+]   Experimental part                                                                                                                
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5 Iodo 2′ deoxy (5′ O,3N dibenzoyl)uridine 
 
 
2.5 g (5.46 mmol) of the compound 74 were coevaporated three times with 
abs. pyridine and dried overnight in vacuum. The nucleoside was dissolved in 50 
ml dry pyridine and treated with 4.7 ml (27.3 mmol) N ethyldiisopropylamine 
and  1.03  ml  (8.2  mmol)  chlorotrimethylsilane.  After  stirring  the  solution  at 
room temperature for 30 min, 0.95 ml (8.2 mmol) benzoyl chloride were added 
and stirring continued for 1 h. The reaction was stopped by the addition of 3 ml 
MeOH with subsequent solvent removal. The oily residue was taken up in 100 
ml CH2Cl2, washed with each 100 ml of water, 5 % aq. NaHCO3 solution and 
brine.  The  organic  layer  was  dried  over  MgSO4,  filtered  and  the  solvent 
evaporated. The residue was dissolved again in 50 ml CH2Cl2/MeOH 1/1 and 
treated with 0.5 ml of trifluoroacetic acid while stirring the mixture at room 
temperature for 30 min. The mixture was diluted in 100 ml CH2Cl2 then and 
washed twice with 100 ml water each. The aqueous layer was back extracted 
with CH2Cl2 (4 x 50 ml) and the combined organic layers were dried over MgSO4, 
filtered  and  concentrated.  The  crude  product  was  purified  on  column 
chromatography  using  CH2Cl2/MeOH  (2  –  5  %  MeOH)  to  furnish  the  pure 
compound as yellowish foam. 
 
Yield:   2.87 g (5.1 mmol, 93 %) 
TLC:   Rf = 0.22 (CH2Cl2/MeOH: 98/2) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.20 (s, 1H, H6), 8.04 – 7.54 (m, 10H, benzoyl H), 6.11 (ψt, 
1H, H1′), 5.51 (d, 1H, 3′ OH), 4.52 (m, 2H, H5′), 4.39 (m, 1H, H3′), 
4.16 (m, 1H, H4′), 2.46 – 2.24 (m, 2H, H2′).  Experimental part                                                                                                                
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13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 168.7  (benzoyl C=O),  165.6  (benzoyl C=O),  159.2  (C2), 
148.7 (C4), 145.3 (C6), 135.7 (benzoyl CC′), 133.6 (benzoyl CC), 130.7 
(benzoyl CA′),  129.5  (benzoyl CA),  129.3  (benzoyl CB′),  128.9 
(benzoyl CB), 86.1 (C1′), 84.5 (C4′), 70.1 (C3′), 68.6 (C5), 64.3 (C5′), 
39.7 (C2′). 
 
ESI(+) MS:   m/z   563.0 [M + H
+] 
 
 
5 Iodo 3′ O (2 cyanoethyl) 2′ deoxy (5′ O,3N dibenzoyl)uridine 
 
 
In a well dried sealable Erlenmeyer flask with magnetic stirrer and triangle 
stirring bar, 2.0 g (3.56 mmol) of nucleoside 76 were dissolved under argon in 
4.6 ml (71.2 mmol) freshly distilled acrylonitrile and 15 ml tert butanol. The 
solution  was  treated  with  1.16  g  (3.56  mmol)  of  cesium  carbonate  and 
vigorously agitated for about 2 h at room temperature. The mixture was taken 
up in 100 ml CH2Cl2 and the insoluble material removed via filtration through 
Celite. The filtrate was concentrated furnishing the crude product which was 
purified on a silica gel column using CH2Cl2/MeOH (0 – 1 % MeOH) as eluent. 
 
Yield:   1.0 g (1.63 mmol, 46 %) 
TLC:   Rf = 0.67 (CH2Cl2/MeOH: 98/2) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.22 (s, 1H, H6), 8.02 (ψd, 4H, benzoyl HA,A  ′, J = 7.32), 
7.79 (t, 1H, benzoyl HC, J = 7.32), 7.7 (t, 1H, benzoyl HC ′), 7.58 (m, 
4H, benzoyl HB,B′, J = 7.68, J = 8.05), 6.08 (ψt, 1H, H1′, J = 6.59), 
4.54 (m, 2H, H5′, J = 3.66), 4.35 (m, 2H, H3′, H4′), 3.69 (t, 2H,  O  Experimental part                                                                                                                
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CH2, J = 6.22), 2.79 (t, 2H, CH2CN, J = 6.22), 2.46 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 166.5  (benzoyl C=O),  166.3  (benzoyl C=O),  158.9  (C2), 
148.9 (C4), 145.3 (C6), 135.7 (benzoyl CC′), 133.7 (benzoyl CC), 130.7 
(benzoyl CA′),  129.5  (benzoyl CA),  129.4  (benzoyl CB′),  128.9 
(benzoyl CB), 119.2 (CN), 86.2 (C1′), 82 (C4′), 78.7 (C3′), 68.8 (C5), 
64.5 (C5′), 63.9 (O CH2), 38.4 (C2′), 18.2 (CH2CN). 
 
ESI(+) MS:   m/z   616.3 [M + H
+] 
 
 
5 Iodo 3′ O (2 cyanoethyl) 2′ deoxyuridine 
 
 
1.0 g (1.63 mmol) of nucleoside 77 was dissolved in 20 ml MeOH and 25 ml 32 % 
aqueous ammonia. The mixture was stirred in a sealable vessel for 24 h at room 
temperature, then the solvents were evaporated, the residue lyophyllized and 
purified on column chromatography using CH2Cl2/MeOH 95/5 to give the pure 
compound as colorless foam. 
 
Yield:   581 mg (1.43 mmol, 88 %) 
TLC:   Rf = 0.46 (CH2Cl2/MeOH: 85/15) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 11.7 (br s, 1H, H3), 8.37 (s, 1H, H6), 6.07 (ψt, 1H, H1′), 
5.24 (t, 1H, 5′ OH, J = 4.8), 4.15 (m, 1H, H3′), 3.97 (m, 1H, H4′), 3.63 
(t, 2H,  O CH2, J = 6.09), 3.61 (m, 2H, H5′), 2.78 (t, 2H, CH2CN, J = 
6.09), 2.24 (m, 2H, H2′). 
 
13C NMR:  (400 MHz, DMSO d6)  Experimental part                                                                                                                
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δ [ppm] = 160.8 (C4), 150.4 (C2), 145.1 (C6), 119.4 (CN), 85.3 (C4′), 
84.8 (C1′), 79.3 (C3′), 69.9 (C5), 63.7 ( O CH2), 61.3 (C5′), 37.2 (C2′), 
18.4 (CH2CN). 
 
ESI( ) MS:   m/z   406.0 [M – H
+]  
 
 
5 [3 Trifluoroacetamido prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxyuridine 
 
 
Under argon, 302 mg (0.74 mmol) of the starting material 78 were dissolved in 
10 ml abs. DMF and 514 µl (3.7 mmol) TEA. The mixture was degassed under 
vacuum three times, then 28 mg (0.15 mmol) copper iodide and 86 mg (0.074 
mmol)  tetrakis (triphenylphosphin)palladium  were  added.  After  stirring  the 
mixture for 2 min, 260 µl (1.84 mmol) of N propargyltrifluoroacetamide were 
injected via syringe through the septum and stirring continued for 24 h under 
argon and in the dark. The crude orange brownish mixture was concentrated 
under reduced pressure then, diluted in 100 ml methylene chloride and washed 
once with 100 ml of a 5 % aqueous disodium EDTA solution. The aqueous layer 
was  extracted  three  times  with  50  ml  2 butanone  for  quantitative  product 
isolation.  The  combined  organic  layers  were  dried  over  MgSO4,  filtered  and 
concentrated again. The oily residue was purified on a short silica gel column 
using CH2Cl2/MeOH (0 – 10 % MeOH) as eluent to give the product as yellow 
crystals. 
 
Yield:   290 mg (0.67 mmol, 91 %)  Experimental part                                                                                                                
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TLC:   Rf = 0.41 (CH2Cl2/MeOH: 85/15) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 11.67 (s, 1H, H3), 10.06 (t, 1H, TFA NH, J = 5.56), 8.18 (s, 
1H, H6), 6.06 (ψt, 1H, H1′), 5.18 (t, 1H, 5′ OH, J = 5.05), 4.32 (d, 2H, 
propargyl CH2, J = 5.30), 4.14 (m, 1H, H3′), 3.95 (m, 1H, H4′), 3.63 
(t, 2H,  O CH2, J = 6.06), 3.59 (m, 2H, H5′), 2.77 (t, 2H, CH2CN, J = 
6.06), 2.25 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 161.5 (C4), 155.9 (TFA C=O), 149.4 (C2), 144.1 (C6), 119.2 
(CN),  117  (CF3),  97.8  (C5),  87.6  (propargyl C CH2 NH),  84.9  (C4′), 
84.7  (C1′),  79.1  (C3′),  75.3  (propargyl C C5),  63.6  ( O CH2),  61.1 
(C5′), 37 (C2′), 29.5 (propargyl CH2 NH), 18.3 (CH2CN). 
 
ESI(+) MS:   m/z   431.1 [M + H
+] 
 
 
5 [3 Amino prop 1 ynyl] 3′ O (2 cyanoethyl) 2′ deoxyuridine 
 
 
294 mg (0.68 mmol) of nucleoside 79 were dissolved in 15 ml MeOH and 10 ml 
of 32 % aq. ammonia. The pale yellow solution was stirred at room temperature 
for 4 h until completion of the reaction. The mixture was concentrated and the 
resulting residue purified on a short silica gel column using CH2Cl2/MeOH (10 – 
100 % MeOH) as eluent to give the product as yellow glassy oil. 
 
Yield:   228 mg (0.68 mmol, 100 %) 
TLC:   Rf = 0.12 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 9.19 (s, 1H, H3), 8.24 (s, 1H, H6), 6.06 (ψt, 1H, H1′), 4.14  Experimental part                                                                                                                
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(m, 1H, H3′), 3.98 (m, 1H, H4′), 3.94 (d, 2H, propargyl CH2, J = 5.30), 
3.60 (t, 2H,  O CH2, J = 6.06), 3.59 (m, 2H, H5′), 2.76 (t, 2H,CH2CN, J 
= 5.86), 2.31 – 2.15 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 161.6 (C4), 149.5 (C2), 144.9 (C6), 119.3 (CN), 97.3 (C5), 
87.6  (propargyl C CH2),  85.2  (C1′),  85.1  (C4′),  79.3  (C3′),  78.9 
(propargyl C C5),  63.7  ( O CH2),  61.3  (C5′),  37.3  (C2′),  29.3 
(propargyl CH2), 18.4 (CH2CN). 
 
ESI(+) MS:   m/z   335.1 [M + H
+] 
 
 
5′ O Benzoyl 2′ deoxythymidine 
 
 
9.69  g  (40  mmol)  of  2′ deoxythymidine  were  dried  by  coevaporation  with 
pyridine and in vacuum overnight. The nucleoside was dissolved in 130 ml abs. 
pyridine under argon and cooled down to  20 °C then. 5.16 ml (44 mmol) of 
benzoyl chloride diluted in 20 ml abs. pyridine were added dropwise via syringe 
within 2 h. The reaction was allowed to proceed at  20 °C for 1 h and then 
overnight at room temperature. After addition of 5 ml MeOH, the mixture was 
concentrated and coevaporated twice with toluene. The residue was purified 
via  column  chromatography  with  CH2Cl2/MeOH  (5  –  10  %  MeOH)  to  give  the 
product as colorless crystals. 
 
Yield:   11.51 g (33.23 mmol, 83 %) 
TLC:   Rf = 0.31 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6)  Experimental part                                                                                                                
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δ [ppm] = 11.3 (br s, 1H, H3), 7.98 (ψd, 2H, benzoyl HA, J = 8.42), 
7.68 (ψt, 1H, benzoyl HC, J = 7.32), 7.54 (ψt, 2H, benzoyl HB, J = 
7.32), 7.39 (s, 1H, H6), 6.21 (ψt, 1H, H1′, J = 6.95), 4.68 (d, 2H, J = 
11.87, O CH2 S), 4.57 – 4.39 (m, 2H, H5′), 4.4 (m, 1H, H3′), 4.05 (m, 
1H, H4′), 2.28 – 2.14 (m, 2H, H2′), 1.59 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 165.6 (benzoyl C=O), 163.6 (C4), 150.4 (C2), 135.6 (C6), 
133.5 (benzoyl CC), 129.4 (benzoyl CA), 129.2 (benzoyl Cquart), 128.9 
(benzoyl CB), 109.7 (C5), 83.8 (C4′), 83.6 (C1′), 70.2 (C3′), 64.4 (C5′), 
38.8 (C2′), 11.8 (CH3). 
 
ESI(+) MS:   m/z   347.1 [M + H
+] 
 
 
 
5′ O Benzoyl 2′ deoxy 3′ O (methylthiomethyl)thymidine 
 
 
11.0 g (31.8 mmol) of compound 82 were dissolved in 106 ml DMSO, 21.3 ml 
glacial acetic acid and 69 ml acetic anhydride and stirred under argon at room 
temperature for 20 h. The solvent was removed under reduced pressure then 
and the orange residue diluted in 250 ml CH2Cl2, washed twice with each 200 
ml  of  water and  sat.  aq.  NaHCO3.  The  organic  layer  was  dried  over  MgSO4, 
filtered and concentrated in vacuum. The resulting yellowish foam was purified 
on column chromatography using CH2Cl2/MeOH (0 – 2 % MeOH) as eluent. The 
solvent residues were removed by recrystallization in toluene to give the pure 
product as colorless crystals. 
 
Yield:   7.95 g (19.6 mmol, 62 %) 
TLC:   Rf = 0.66 (CH2Cl2/MeOH: 9/1)  Experimental part                                                                                                                
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1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.65 (br s, 1H, H3), 8.03 (d, 2H, benzoyl HA, J = 7.82), 7.61 
(t, 1H, benzoyl HC, J = 7.36), 7.47 (t, 2H, benzoyl HB, J = 7.72), 7.23 
(s, 1H, H6), 6.29 (dd, 1H, H1′, J = 5.97 and J = 7.77), 4.68 (d, 2H, J = 
11.87, O CH2 S), 4.61 (m, 2H, H5′) 4.57 (m, 1H, H3′), 4.36 (q, 1H, 
H4′. J = 3.54), 2.51 (m, 1H, H2′), 2.15 (s, 3H, SCH3), 2.13 (m, 1H, 
H2′), 1.67 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 166.2 (benzoyl C=O), 163.65 (C4), 150.2 (C2), 134.9 (C6), 
133.8 (benzoyl CC), 129.7 (benzoyl CA), 129.5 (benzoyl Cquart), 128.9 
(benzoyl CB), 111.5 (C5), 85.4 (C1′), 82.4 (C4′), 76.0 (C3′), 74.1 ( O 
CH2 S ), 64.3 (C5′), 37.9 (C2′), 14.0 (SCH3) 12.4 (CH3). 
 
ESI(+) MS:   m/z   406.9 [M + H
+] 
 
 
5′ O Benzoyl 3′ O [(2 cyanoethoxy)methyl] 2′ deoxythymidine 
 
 
After  drying  2.03  g  (5  mmol)  of  nucleoside  83  in  vacuum  overnight,  it  was 
dissolved under argon in 25 ml dry 1,2 dichloroethane followed by addition of 
preactivated molecular sieves (3 Å). The mixture was treated with 696 µl (5 
mmol) triethylamine and stirred for 2 h at room temperature. The suspension 
was cooled down to 0 °C and 456 µl (5.5 mmol) sulfuryl chloride, diluted in 2 
ml dry 1,2 dichloroethane were added dropwise within 5 min. The reaction was 
allowed  to  proceed  for  1  h  at  0  °C,  then  715  µl  (11  mmol)  3 hydroxy 
propionitrile were added via syringe within 10 min. The mixture was warmed 
up to room temperature then and stirred overnight under argon. The clear 
yellow suspension was diluted with 100 ml methylene chloride, washed once  Experimental part                                                                                                                
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with  100  ml  sat.  aqueous  NaHCO3,  dried  over  Na2SO4,  filtered  and 
concentrated. The residue of the organic layer was taken up in 100 ml CH2Cl2 
again,  filtered  over  Celite  and  concentrated  under  reduced  pressure.  The 
resulting syrup was purified on a silica gel column using CH2Cl2/MeOH (2 – 5 % 
MeOH) to give the product as colorless foam. 
 
Yield:   1.49 g (3.47 mmol, 69 %) 
TLC:   Rf = 0.46 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.67 (br s, 1H, NH3), 8.03 (d, 2H, benzoyl HA, J = 7.01), 
7.61 (t, 1H, benzoyl HC, J = 7.31), 7.43 (t, 2H, benzoyl HB, J = 7.31), 
7.22 (s, 1H, H6), 6.29 (dd, 1H, H1′, J = 6.09 and J = 7.92), 4.81 (s, 
2H,  O CH2 O ), 4.62 (m, 2H, H5′), 4.51 (m, 1H, H3′), 4.36 (q, 1H, 
H4′, J = 3.35), 3.81 (t, 2H,  O CH2, J = 6.09), 2.64 (t, 2H, CH2CN, J = 
6.09), 2.59 – 2.10 (m, 2H, H2′), 1.67 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 166.2 (benzoyl C=O), 163.5 (C4), 150.2 (C2), 134.8 (C6), 
133.8 (benzoyl CC), 129.7 (benzoyl CA), 129.5 (benzoyl Cquart), 128.9 
(benzoyl CB),  117.7  (CN),  111.5  (C5),  94.7  ( O CH2 O ),  85.2  (C1′), 
82.8  (C4′),  77.4  (C3′),  64.2  (C5′),  63.2  ( O CH2),  38.4  (C2′),  19.1 
(CH2CN), 12.4 (CH3). 
 
ESI(+) MS:   m/z   430.1 [M + H
+] 
 
 
3′ O [(2 Cyanoethoxy)methyl] 2′ deoxythymidine 
 
 
1.2 g (2.8 mmol) of compound 85 were dissolved in 30 ml MeOH and treated 
with 20 ml 32 % aq. ammonia. The solution was stirred at room temperature  Experimental part                                                                                                                
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overnight,  concentrated  and  the  resulting  residue  purified  by  column 
chromatography  with  CH2Cl2/MeOH  (5  –  10  %  MeOH)  to  give  the  product  as 
yellow glassy oil. 
 
Yield:   708 mg (2.18 mmol, 78 %) 
TLC:   Rf = 0.33 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.97 (br s, 1H, NH3), 7.47 (s, 1H, H6), 6.18 (ψt, 1H, H1′), 
4.77 (s, 2H,  O CH2 O ), 4.52 (m, 1H, H3′), 4.08 (q, 1H, H4′, J = 3.03), 
3.89 (m, 2H, H5′), 3.78 (t, 2H,  O CH2, J = 6.06), 2.66 (t, 2H, CH2CN, 
J = 6.32), 2.36 (m, 2H, H2′), 1.90 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 163.9 (C4), 150.6 (C2), 136.7 (C6), 118.2 (CN), 111.3 (C5), 
94.4 ( O CH2 O ), 86.3 (C1′), 85.4 (C4′), 77 (C3′), 63 (C5′), 62.4 ( O 
CH2), 37.9 (C2′), 19.2 (CH2CN), 12.6 (CH3). 
 
ESI(+) MS:   m/z   325.9 [M + H
+] 
 
 
3′ O [(2 Cyanoethoxy)methyl] 2′ deoxythymidine 5′ phosphate 
 
 
150 mg (0.46 mmol) of nucleoside 86 were coevaporated three times with dry 
pyridine  and  dried  overnight  in  vacuum.  Under  argon,  the  nucleoside  was 
dissolved in 3 ml dry dioxane and 1.5 ml abs. pyridine, then 121 mg (0.6 mmol) 
of 2 chloro 1,3,2 benzodioxa phosphorin 4 one, dissolved in 1 ml dry dioxane 
were added within 2 min. The clear solution was stirred for 30 min at room 
temperature, the reaction was subsequently stopped by the addition of 0.25 ml  Experimental part                                                                                                                
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water and 0.16 ml triethylamine (1.15 mmol). After solvent removal, the oily 
residue was lyophilized over four days. The resulting H phosphonate 87 was 
dissolved  in  50  ml  dry  pyridine,  treated  with  5.82  ml  (46  mmol)  chlorotri 
methylsilane and stirred at room temperature for 5 min. A freshly prepared 
solution of 420 mg (1.38 mmol) iodine in 10 ml abs. pyridine was added in one 
lot and stirring continued for 30 min. The solvents were evaporated, the crude 
residue was diluted again in 5 ml pyridine and treated with 1 ml triethylamine 
and 2 ml water with stirring for a few minutes. After concentrating the mixture 
under reduced pressure, the residue was taken up in 8 ml water and purified in 
two portions on RP FPLC and RP HPLC under the conditions given below. The 
crude product obtained as yellow glassy oil was precipitated as sodium salt by 
employing  the  following  procedure:  The  resulting  18  mg  (0.044  mmol)  of 
monophosphate 88 were rendered anhydrous by freeze drying over three days. 
Under argon, the nucleotide was dissolved at 4 °C in 440 µl abs. MeOH to give a 
water free  methanolic  0.1  M  monophosphate  solution.  A  freshly  prepared 
anhydrous sodium perchlorate solution, made from 82 mg (0.67 mmol) sodium 
perchlorate in 2 ml abs. acetone was added dropwise at 4 °C, and subsequently 
product 88 precipitated as white sodium salt. The solid was centrifuged (5 min, 
4 °C, 12000 rpm), the liquid layer was transfused and the white residue dried 
in vacuum. 
 
Yield:   17 mg (0.042 mmol as Na
+ salt, 9 %) 
 
RP FPLC:  Method FPLC 3, Retention time 32 – 34 min 
RP HPLC:  Method D, Retention time 18.36 min 
 
1H NMR:  (400 MHz, D2O) 
δ [ppm] = 7.78 (s, 1H, H6), 6.35 (dd, 1H, H1′, J = 6.26 and J = 7.83), 
4.92 (s, 2H,  O CH2 O), 4.60 (m, 1H, H3′), 4.35 (m, 1H, H4′), 4.10 (m, 
2H,  H5′),  3.91  (t,  2H,   O CH2,  J  =  6.26),  2.85  (t,  2H,  CH2CN,  J  = 
6.26), 2.53   2.37 (m, 2H, H2′), 1.93 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, D2O) 
δ [ppm] = 166.4 (C4), 151.6 (C2), 137.1 (C6), 119.5 (CN), 111.6 (C5), 
94.3 ( O CH2 O), 84.8 (C1′), 83.7 (C4′), 77.7 (C3′), 64.8 ( O CH2), 63 
(C5′), 36.7 (C2′), 18.1 (CH2CN), 11.4 (CH3).  
 
31P NMR:  (162 MHz, D2O)  Experimental part                                                                                                                
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δ [ppm] = 0.05 (s, monophosphate). 
 
ESI( ) MS: H phosphonate 87    m/z   388.1  [M – H
+] 
phosphate 88    m/z   404.2  [M – H
+] 
 
 
3N Benzoyl 2′ deoxythymidine 
 
 
6.06 g (25 mmol) of compound 81, which were rendered anhydrous by repeated 
coevaporation with dry pyridine before, were dissolved in a mixture of 50 ml 
abs.  pyridine,  21.8  ml  (125  mmol)  N diisopropylethylamine  and  8  ml  (62.5 
mmol) chlorotrimethylsilane. Stirring the solution under argon for about 30 min 
at room temperature led to complete silylation of the nucleoside. Subsequently 
4.4 ml (37.5 mmol) of benzoyl chloride were added and stirring continued for 1 
h until no starting material was detected by TLC. The reaction was stopped by 
the addition of 20 g KH2PO4 and 100 ml ice water on cooling then. After stirring 
the mixture a few minutes, colorless crystals precipitated which were collected 
by filtration, washed with 200 ml cold water and dried in vacuum. The crude 
solid  was  dissolved  in  200  ml  CH2Cl2/MeOH  1/1  and  treated  with  3.5  ml 
trifluoroacetic. The solution was stirred for 30 min at room temperature until 
all starting material was desilylated. The reaction mixture was filled into a 
separatory funnel then and washed once with 100 ml aq. 5 % NaHCO3 solution. 
The aqueous layer was extracted three times with 100 ml CH2Cl2 each and the 
combined  organic  layers  were  dried  over  MgSO4.  After  filtration  and 
evaporation  of  the  solvent,  the  crude  product  was  purified  by  column 
chromatography using CH2Cl2/MeOH (5 – 10 % MeOH) as eluent.  Experimental part                                                                                                                
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Yield:   7.2 g (20.8 mmol, 83 %) 
TLC:   Rf = 0.29 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 7.97 (dd, 2H, benzoyl HA, J = 7.32 and J = 8.42), 7.78 (t, 
1H, benzoyl HC, J = 7.46), 7.60 (t, 2H, benzoyl HB , J = 7.63), 6.15 
(ψt, 1H, H1′, J = 6.57), 5.26 (d, 1H, 3′ OH, J = 4.29), 5.11 (t, 1H, 5′ 
OH, J = 5.07), 4.29 (m, 1H, H3′), 3.81 (m, 1H, H4′), 3.62 (m, 2H, H5′), 
2.24 – 2.14 (m, 2H, H2′), 1.86 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 169.6  (benzoyl C=O),  162.5  (C4),  149  (C2),  137.1  (C6), 
135.5 (benzoyl CC), 131.1 (benzoyl Cquart), 130.3 (benzoyl CA), 129.5 
(benzoyl CB), 109.3 (C5), 87.6 (C4′), 84.5 (C1′), 70.2 (C3′), 61.1 (C5′), 
39.6 (C2′), 12.2 (CH3). 
 
ESI(+) MS:   m/z   346.9 [M + H
+] 
 
 
3N Benzoyl 2′ deoxy 5′ O (4 monomethoxytrityl)thymidine 
 
 
3.46  g  (10  mmol)  of  well dried  nucleoside  90  were  dissolved  in  40  ml  abs. 
pyridine under argon and treated with 4.14 g (13 mmol) of p monomethoxy 
trityl chloride. The yellow solution was stirred at room temperature overnight, 
then the reaction was stopped by addition of 10 ml MeOH then and stirring for 
another 30 min. After solvent removal, the resulting oil was diluted in 200 ml 
CH2Cl2, washed three times with 100 ml water each, dried over MgSO4, filtered 
and  concentrated.  The  residue  was  purified  on  a  silica  gel  column  using 
CH2Cl2/MeOH (2 – 5 % MeOH) to furnish the product as yellow foam. 
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Yield:   4.85 g (7.8 mmol, 78 %) 
TLC:   Rf = 0.36 (CH2Cl2/MeOH: 95/5) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 7.93 (m, 2H, benzoyl HA), 7.70 (s, 1H, H6), 7.63 (t, 1H, 
benzoyl HC, J = 7.36), 7.48 (t, 2H, benzoyl HB, J = 7.58), 7.44 – 7.27 
(m, 12H, MMT), 6.87 (d, 2H, MMT, J = 8.84), 6.38 (dd, 1H, H1′, J = 
6.06 and J = 7.33 ), 4.59 (m, 1H, H3′), 4.04 (q, 1H, H4′, J = 3.03), 
3.81 (s, 3H,  OCH3), 3.45 (ddd, 2H, H5′, J = 3.03, J = 10.61 and J = 
32.59), 2.39 (m, 2H, H2′), 1.49 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm]  = 169.2  (benzoyl C=O),  163.0  (C4),  159.0  (MMT C OCH3), 
149.4  (C2),  143.9  (MMT),  135.6  (C6),  135.1  (benzoyl CC),  134.9 
(MMT), 131.1 (benzoyl Cquart), 130.7 (benzoyl CA), 130.5 (MMT), 129.3 
(benzoyl CB), 128.5 (MMT), 128.2 (MMT), 127.5 (MMT), 113.5 (MMT), 
111.5 (C5), 86.3 (C4′), 85.1 (C1′), 72.5 (C3′), 63.7 (C5′), 55.4 (MMT 
OCH3), 41.3 (C2′), 12 (CH3). 
 
ESI( ) MS:   m/z   641.2 [M + Na
+] 
 
Elemental analysis:  calculated:  C, 71.83; H, 5.54; N, 4.53; O, 18.10 
        found:    C, 71.81; H, 5.59; N, 4.55 
 
 
3N Benzoyl 3′ O (2 cyanoethyl) 2′ deoxy 5′ O (4 monomethoxytrityl)thymidine 
 
   
In a well dried sealable Erlenmeyer flask with magnetic stirrer, 1.24 g (2 mmol) 
of compound 91 was dissolved in 2.7 ml (40 mmol) freshly distilled acrylonitrile 
and 5 ml tert butanol with stirring. After complete dilution, 652 mg (2 mmol) 
of cesium carbonate were added and the pale yellow suspension was vigorously 
stirred for about 2.5 h at room temperature under argon. The reaction mixture  Experimental part                                                                                                                
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was diluted with 100 ml CH2Cl2 and filtered through Celite. The filtrate was 
concentrated and the residue purified on a silica gel column with CH2Cl2/MeOH 
(0 – 1 % MeOH), yielding the product as pale yellow foam. 
 
Yield:   1.23 g (1.83 mmol, 92 %) 
TLC:   Rf = 0.43 (CH2Cl2) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 7.93 (dd, 2H, benzoyl HA, J = 7.07 and J = 8.59), 7.71 (s, 
1H, H6), 7.64 (t, 1H, benzoyl HC, J = 7.58), 7.49 (t, 2H, benzoyl HB, J 
= 7.58), 7.43 – 7.26 (m, 12H, MMT), 6.87 (d, 2H, MMT, J = 8.84), 6.31 
(dd, 1H, H1′, J = 5.81 and J = 8.08), 4.24 (m, 1H, H3′), 4.15 (q, 1H, 
H4′, J = 2.78), 3.81 (s, 3H, OCH3), 3.63 (t, 2H,  O CH2 ,
 J = 6.32), 3.54 
– 3.33 (m, 2H, H5′), 2.55 (t, 2H, CH2CN,
 J = 6.32), 2.51 (m, 1H, H2′), 
2.28 (m, 1H, H2′), 1.51 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm]  = 169.2  (benzoyl C=O),  162.9  (C4),  159.0  (MMT C OMe), 
149.4 (C2), 143.8 (MMT Cquart), 135.4 (C6), 135.1 (benzoyl CC), 134.8 
(C2,  C2′,  trityl),  131.1  (benzoyl Cquart),  130.6  (benzoyl CA),  130.5 
(MMT), 129.8 (MMT), 129.3 (benzoyl CB), 128.5 (MMT), 128.3 (MMT), 
127.6 (MMT), 117.5 (CN), 113.5 (MMT), 111.4 (C5), 87.5 (C1′), 85.1 
(C4′),  80.5  (C3′),  64.1  ( O CH2),  63.7  (C5′),  55.4  (MMT OCH3),  37.9 
(C2′), 19.1 (CH2CN), 12.0 (CH3). 
 
MALDI(+) MS:   m/z   694.79  [M + Na
+] 
 
Elemental analysis:  calculated:  C, 71.52; H, 5.55; N, 6.26; O, 16.67 
        found:      C, 71.24; H, 5.54; N, 6.35 
 
 
3N Benzoyl 3′ O (2 cyanoethyl) 2′ deoxythymidine 
  Experimental part                                                                                                                
211 
671 mg (1 mmol) of compound 92 were dissolved in 20 ml of a solution of 10 % 
p toluenesulfonic acid in CH2Cl2/EtOH 1/1. The reaction mixture was stirred at 
room  temperature  for  2  h  until  all  starting  material  was  consumed.  The 
solution was treated with 100 ml aq. sat. NaHCO3 solution then and the organic 
layer separated from the aqueous layer. The aqueous layer was extracted three 
times with 100 ml CH2Cl2 each and the combined organic layers were dried over 
MgSO4, filtered and concentrated. The resulting colorless oil was purified on 
column  chromatography  with  CH2Cl2/MeOH  95/5  to  give  the  product  as 
colorless foam. 
 
Yield:   399 mg (1 mmol, 100 %) 
TLC:   Rf = 0.67 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 8.0 – 7.56 (m, 6H, H6, benzoyl H), 6.11 (t, 1H, H1′), 5.20 
(t, 1H, 3′ OH), 4.19 (m, 1H, H3′), 3.97 (m, 1H, H4′), 3.64 (t, 2H,  O 
CH2 ,
 J = 6.04), 3.63 (m, 2H, H5′), 2.78 ( t, 2H, CH2CN ,J = 6.04), 2.35 
– 2.28 (m, 2H, H2′), 1.87 (s, 3H, CH3). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm] = 169.6 (benzoyl C=O), 162.5 (C4), 149.0 (C2), 137.0 (C6), 
135.5 (benzoyl CC), 131.1 (benzoyl Cquart), 130.4 (benzoyl CA), 129.5 
(benzoyl CB),  119.2  (CN),  109.5  (C5),  84.9  (C1′),  84.5  (C4′),  70.2 
(C3′), 63.5 ( O CH2), 61.4 (C5′), 36.5 (C2′), 18.3 (CH2CN), 12.2 (CH3). 
 
ESI(+) MS:   m/z   399.9 [M + H
+] 
 
Elemental analysis:  calculated:  C, 60.14; H, 5.30; N, 10.52; O, 24.04 
        found:    C, 60.39; H, 5.47; N, 10.66 
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3′ O (2 Cyanoethyl) 2′ deoxythymidine 
 
 
300 mg (0.75 mmol) of nucleoside 93 were dissolved in 10 ml MeOH and cooled 
down to 0 °C. To this solution, 3 ml of 27 % aq. ammonia were added dropwise 
and  the  mixture  was  stirred  for  30  min  at  0  °C,  then  1.5  h  at  room 
temperature. After complete conversion of the starting material the reaction 
mixture was concentrated. The residual oil was purified on a silica gel column 
with CH2Cl2/MeOH 95/5 to furnish the product as colorless crystals. 
 
Yield:   212 mg (0.72 mmol, 96 %) 
TLC:   Rf = 0.30 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (250 MHz, DMSO d6) 
δ [ppm] = 11.31 (br s, 1H, H3), 7.68 (s, 1H, H6), 6.12 (ψt, 1H, H1′), 
5.12 (m, 1H, 5′ OH, J = 5.38), 4.14 (m, 1H, H3′), 3.92 (m, 1H, H4′), 
3.63 (t, 2H, O CH2, J = 6.04), 3.58 (m, 2H, H5′), 2.78 (t, 2H, CH2CN, J 
= 6.04), 2.28 – 2.09 (m, 2H, H2′), 1.77 (s, 3H, CH3). 
 
13C NMR:  (63 MHz, DMSO d6) 
δ [ppm] = 163.7 (C4), 150.5 (C2), 136.0 (C6), 119.2 (CN), 109.6 (C5), 
84.5 (C1′), 83.7 (C4′), 79.4 (C3′), 63.5 ( O CH2), 61.4 (C5′), 36.2 (C2′), 
18.3 (CH2CN), 12.3 (CH3). 
 
ESI(+) MS:   m/z   318.0 [M + Na
+] 
 
Elemental analysis:  calculated:  C, 52.88; H, 5.80; N, 14.23; O, 27.09 
        found:      C, 53.07; H, 5.91; N, 14.23 
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3′ O (2 Cyanoethyl) 2′ deoxythymidine 5′ phosphate 
 
 
385 mg (1.3 mmol) of nucleoside 94 were dissolved in 10 ml dry trimethyl 
phosphate and cooled down to 0 °C. The solution was treated with 418 mg 
(1.95 mmol) 1,8 bis (dimethylamino)naphthalene and, after stirring for 5 min, 
0.16 ml (1.7 mmol) of phosphorus oxychloride were added dropwise on cooling. 
The pale yellow clear solution was stirred for 3 h at 0 °C and immediately 
quenched by addition of 20 ml cold triethylammonium bicarbonate buffer (pH 
7) with agitating the mixture for 1 h more. The aqueous layer was extracted 
five  times  with  100  ml  methyl  tert butyl  ether  for  removal  of  the  proton 
sponge and of trimethyl phosphate residues. The aqueous layer was lyophilized 
and purified on RP HPLC. The crude product was obtained as colorless glassy oil 
which was characterized via NMR  and mass spectrometry. For easier handling 
and storage of the product, it was precipitated as sodium salt: The resulting 
250 mg (0.66 mmol) of monophosphate 95 were rendered anhydrous by freeze 
drying over three days. Under argon, the nucleotide was dissolved at 4 °C in 
6.6  ml  abs.  MeOH  to  give  a  water free  methanolic  0.1  M  monophosphate 
solution. A freshly prepared anhydrous sodium perchlorate solution (made from 
1.21  g  (9.9  mmol)  sodium  perchlorate  in  33  ml  abs.  acetone)  was  added 
dropwise at 4°C causing the sodium salt’s precipitation. The precipitation was 
centrifuged  (5  min,  4  °C,  12000  rpm),  the  liquid  layer  transfused  and  the 
colorless crystals of monophosphate 95 were isolated and dried in vacuum. 
 
Yield:   251 mg (0.67 mmol, 52 %) 
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RP HPLC:  Method B, Retention time: 10.88 min 
 
1H NMR:  (400 MHz, D2O) 
δ [ppm] = 7.69 (s, 1H, H6), 6.22 (ψt, 1H, H1′), 4.31 (m, 1H, H3′), 4.22 
(m, 1H, H4′), 3.95 (m, 2H, H5′), 3.72 (t, 2H, O CH2, J = 6.04), 2.71 (t, 
2H, CH2CN, J = 6.04), 2.39 (m, 1H, H2′), 2.23 (m, 1H, H2′), 1.81 (s, 
3H, CH3). 
 
13C NMR:  (100 MHz, D2O) 
δ [ppm] = 166.3 (C4), 151.5 (C2), 137.2 (C6), 119.6 (CN), 111.6 (C5), 
85.0 (C1′), 83.5 (C4′), 80.0 (C3′), 64.9 (O CH2), 63.7 (C5′), 36.2 (C2′), 
18.3 (CH2CN), 11.5 (CH3). 
 
31P NMR:  (162 MHz, D2O) 
δ [ppm] = 2.11 (s, monophosphate). 
 
MALDI( ) MS:  m/z   373.8 [M   2H
+] 
 
 
3′ O (2 Cyanoethyl) 2′ deoxythymidine 5′ (N,N diisopropyl)phosphoramidite 
 
 
236 mg (0.8 mmol) of the well dried nucleoside 94 were dissolved under argon 
in 8 ml abs. CH2Cl2 and treated with 381 µl (1.2 mmol) (2 cyanoethyl) di(N,N 
diisopropyl)phosphine  and  110  mg  (0.92  mmol)  4,5 dicyanoimidazole.  The 
yellow clear solution was stirred at room temperature for 4 h, then diluted 
with 20 ml CH2Cl2 and washed once with 25 ml aq. sat. NaHCO3. The organic 
layer was separated, dried over Na2SO4, filtered and concentrated. The crude 
product was purified on a short silica gel column under slight positive argon 
pressure. The pure product was obtained as glassy oil (containing both isomers 
of 94) which was stored at  20 °C under argon.  Experimental part                                                                                                                
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Yield:   328 mg (0.66 mmol, 83 %) 
TLC:   Rf = 0.4 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, acetone d6) 
δ [ppm] = 9.88 (br s, 2H, NH), 7.69 (s, 1 H, H6), 7.56 (s, 1 H, H6), 
6.31 (dd, 1 H, H1′, J = 5.83, J = 8.38), 6.25 (dd, 1 H, H1′, J = 5.60, J = 
8.60), 4.36 (m, 1 H, H3′), 4.32 (m, 1 H, H3′), 4.21 (m, 2 H, H4′), 4.0 – 
3.63 (m, 10 H, H5′, phosphine iso propyl H, phosphine O CH2), 3.91 
(t,  2  H,  H8,  J  =  6.10),  3.81  (t,  2  H,  H8,  J  =  6.10),  2.80  (t,  2  H, 
phosphine CH2CN, J = 5.81), 2.77 (t, 2 H, H9, J = 6.06), 2.41 – 2.26 
(m, 4 H, H2′), 1.87 (s, 3 H, CH3), 1.86 (s, 3 H, CH3), 1.28 – 0.99 (m, 
24 H, phosphine iso propyl H). 
 
13C NMR:  (100 MHz, acetone d6) 
δ [ppm]  = 163.2  (C4),  150.2  (C2),  135.4  (C6),  135.2  (C6),  118.2 
(phosphine CN), 118 (CN), 110 (C5), 84.6 (C1′), 84.3 (C1′), 83.5 (C4′), 
80.1 (C3′), 63.8 ( O CH2), 63.2 ( O CH2), 61.4 (C5′), 58.4 (phosphine 
O CH2), 42.7 (phosphine C iso propyl), 36.6 (C2′), 23.9 (phosphine C 
iso propyl), 19.8 (phosphine CH2), 18.0 (CH2CN), 11.5 (CH3) 
 
31P NMR:  (75 MHz, acetone d6) 
δ [ppm] = 148.8 (s, P α), 148.2 (s, P α). 
 
ESI( ) MS:   m/z   494.4 [M   H
+] 
 
 
2′ Deoxythymidine 5′ phosphate 
 
 
315 mg (1.3 mmol) of 2′ deoxythymidine were dissolved under argon in 10 ml 
abs. trimethylphosphate and cooled down to –4 °C. At that temperature, 0.25 
ml (2.6 mmol) of phosphorus oxychloride were added dropwise and the reaction 
mixture was stirred for 6 h at –4 °C. The reaction was stopped by the addition  Experimental part                                                                                                                
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of 20 ml TEAB buffer (pH 7) and stirring continued for 30 min. The aqueous 
layer  was  extracted  five  times  with  100  ml  methyl  tert butyl  ether  each, 
lyophilized  and  purified  on  RP HPLC.  The  crude  product  was  obtained  as 
colorless glassy oil which was characterized via NMR  and mass spectrometry. 
For easier handling and storage of the product, it was precipitated as sodium 
salt: The resulting 213 mg (0.66 mmol) of monophosphate 97 were rendered 
anhydrous by freeze drying over three days. Under argon, the nucleotide was 
dissolved at 4 °C in 6.6 ml abs. MeOH to give a water free methanolic 0.1 M 
monophosphate  solution.  A  freshly  prepared  anhydrous  sodium  perchlorate 
solution  (made  from  1.21  g  (9.9  mmol)  sodium  perchlorate  in  33  ml  abs. 
acetone) was added dropwise at 4 °C causing precipitation of the nucleotide as 
colorless crystals. The precipitated sodium salt of 97 was centrifuged (5 min, 4 
°C, 12000 rpm), the liquid layer was transfused and the product dried. 
 
Yield:   287 mg (0.89 mmol, 69 %) 
 
RP HPLC:  Method C, Retention time 8.57 min 
 
1H NMR:  (400 MHz, D2O) 
δ [ppm] = 7.58 (s, 1H, H6), 6.15 (ψt, 1H, H1′), 4.37 (m, 1H, H3′), 3.97 
(m, 1H, H4′), 3.87 (m, 2H, H5′), 2.16 (m, 2H, H2′), 1.71 (s, 3H, CH3). 
 
13C NMR:  (400 MHz, D2O) 
δ [ppm] = 166.4 (C2), 151.5 (C4), 137.3 (C6), 111.5 (C5), 85.4 (C1′), 
84.9 (C4′), 71.0 (C3′), 64.6 (C5′), 38.6 (C2′), 11.5 (CH3). 
 
31P NMR:  (162 MHz, D2O) 
δ [ppm] = 0.66 (s, monophosphate). 
 
MALDI(+) MS:  m/z   362.13 [M + K
+ + 2H
+] 
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4N (N,N Dimethylaminomethylidenyl) 2′ deoxyadenosine 
 
 
7.54 g (30 mmol) of 2′ deoxyadenosine were dissolved in 40 ml dry DMF and 
treated with 41 ml (300 mmol) of N,N dimethylformamide dimethyl acetal. The 
solution was heated for 3 h at 55 °C and concentrated under reduced pressure 
then. The residue was purified on silica gel column with CH2Cl2/MeOH (10 – 20 
% MeOH) as eluent to give the product as colorless crystals. 
 
Yield:   7.23 g (23.6 mmol, 79 %) 
TLC:   Rf = 0.05 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.9 (s, 1H, formamidino CH), 8.44 (s, 1H, H6), 8.40 (s, 1H, 
H2), 6.39 (dd, 1H, H1′, J = 6.59, J = 7.32), 5.32 (d, 1H, 3′ OH, J = 
4.12), 5.14 (t, 1H, 5′ OH, J = 5.16), 4.42 (m, 1H, H3′), 3.89 (m, 1H, 
H4′), 3.57 (m, 2H, H5′), 3.18 (s, 3H, CH3), 3.12 (s, 3H, CH3), 2.77    
2.26 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 159.4  (C4),  158.2  (formamidino C=N),  151.9  (C2),  151.1 
(C7a), 141.3 (C6), 125.8 (C4a), 88 (C4′), 83.9 (C1′), 71 (C3′), 61.9 
(C5′), 40.8 (formamidino CH3), 39.5 (C2′), 34.6 (formamidino CH3). 
 
ESI( ) MS:   m/z   305.1 [M – H
+] 
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  4N (N,N Dimethylaminomethylidenyl) 5′ O benzoyl 2′ deoxyadenosine 
 
 
1.53  g  (5  mmol)  of  compound  99  were  coevaporated  three  times  with  dry 
pyridine and dried overnight in vacuum. The nucleoside was dissolved in 100 ml 
abs. pyridine and cooled down to – 20 °C. In a separate flask, 640 µl (5.5 mmol) 
of benzoyl chloride were diluted in 8 ml abs. pyridine, taken up with a syringe 
and  added  dropwise  through  a  septum  to  the  nucleoside  within  1  h.  After 
consumption of the starting material (roughly 2.5 h), the reaction was stopped 
by addition of 5 ml MeOH and stirring the mixture for 15 min. The solvent was 
removed under reduced pressure and the resulting syrup purified on silica gel 
column using CH2Cl2/MeOH (2 – 10 % MeOH) as eluent. 
 
Yield:   1.66 g (4.04 mmol, 81 %) 
TLC:   Rf = 0.3 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.89 (s, 1H, formamidino CH), 8.41 (s, 1H, H6), 8.39 (s, 
1H, H2), 7.91 (ψd, 2H, benzoyl HA, J = 7.68), 7.65 (ψt, 1H, benzoyl 
HC, J = 7.32), 7.49 (ψt, 2H, benzoyl HB, J = 7.68), 6.43 (ψt, 1H, H1′, 
J = 6.59), 5.60 (d, 1H, 3′ OH, J = 4.39), 4.64 (m, 1H, H3′), 4.57 – 4.40 
(m, 2H, H5′), 4.15 (m, 1H, H4′), 3.19 (s, 3H, formamidino CH3), 3.12 
(s, 3H, formamidino CH3), 2.97 – 2.35 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm] = 165.6 (benzoyl C=O), 159.1 (C4), 158.1 (formamidino C=N), 
151.8  (C2),  151.1  (C7a),  141.5  (C6),  133.4  (benzoyl CC),  129.4 
(benzoyl Cquart), 129.2 (benzoyl CA), 128.7 (benzoyl CB), 125.8 (C4a), 
84 (C4′), 83.5 (C1′), 70.5 (C3′), 64.5 (C5′), 40.7 (formamidino CH3), 
38.4 (C2′), 34.6 (formamidino CH3). 
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ESI(+) MS:   m/z   411.3 [M + H
+] 
 
 
4N (N,N Dimethylaminomethylidenyl) 5′ O benzoyl 3′ O (2 cyanoethyl) 2′ 
deoxyadenosine 
 
 
820  mg  (2  mmol)  of  nucleoside  100  were  dissolved  under  argon  in  an 
Erlenmeyer flask with triangle stirrer bar in 6.6 ml (100 mmol) freshly distilled 
acrylonitrile  and  in  5  ml  tert butanol.  After  stirring  the  mixture  for  a  few 
minutes,  652  mg  (2  mmol)  of  cesium  carbonate  were  added in  one  lot  and 
vigorous  stirring  continued  for  2  h.  After  completion  of  the  reaction,  the 
mixture was diluted in 150 ml CH2Cl2 and filtered through Celite for removal of 
the insoluble carbonate. After concentration of the filtrate and purification of 
the residue on a silica gel column CH2Cl2/MeOH (5 – 10 % MeOH) as eluent, the 
product was obtained as yellowish foam. 
 
Yield:   487 mg (1.05 mmol, 53 %) 
TLC:   Rf = 0.38 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, CDCl3) 
δ [ppm] = 8.92 (s, 1H, formamidino CH), 8.49 (s, 1H, H2), 8.0 (s, 1H, 
H6), 7.98 (ψd, 2H, benzoyl HA, J = 8.42), 7.56 (ψt, 1H, benzoyl HC, J 
= 7.32), 7.42 (ψt, 2H, benzoyl HB, J = 7.68), 6.4 (ψt, 1H, H1′, J = 
6.59), 4.61 (m, 2H, H5′), 4.51 (m, 1H), 4.44 (m, 1H), 3.77 (t, 2H,  O 
CH2,  J  =  6.22),  3.25  (s,  3H,  formamidino CH3),  3.19  (s,  3H, 
formamidino CH3), 3.06 (m, 1H, H2′), 2.66, (t, 2H, CH2CN, J = 6.22), 
2.64 (m, 1H, H2′). 
 
13C NMR:  (100 MHz, CDCl3) 
δ [ppm] = 166.4 (benzoyl C=O), 159.9 (C4), 158.1 (formamidino C=N),  Experimental part                                                                                                                
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152.8  (C2),  151.3  (C7a),  140.4  (C6),  133.5  (benzoyl CC),  129.8 
(benzoyl CA), 129.6 (benzoyl Cquart), 128.7 (benzoyl CB), 126.9 (C4a), 
117.5 (CN), 85 (C4′), 82.5 (C1′), 80.5 (C3′), 64.6 ( O CH2), 64.3 (C5′), 
41.4  (formamidino CH3),  37.1  (C2′),  35.3  (formamidino CH3),  19.2 
(CH2CN). 
 
ESI(+) MS:   m/z   464.3 [M + H
+] 
 
 
3′ O (2 Cyanoethyl) 2′ deoxyadenosine 
 
 
750  mg  (1.62  mmol)  of  compound  101  were  filled  in  a  sealable  bottle  and 
dissolved  in  20  ml  MeOH.  50  ml  of  32  %  aq.  ammonia  were  added and the 
mixture was agitated overnight at room temperature. After solvent removal, 
the residue was purified on a silica gel column with CH2Cl2/MeOH (5 – 10 % 
MeOH) to furnish the product as yellowish crystals. 
 
Yield:   318 mg (1.05 mmol, 65 %) 
TLC:   Rf = 0.18 (CH2Cl2/MeOH: 9/1) 
 
1H NMR:  (400 MHz, DMSO d6) 
δ [ppm] = 8.34 (s, 1H, H6), 8.13 (s, 1H, H2), 7.31 (br s, 2H, NH2), 6.3 
(dd, 1H, H1′, J = 5.48, J = 8.61), 5.37 (br s, 1H, 5′ OH), 4.31 (m, 1H, 
H3′), 4.03 (m, 1H, H4′), 3.68 (t, 2H, O CH2, J = 6.26), 3.58 (m, 2H, 
H5′), 2.81 (t, 2H, CH2CN, J = 6.26), 2.82   2.46 (m, 2H, H2′). 
 
13C NMR:  (100 MHz, DMSO d6) 
δ [ppm]  = 156.1  (C4),  152.4  (C2),  148.9  (C7a),  139.6  (C6),  129.2 
(C4a), 119.3 (CN), 85.3 (C4′), 84 (C1′), 80 (C3′), 63.4 ( O CH2), 61.9 
(C5′), 36.2 (C2′), 18.3 (CH2CN). 
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MALDI( ) MS:  m/z   304.4    
 
 
3′ O (2 Cyanoethyl) 2′ deoxyadenosine 5′ phosphate 
 
 
84 mg (0.275 mmol) of well dried nucleoside 102 were dissolved in 3 ml dry 
dioxane  and  1.5  ml  dry  pyridine,  then  73  mg  (0.358  mmol)  of  2 chloro 4H 
1,3,2 benzodioxaphosphorinan 4 one in 1 ml anhydrous dioxane were added via 
syringe within 1 min. The mixture was stirred 30 min at room temperature, the 
reaction was immediately stopped by addition of 0.5 ml water and 0.2 ml TEA. 
After stirring the mixture for another 5 min, the solvents were removed under 
reduced pressure and the residue freeze dried over three days. The resulting H 
phosphonate 103, as identified by mass spectroscopy, was dissolved again in 50 
ml abs. pyridine and treated with 3.48 ml (27.5 mmol) chlorotrimethylsilane 
under argon. After 5 min, a freshly prepared solution of 251 mg (0.825 mmol) 
iodine in 10 ml anhydrous pyridine was added and stirring maintained for 30 
min at room temperature. The solvents were removed under reduced pressure, 
the residue was taken up in 5 ml dry pyridine again and treated with 2 ml 
water for completion of the oxidation. The excess of iodine was reduced by 
adding 200 mg solid Na2S2O5 to the solution, then the mixture was evaporated 
to dryness. The resulting crude material was diluted again in 4 ml Millipore 
water, filtered through syringe filter and submitted to RP FPLC for the first 
purification step. After identification of the product containing fraction, it was 
concentrated and further purified on RP HPLC to give the nucleotide as yellow 
oil. The resulting 17 mg (0.044 mmol) of monophosphate 104 were rendered  Experimental part                                                                                                                
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anhydrous by freeze drying over three days. Under argon, the nucleotide was 
dissolved at 4 °C in 0.44 ml abs. MeOH to give a water free methanolic 0.1 M 
monophosphate  solution.  A  freshly  prepared  anhydrous  sodium  perchlorate 
solution (made from 81 mg (0.664 mmol) sodium perchlorate in 2.2 ml abs. 
acetone) was added dropwise at 4 °C causing precipitation of the nucleotide as 
sodium salt. The crystalline product was centrifuged (5 min, 4 °C, 12000 rpm), 
the liquid layer was transfused and the product isolated and dried in vacuum. 
 
Yield:   30 mg (0.078 mmol, 28 %) 
 
RP FPLC:  Method FPLC 3, Retention time 28 – 30 min 
RP HPLC:  Method D, Retention time 19.45 min 
 
1H NMR:  (400 MHz, D2O) 
δ [ppm] = 8.41 (s, 1H, H6), 8.14 (s, 1H, H2), 6.41 (dd, 1H, H1′, J = 
6.26 and J = 7.83), 4.54 (m, 1H, H3′), 4.42 (m, 1H, H4′), 4.05 (m, 2H, 
H5′), 3.89 (t, 2H, O CH2, J = 6.26), 2.86 (t, 2H, CH2CN, J = 6.26), 
2.75 (m, 2H, H2′), 1.81 (s, 3H, CH3). 
 
13C NMR:  (100 MHz, D2O) 
δ [ppm] = 155.1 (C4), 152.3 (C2), 148.5 (C7a), 139.9 (C6), 119.9 (CN), 
118.4 (C4a), 84 (C4′), 83.9 (C1′), 80.3 (C3′), 64.9 (C5′), 64 (O CH2), 
36.9 (C2′), 18.4 (CH2CN). 
 
31P NMR:  (162 MHz, D2O) 
δ [ppm] = 0.45 (s, monophosphate). 
 
ESI( ) MS: H phosphonate 103    m/z   367.1  [M – H
+] 
    Phosphate       104  m/z   383.1  [M   H
+]  Experimental part                                                                                                                
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7.3  Oligonucleotide Synthesis 
 
The 3′ phosphoramidites for the synthesis (direction 3′ to 5′) of the unmodified 
DNA 8mer were purchased from Pharmacia Biotech, the 5′ phosphoramidites for 
the inverse synthesis (direction 5′ to 3′) of the modified DNA 8mer from Glen 
Research. The oligo deoxynucleotides were synthesized on an Expedite Nucleic 
Acid  Synthesis  System  using  500  Ångstrøm  CPG  columns  from  Applied 
Biosystems.  The  sequence  of  the  unmodified  reference  oligomer  is  3′ 
TATGCGGT 5′,  the  sequence  of  the  modified  oligomer  is  3′ ce TATGCGGT 5′ 
with ce = cyanoethyl. The deprotection test on the oligomer was performed in 
a heating block Thermomixer comfort from Eppendorf. OD measurements were 
carried  out  with  a  Hitachi  U 1100  Spectrophotometer  at  λ  =  260  nm.  The 
oligomers were purified on an anion exchange HPLC (Method E) and desalted 
with PD 10 columns (prepacked with Sephadex
TM G 25 M) from GE Healthcare, 
dried under reduced pressure and characterized by MALDI TOF mass using 6 
Aza 2 thiothymine (ATT) / ammonium citrate matrix.
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8 8    Annex 
 
8.1  NMR and mass spectra 
 
ESI(+) mass spectrum of nucleoside 4 
 
 
 
 
1H NMR spectrum of nucleoside 31 (DMSO d6, 400 MHz) 
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1H NMR spectrum of nucleoside 54 (DMSO d6, 400 MHz) 
 
 
 
 
 
1H NMR spectrum of nucleoside 72 (DMSO d6, 250 MHz) 
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1H NMR spectrum of nucleoside 80 (DMSO d6, 300 MHz) 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of monophosphate 88 (D2O, 300 MHz) 
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1H NMR spectrum of monophosphate 95 (D2O, 400 MHz) 
 
 
 
 
1H NMR spectrum of phosphoramidite 96 (acetone d6, 400 MHz) 
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1H NMR spectrum of monophosphate 97 (D2O, 400 MHz) 
 
 
 
 
 
 
1H NMR spectrum of monophosphate 104 (D2O, 400 MHz) 
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8.2  Abbreviations 
 
A A   
  A    Adenosine 
  abs.    absolute 
  Ac    acetyl 
  ACN    acetonitrile 
  AcOH    acetic acid 
ant    anthranyloyl 
  aq.    aqueous 
  approx.  approximately 
  Asp    asparagine 
 
B B   
  BASS    Base Addition Sequencing Scheme 
bp    boiling point 
BSA    N,O Bis(trimethylsilyl)acetamide 
  Bz    benzoyl 
 
C C   
  C    Cytosine 
  CCD    charge coupled device 
  CDCl3    chloroform d1 
  CE    cyanoethyl 
  CEM    cyanoethoxymethyl 
  conc.    concentrated 
  CRT    cyclic reversible termination 
 
D D   
  d    duplet 
  dAMP    2′ deoxyadenosine 5′ monophosphate 
  DCE    1,2 dichloroethane 
  DCM    dichloromethane (methylene chloride) 
  ddNTP   dideoxynucleoside 5′ triphosphate (with N = A, C, G, U and T) 
  DIPEA    N,N′ diisopropylethylamine 
  dist.    distilled 
  DMAP    4 (N,N′ dimethylamino)pyridine 
  DMF    N,N dimethylformamide 
  DMSO    dimethylsulfoxide 
  DNA    deoxyribonucleic acid 
  dNTP    2′ deoxynucleoside 5′ triphosphate (with N = A, C, G, U and T) 
  DTM    dithiomethyl  
   
E E   
  EDTA    ethylenediaminetetraacetic acid 
equiv.   (molar) equivalents 
ESI( )    Electronspray Ionisation in negative mode 
  ESI(+)    Electronspray Ionistaion in positive mode 
  EtOH    ethanol 
et al.    et alii 
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F F   
  FC    flash chromatography 
  FITC    fluoresceinisothiocyanate 
  FPLC    fast protein liquid chromatography 
 
G G   
  G    Guanosine 
  [g]    gram  
 
H H   
  h    hour 
  HCl    hydrochloric acid 
  HF    hydrofluoric acid 
  HPLC    high pressure liquid chromatography 
   
I I   
  i    iso 
  i. e.    id est 
 
K K   
  KF    potassium fluoride 
  KHMDSA  potassium hexamethyldisilylamide 
  KOH    potassium hydroxide  
   
M M   
  m    multiplet 
  M    molar 
  MALDI    Matrix assisted laser desorption ionization 
  mCPBA    3 chloroperoxybenzoic acid 
Me    methyl 
  MeOH    methanol 
  [mg]    milligram 
  min    minutes 
  [µl]    microliter 
  [µm]    micrometer 
  MMT    p monomethoxytrityl 
  mp    melting point 
  MTM    methylthiomethyl 
MS    mass spectroscopy 
   
N N   
  NaH    sodium hydride 
NaOAc   sodium acetate 
NaOH    sodium hydroxide 
  NaOMe   sodium methoxide 
NIS    N iodosuccinimide 
  [nm]    nanometer 
NMR    nuclear magnetic resonance 
nt    nucleotide 
 
O O   
  OD    Optical density Annex                                                                                                                                       
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  ODN    Oligodeoxynucleotide 
 
P P   
  p.a.    pro analysi 
  PAA    polyacrylamide   
PAGE    polyacrylamide gelelectrophoresis 
  PCR    polymerase chain reaction 
  PG    protecting group 
pH    potentia hydrogenii 
  PPi    pyrophosphate 
  pTSA    para toluenesulfonic acid 
  py    pyridine 
 
Q Q   
  q    quartet 
 
R R   
  Rf    retention factor (“relate to front”) 
  RP    reversed phase 
  rt    room temperature 
 
S S   
  s    singlet 
  sat.    saturated 
  SBH    Sequencing by Hybridization 
  SBS    Sequencing by Synthesis 
  SNP    single nucleotide polymorphism 
 
T T   
  T    Thymidine 
  T    temperature 
  t    triplet 
  Taq    Thermus aquaticus 
  TASF    tris(dimethylamino)sulfonium difluorotrimethylsilicate 
  TBAF    tetrabutylammoniumfluoride 
  TBDMS   tert. butyldimethylsilyl 
  tBuOH   tert. butanol 
  TDA 1    tris(dioxa 3,6 heptyl)amine 
  TEA    triethylamine 
  TEAB    triethylammonium bicarbonate 
  tert.    tertiary 
  TFA    trifluoroacetic acid 
  THF    tetrahydrofurane 
  tiPDSCl  1,1,3,3 tetraisopropyldichlordisiloxane 
  TLC    thin layer chromatography 
TMS    trimethylsilyl 
TMSCl    chlorotrimethyl silane 
TOF    time of flight 
Tol    toluoyl 
U U   
  U    Uridine 
  UV    ultraviolet 
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